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SUMMARY 
 
Inhibitory neurotransmission in the central nervous system (CNS) largely relies on the 
actions of gamma aminobutyric acid (GABA) on GABAA receptors, heteropentameric 
ligand-gated chloride channels assembled from 19 possible subunits (α1-6, β1-3, γ1-3, δ, ε, θ, π, 
ρ1-3). GABA-induced chloride influx through GABAA receptors causes neuronal 
hyperpolarization and inhibition of further action potentials. Therefore, impaired GABAergic 
function results in CNS conditions such as epilepsy, insomnia, anxiety, and mood disorders. 
A number of clinically important drugs like benzodiazepines, barbiturates, neuroactive 
steroids, anesthetics, and certain other CNS depressants bind GABAA receptors. However, 
these drugs lack of subunit specificity and, therefore, induce serious side effects.  
 
In the search for GABAA receptor modulators with new scaffolds, a plant extract library was 
screened at Prof. Hamburger’s group by means of an automated two-microelectrode voltage 
clamp functional assay in Xenopus laevis oocytes. Among others, the lipophilic extracts of 
Bupleurum chinense roots, Pholidota chinensis stems and roots, Adenocarpus cincinnatus 
roots and tubers, and Boswellia thurifera resin positively modulated GABAA receptors of the 
subtype α1β2γ2s, the most abundant one in the human brain. 
 
In this work, GABAergic activity in the four extracts was tracked using of an HPLC-based 
activity profiling approach. In total, 22 natural products, eight of them new, were isolated by 
diverse chromatographic methods and characterized by HR-TOF-MS and microprobe NMR. 
Absolute configuration of chiral compounds was determined by CD-spectroscopy and 
polarimetry. Fourteen of the 22 isolates showed GABAA receptor modulatory activity in the 
oocyte functional assay. Dihydrostilbenes, cis-pterocarpans, and abietane diterpenes were 
identified as new scaffolds for GABAA receptor modulators with favorable physicochemical 
properties for blood-brain barrier permeation.  
 
HPLC-based activity profiling of P. chinensis enabled the identification of the 
dihydrostilbene batatasin III as a very efficient, non-selective GABAA receptor modulator 
(maximal potentiation of IGABA 1500%). Two structurally related non-flexible stilbenoids, 
coelonin and pholidotol D, were also isolated from the extract but they were inactive in the 
oocyte assay. A preliminary structure-activity relationship study conducted with a series of 
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commercially available stilbenes and their dihydro derivatives, revealed that conformational 
flexibility is crucial for GABAA receptor modulatory activity of stilbenoids. 
 
Fifteen flavonoid and isoflavonoid derivatives, including eight new natural products, were 
isolated from A. cincinnatus and tested in the oocyte assay. At a concentration of 100 µM, 12 
of the 15 compounds enhanced the GABA-induced chloride current through GABAA 
receptors by more than 190%. Two pterocarpans and one isoflavone showed remarkably 
higher potency than other natural products previously isolated in this working group (EC50 
below 10 µM).  
 
B. thurifera and B. chinense yielded two more GABAA receptor modulators, dehydroabietic 
acid and aristolactone, respectively. However, isolation of aristolactone from a commercial 
sample of the traditional Chinese herbal drug Chaihu (Bupleurum chinense roots) led to 
detection of adulteration of the sample with roots of the nephrotoxic species Aristolochia 
manshuriensis. This case raised concerns about adequate quality control of TCM drugs 
commercialized in Europe. 
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ZUSAMMENFASSUNG 
 
Die inhibitorische Neurotransmission im zentralen Nervensystem (ZNS) basiert grössenteils 
auf der Wechselwirkung zwischen γ-Aminobuttersäure (GABA) und GABAA-Rezeptoren – 
hetreopentameren, Ligand-gesteuerten Chloridionenkanälen, die aus 19 möglichen 
Untereinheiten (α1-6, β1-3, γ1-3, δ, ε, θ, π, ρ1-3) aufgebaut sind. Der durch GABA induzierte 
Einstrom von Chloridionen durch GABAA-Rezeptoren verursacht eine neuronale 
Hyperpolarisation und hemmt den Aufbau weiterer Aktionspotentiale. Daher führt eine 
beinträchtigte GABAerge Funktion zu funktionellen Störungen des ZNS wie Epilepsie, 
Schlafstörungen, Angstzuständen und Gemütsschwankungen. Viele klinisch relevante 
Arzneimittel wie Benzodiazepine, Barbiturate, neuroaktive Steroide, Anästhetika und andere 
Substanzen mit ZNS-dämpfendender Wirkung binden an GABAA-Rezeptoren. Da diese 
jedoch keine Spezifität bezüglich der bestimmten Subtypen aufweisen, rufen diese 
Arzneimittel ernsthafte unerwünschte Nebenwirkungen hervor. 
 
Im Zuge der Suche nach neuartigen GABAA-Rezeptor Modulatoren wurde in der 
Arbeitsgruppe von Prof. Hamburger eine Bibliothek von Pflanzenextrakten unter 
Verwendung eines automatisierten zwei-Mikroelektroden-Spannungsklemmen-Verfahrens an 
Xenopus laevis Oozyten gescreent. Unter anderem zeigten die lipophilen Extrakte von 
Bupleurum chinense Wurzeln, Pholidota chinensis Stamm und Wurzeln, Adenocarpus 
cincinnatus Wurzeln und Knollen und Boswellia thurifera Harz positive modulatorische 
Effekte auf GABAA-Rezeptoren des Subtyps α1β2γ2s – den Subtyp, der im menschlichen 
Gehirn am häufigsten vorkommt. 
 
In dieser Arbeit wurde die GABAerge Aktivität in den vier beschriebenen Extrakten mittels 
HPLC basiertem Aktivitäts-Profiling charakterisiert. Im Ganzen wurden 22 Naturstoffe, acht 
davon bisher unbekannt, mittels verschiedener chromatographischer Methoden isoliert und 
ihre Struktur anhand von HR-TOF-MS und microprobe NMR aufgeklärt. Die absolute 
Konfiguration von chiralen Strukturen liess sich durch CD-Spektroskopie und Polarimetrie 
bestimmen. Vierzehn der 22 Substanzen zeigten positive modulatorische Effekte auf 
GABAA-Rezeptoren im Oozyten-Assay. Dihydrostilbene, cis-Pterocarpane und Abietan-
Diterpene wurden als neue Grundstrukturen für GABAA-Rezeptor Modulatoren mit für den 
Bluthirnschranken Übergang günstigen physikochemischen Eigenschaften identifiziert. 
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 Aus dem HPLC basierten Aktivitäts-Profiling von P. chinensis ging das Dihydrostilben 
Batatasin III als sehr effizienter, nicht selektiver GABAA-Rezeptor Modulator hervor 
(maximale Potenzierung von IGABA 1500%). Zwei strukturell verwandte, nicht flexible 
Stilbene, Coelonin and Pholidotol D, wurden aus demselben Extrakt isoliert, waren im 
Oozyten-Assay allerdings nicht aktiv. 
 
Eine erste Untersuchung der Sturktur-Aktivitäts Beziehung anhand einer Serie kommerziell 
erhältlicher Stilbene und ihrer Dihydro-derivate zeigte, dass die Flexibilität der Konformation 
für die modulatorische Aktivität von Stilbenen am GABAA-Rezeptor essentiell ist. 
 
Fünfzehn Flavonoid- und Isoflavonoid-Derivate, davon acht neue Naturstoffe, konnten aus A. 
cincinnatus isoliert und im Oozyten-Assay getestet werden. Bei einer Konzentration von 100 
µM, erhöhten 12 der 15 Substanzen den GABA induzierten Chloridionen Einstrom durch die 
GABAA-Rezeptoren um mehr als 190%. Zwei Pterocarpane und ein Isoflavon zeigten eine 
deutlich höhere Potenz als bisher in der Arbeitsgruppe isolierte Substanzen (EC50 < 10 µM). 
 
B. thurifera und B. chinense lieferten zwei weitere GABAA-Rezeptor Modulatoren, 
Dehydroabietis-säure bzw. Aristolacton. Dass Aristolacton aus Chaihu (Bupleurum chinense 
Wurzeln), einem kommerziell erhältlichen Produkt der traditionellen Chinesischen Medizin, 
isoliert wurde, deckte auf, dass das Produkt mit Wurzeln der nephrotoxischen Spezies 
Aristolochia manshuriensis versetzt war. Dieser Fall wirft Fragen auf über die angemessene 
Qualitätskontrolle von kommerziell erhältlichen TCM Produkten in Europa. 
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“The journey of a thousand miles begins with a single step” 
Laozi (604-531 BC) 
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1. AIM OF THE WORK 
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Pharmacological management of CNS conditions such as epilepsy, insomnia, anxiety, and 
mood disorders involves, for the most part, positive modulation of GABAA receptors by 
clinically relevant drugs like benzodiazepines and several other CNS depressants. However, 
these drugs interact in a non-selective way with several GABAAR subtypes and thus induce a 
number of serious side effects like reduced coordination, cognitive impairment, tolerance, 
and drug dependence. Selective modulators are expected to improve the safety profile of the 
current treatments. However, despite the availability of experimental subunit-specific 
GABAergic drugs for more than a decade, no subtype-selective GABAA receptor modulator 
has been introduced into clinical practice to this day [1]. 
 
Historically, natural products have been a very important source of drugs, providing myriads 
of biologically relevant compounds of great chemical diversity. At least 50% of the currently 
marketed drugs including antibiotics and anticancer agents have counted directly or indirectly 
on natural products for their development [2]. The occurrence of GABAA receptor 
modulators has been reported for several plant species and a number of structurally diverse 
natural products have been identified to interact with this receptor [3]. However, the number 
of structural templates is still limited, and the search for selective GABAAR modulators with 
new scaffolds must be continued. 
 
In our research group, previous works have been carried out on the identification of GABAA 
receptor modulators from nature. The starting material for these studies was an extract library 
assembled on the basis of traditional use of plants as tranquilizers and sleep-inducers in 
different cultures. These extracts were preliminarily screened in a two-microelectrode voltage 
clamp (TEVC) assay in Xenopus oocytes, using potentiation of GABA-induced chloride 
current (IGABA) through α1β2γ2s GABAA receptors as the evaluation parameter. Extracts that 
potentiated IGABA by more than 30% at 100 µg/mL, were selected for further isolation of 
potentially active compounds. 
 
The aim of the present work was to trace GABAergic activity in four of those plant extracts 
in order to find at least one new scaffold for GABAA receptor modulators with suitable 
physicochemical properties for further optimization and development. The extracts were 
chosen based chemotaxonomic considerations and potentiation of IGABA. Using an HPLC-
based activity profiling approach in combination with the TEVC functional assay in Xenopus 
oocytes, the major bioactive compounds in each extract were to be isolated by means of 
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diverse chromatographic methods and identified using spectrometric and spectroscopic 
techniques. Concomitant isolation and identification of structurally related compounds had to 
be performed for evaluation of possible structure-activity relationships. 
 
Pharmacological characterization of the isolates as GABAA receptor modulators had to be 
carried out in the oocyte assay, by determining potency (EC50) and efficiency (maximal 
potentiation of IGABA) from concentration-response experiments in receptors of the subtype 
α1β2γ2s. Compounds with outstanding activity at this receptor subtype and favorable 
physicochemical properties, would be submitted to subunit specificity evaluation in receptors 
with varying α and β subunit composition.   
 
References 
[1] Griebel G, Holmes A. 50 years of hurdles and hope in anxiolytic drug discovery. Nat Rev Drug Discov 
2013;12:667–87. 
[2] Cragg GM, Newman DJ. Natural products: A continuing source of novel drug leads. Biochim Biophys Acta 
BBA - Gen Subj 2013;1830:3670–95. 
[3] Zaugg J. Discovery of new scaffolds for GABAA receptor modulators from natural origin. Univertität Basel, 
Basel; 2011. 
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2. INTRODUCTION 
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2.1. Natural products in drug discovery 
 
“(…) but nature is always more subtle, more intricate, 
 more elegant than what we are able to imagine” 
 
Carl Sagan in The Demon-Haunted World: Science as a Candle in the Dark (1995) 
 
 
Natural products: an invaluable source of novel drug leads 
The use of plants to alleviate and treat human diseases can be traced to prehistoric times. 
Plants, in particular, have formed the basis of sophisticated traditional medicine systems [1]. 
Earliest written documentation of knowledge on medicinal properties of plants is found on 
Assyrian clay tablets dated about 2000 B.C. Millenary cultures such as Egyptian, Indian, and 
Chinese hold a well-established tradition on the popular use of medicinal plants [2]. The 
Greeks and Romans significantly influenced the rational use of herbal drugs in the ancient 
Western world, with the contributions of Dioscorides (100 A.D) and Galen (130-200 A.D). 
During the Dark and Middle Ages (5th to 12th centuries), the Greco-Roman knowledge was 
preserved by the Arabs, who expanded it to include the use of their own sources, together 
with Chinese and Indian herbs [1].  Centuries later, Paracelsus (1493 – 1541) developed the 
first idea of active principles in plants (the so-called Arcanum, which he considered as an 
immaterial principle) and the concept of dose dependency of drug action and toxicity (sola 
dosis facit venum) [2].  
 
In 1806, the German pharmacist Friedrich Sertürner reported the first isolation of a 
pharmacologically active pure natural product (NP), a white crystalline powder from opium 
(Papaver somniferum) which he named morphine after Morpheus, the Greek god of dreams 
[3]. Thus began an era in which drugs from natural sources could be purified, studied, and 
administered, eventually leading to pharmaceutical drug development as it stands today [4]. 
Microorganisms, plants, and more recently marine organisms, became prolific sources of 
structurally diverse bioactive metabolites that have yielded a number of very important drugs 
[1,5]. Quinine, isolated from the bark of cinchona tree (1820), salicylic acid from willow bark 
extract (1838), and penicillin from Penicillium fungi (1938), are some of the most popular 
examples (Figure 2.1) [3].  
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Pharmaceutical research expanded after the Second World War to include massive screening 
of microorganisms for new antibiotics after the discovery of penicillin [4]. Research on NPs 
as source of novel drugs reached its peak in the Western drug industry in the period 1970-
1980, which resulted in a pharmaceutical landscape heavily influenced by non-synthetic 
molecules [6]. By 1990, about 80% of the drugs were either NPs or had a NP-origin. 
Antibiotics, antiparasitics, antimalarials, lipid lowering agents, immunosuppressants for 
organ transplants, and anticancer drugs, all of them based on the exquisite structural diversity 
and biological specificity of NPs, revolutionized medicine [4].  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Structures of representative natural product-derived drugs (adapted from Wetzel et al. 
2010 [3]). 
 
According to Newmann and Cragg in their review of 2012 [7], the NP field was still 
producing or was involved in ca. 50% of all small molecules approved in the years 2000-
2010. In their review of 2013 [1], the authors revealed that of the 1073 small-molecule New 
Chemical Entities (NCEs) approved between 1981 and 2010, only 36% can be classified as 
truly synthetic (i.e., devoid of natural inspiration) in origin. The two main disease categories 
in which NPs have played a crucial role in drug discovery are infectious diseases (caused by 
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bacteria, fungi, parasites, or viruses) and oncology, with 69% and 75% of the approved drugs 
being NP-derived or -inspired, respectively. 
  
These data highlight the continuing importance of NPs as a source and inspiration for novel 
drugs, representing a highly validated strategy in drug discovery. Even more remarkable is 
the fact that, despite the intensive investigation, this potential remains virtually unexplored. It 
is estimated that only 6% of the total number of higher plant species have been studied 
pharmacologically and 15%, phytochemically. The surface of this unique source for bioactive 
compounds has barely been scratched. Many interesting drugs from natural sources remain to 
be discovered [1]. 
 
Challenges to natural product-based drug discovery 
Despite the success of natural product-based drug discovery over the last decades, the search 
for new drug substances from “Mother Nature’s Combinatorial Libraries” has fallen out of 
favor in recent years [5]. Many pharmaceutical companies have discontinued their NP 
screening programs [8] and rather embraced the ‘biopharma’ approach for innovation in drug 
discovery, relying on biological macromolecules such as monoclonal antibodies. On the other 
hand, a number of innovative strategies such as combinatorial chemistry, diversity-oriented 
synthesis, fragment-based drug discovery, chemical biology, and in silico screening have, for 
the most part, replaced NPs in drug discovery process [9].  
 
Drug discovery and development is an extremely competitive and cost-intensive business. 
Due to the financial pressure, firms involved in drug discovery must hit the target accurately, 
as quickly and profitably as possible [4]. As a result, major pharmaceutical companies are 
currently working under an increasingly sophisticated high-throughput screening (HTS) 
scheme that allows the evaluation of libraries containing hundreds of thousands of 
compounds a week, using enzyme- or receptor-based assays designed to discover leads with 
specific mechanisms of action [5]. The classical approach of NP discovery based on 
bioactivity-guided fractionation does not fit too well in this picture, for it requires 
multidisciplinary expertise, is more time consuming and costly than most current approaches, 
and poses a number of technical challenges [9].  
 
When working with NPs, libraries of crude extracts rather than pure compounds are typically 
screened for activity. Although operatively it is similar to the screening of small-molecule 
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libraries, results are influenced by the complex chemical composition of crude extracts. Low 
concentration of active compounds, poor solubility, chemical instability, presence of 
compounds with opposite activity, fluorescent or colored contaminants, or synergistic action 
of several constituents, are only few of the factors that can originate unreliable results [9]. 
Additional complications include insufficient access and supply of natural sources, low 
reproducibility of the activity or chemical composition of the source (easily affected by 
environmental or seasonal factors), and intellectual property rights [4].  
 
In the light of the increased demand for compounds generated from the HTS approach, 
combinatorial chemistry appeared as a perfect fit due to its ability to generate large libraries 
of chemically diverse small molecule hits. However, only few drug candidates have been 
discovered with the fusion HTS-combinatorial chemistry [5,10], and only one de novo NCE 
has been approved for drug use in the period 1981-2010 (Bayer’s antitumor compound 
sorafenib) [7]. In recent years, the output of the R&D programs of the pharmaceutical 
industry has declined considerably from over 60 NCEs/year in the late 1980s to over 23 in 
2001-2010 [1], and  it seems likely that the decreased emphasis on NPs in drug discovery has 
contributed to this decline [11].  
 
These unexpected results have pointed out that success in drug discovery depends on the 
quality, rather than the quantity of the library members, and quality is determined by three 
factors: chemical diversity, lead-likeness, and biological relevance [11]. NP-based libraries 
are superior to combinatorial ones in every aspect. NPs offer a source of chemical diversity 
unmatched by any synthetic combinatorial collection: They are sterically more complex, 
cover a much larger volume of the chemical space, and display a broader dispersion of 
structural and physicochemical properties. In addition, many NP exhibit more favorable 
ADME properties than synthetic products [10,12]. Analyses of the database Dictionary of 
Natural Products (DNP) have revealed that at least 60% of the entries comply with Lipinski’s 
Rule of 5 for lead-like properties (see section 2.4), with only about 10% exhibiting two or 
more violations. Last but not least, most NPs have the imprinted ability to recognize and 
interact with protein surfaces, as a result of their biosynthetic origin. They constitute thus 
privileged structures for drug design from both a chemical and a biological point of view 
[5,9,11]. 
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Besides their potential as lead structures, NPs also provide attractive scaffolds for 
combinatorial synthesis and remain essential tools for the validation of new drug targets 
[10,12]. Research on NPs must turn into a multidisciplinary process to remain competitive in 
drug discovery. Integration with current strategies of drug discovery like combinatorial 
chemistry for optimization of active NP templates, derivatization of existing NPs, diverted 
total synthesis, and the high-throughput de novo construction of NP-like scaffolds, must be 
attempted [1,9].  
 
Although pharmaceutical industry has largely abandoned NP research, there are signs that 
NPs are experiencing a renaissance. In view of the recent achievements and ongoing 
developments, exploiting nature’s diversity will continue to be an invaluable tool in the 
never-ending quest for new drugs [3]. In a time where the number of NCEs launched by the 
pharmaceutical industry is in steady decline, natural products appear more than ever to be an 
indispensable source for novel and structurally new scaffolds [8]. 
 
Tracing bioactivity in natural extracts 
Challenges posed by modern drug discovery have been, at the same time, the driving force 
for unprecedented technological advances in NP-based lead discovery. Generation of large 
libraries of pre-purified extracts or fractions more suitable for HTS, is now possible thanks to 
laboratory automation, and the use of hyphenated techniques has accelerated the fractionation 
and structure elucidation processes. However, despite these remarkable achievements, there 
is still an urgent need for faster and more efficient strategies to track bioactivity of NPs. The 
greatest challenges remain the generation of high quality sample libraries and the efficient 
interfacing of biological data with chemo-analytical information [8,9]. 
 
The general strategy to discover new leads from plants involves primarily i) screening of 
extracts, ii) dereplication of active compounds, iii) bioassay-guided purification and isolation, 
and iv) structure elucidation of new bioactive constituents [9]. A brief description of each 
step is provided here.  
 
i) Screening of extracts 
After having established a validated target and a suitable bioassay, plant samples must be 
processed into a form suitable for screening. Common forms, in increasing order of purity, 
include the following [11]: 
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• Crude extract libraries 
• Pre-fractionated libraries of crude extracts: by chromatographic methods or liquid-
liquid partitioning 
• Semipurified extract libraries 
• Pre-fractionated libraries of semipurified extracts 
• Pure NPs 
 
The degree of pre-purification applied to the samples has a direct impact on the reliability of 
the screening results, reducing the occurrence of false positives/negatives. Additionally, 
purification increases the chances of detecting minor bioactive compounds in enriched 
fractions. Companies like Wyeth have reported that for about 80% of the fractions that 
proved to be active in the screening, the original extract was not found active, implying that 
the bioactive compounds would have been missed if only crude extracts had been tested. 
However, these positive results must be weighed against the rising production and screening 
costs of the process [8,11]. 
 
ii) Dereplication 
Dereplication is the use of chromatographic and spectroscopic analysis to get information 
about the composition of active extracts or fractions, with the aim of discriminating 
previously isolated substances from novel compounds. For this rapid identification of known 
compounds, HPLC-MS or HLPC-NMR coupled with reference libraries of NPs (e.g. DNP) is 
most commonly used. Dereplication is also useful to detect the presence of interfering 
substances such as tannins or saponins in the mixtures. Furthermore, multiple extracts or 
fractions containing the same active component can also be identified [5,9,11]. 
 
iii) Bioassay-guided purification and isolation 
The classical process leading from a bioactive extract to bioactive pure compounds was, for 
many years, a long and tedious procedure consisting of consecutive preparative separation 
steps guided by activity assessment of each of the resulting fractions. This slow and costly 
approach led many times to loss of bioactivity in the course of the purification process and 
left little room for dereplication in early stages, resulting in disappointing outcomes. In recent 
years, analysis, purification, and structure elucidation of NPs have experienced a 
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breakthrough, becoming a technology-driven process with new approaches like HPLC-based 
and affinity-based methods for the correlation of bioactivity with structural information [12].  
 
HPLC-based methods constitute a sensitive miniaturized approach for the identification of 
active principles in early stages of the purification process, by combining chemoanalytical 
and biological data. Among the HPLC-based methods, three different approaches have been 
developed: on-line post-column bioassays, at-line settings, and off-line activity profiling. The 
latter, commonly referred to as HPLC-based activity profiling, offers the highest versatility 
and can be implemented in a high-throughput environment. The procedure starts with the 
fractionation of bioactive extracts by analytical or semipreparative HPLC and on-line 
recording of spectroscopic data, generally UV-vis and MS spectra. Simultaneous fraction 
collection for bioassay is carried out via a T-split of the column effluent. Fractions are dried, 
re-dissolved in a small volume of a suitable solvent, generally DMSO, and submitted to a 
bioassay. After assessment of each fraction, the activity profile can be matched with the 
HPLC chromatogram and correlated with the spectroscopic data recorded on-line, to identify 
active peaks. The general principle is shown in Figure 2.2. A targeted preparative isolation is 
then performed, if the compounds in the active time window are proven to be of interest after 
dereplication. This isolation does not require biological testing after each chromatographic 
step and therefore, consists of a straightforward peak-guided separation. The whole procedure 
requires only minute amounts of crude extract [13]. 
 
 
 
 
 
 
 
 
Figure 2.2. Experimental platform for HPLC-based activity profiling of bioactive extracts (adapted 
from Potterat and Hamburger 2013 [8]) 
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 HPLC-based activity profiling is a powerful approach for the rapid identification of bioactive 
compounds, suitable to be coupled to basically any bioassay that can be performed in a 
miniaturized format. It can be implemented in any laboratory equipped with the appropriate 
HPLC instrumentation. A number of research groups have set up platforms for HPLC-based 
activity profiling [8]. In our group, this approach has been successfully applied to the 
prioritization and subsequent identification of hits from screening projects using diverse 
bioassay formats, such as whole organism assays (tropical parasitic diseases) [14–17], cell-
based functional assays (e.g. GABAA receptor modulation) [18–22], and mechanism-based 
screens (e.g. DYRK1A kinase) [23].  
 
iv) Structure elucidation 
Solving the structure of unknown compounds was once considered the bottleneck of the NP 
discovery process. Fifty years ago, tedious decomposition into fragments or, alternatively, 
total chemical synthesis were still required to corroborate structure proposals [24]. Modern 
spectroscopic techniques have revolutionized structure elucidation and quantification. 
Introduction of novel spectroscopic techniques, and significant advances in sensitivity and 
resolution have dramatically reduced data acquisition times and required sample amounts, 
which is key when dealing with NPs [11]. 
 
Full structural characterization of compounds eluted in microgram amounts from an HPLC 
column has become routine thanks to the concerted use of HPLC-DAD, -MS, and -NMR [8]. 
Among all HPLC detectors, UV is the most common and widely used. A broad range of NPs 
can be detected provided that they possess UV chromophores. Absorption for most NPs 
occurs in the range of 200-550 nm. DAD-UV analysis allows the identification of NP classes 
(terpenoids, alkaloids, polyphenols, etc) based on the absorption patterns of characteristic 
chromophores [25]. On the other hand, high-resolution MS constitutes a key technique for the 
identification of NPs. Different ionization sources and mass analyzers are available for the 
detection of non-volatile NPs. The most common ionization sources are electrospray 
ionization (ESI) and atmospheric pressure chemical ionization (APCI), since they produce a 
soft ionization ideal for thermo-labile NPs. Among mass analyzers, single quadrupole, triple 
quadrupole MS-MS, ion trap, and time-of-flight (TOF) spectrometers are the most used 
[26,27]. TOF spectrometers are used for routinely accurate mass measurements, which allow 
the assignment of molecular formulae with high confidence on subnanogram amounts of 
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compound [11]. Furthermore, HPLC-MS-MS or MSn experiments provide complementary 
information through fragmentation of the molecular species by in-source collision-induced 
dissociation (CID), which can be useful in the case of NPs such as glycosides or prenylated 
compounds, and the differentiation of isomers [25].  
 
Although MS is a powerful tool in structure elucidation, NMR spectroscopy still provides the 
most complete information to fingerprint molecules [11]. Technological developments over 
the past 50 years have significantly improved sensitivity and resolution in NMR, making it 
suitable for the analysis of small sample quantities. This is mostly enabled by the increase of 
magnetic field strength and the development of pulse-field gradient experiments. However, 
big magnets are pricy and may require considerable physical infrastructure and space, making 
it difficult for most users to acquire, maintain, and operate. A far more practical solution to 
improve S/N for most NPs is to choose the appropriate NMR probe according to the 
particular needs. A number of different probes can be chosen based on the available amount 
of sample, sample solubility, and budget. The most flexible probes are standard 5-mm, 
operating at room temperature. Smaller diameter (e.g. 1-mm probe) increases mass sensitivity 
but restricts the analysis of samples with limited solubility. The highest sensitivity can be 
achieved with small-volume, cryogenically cooled probes, which improve sensitivity by 
lowering thermal noise. However, costs rise considerably as sensitivity increases [24,28]. 
 
The routine strategy for full structure elucidation by NMR begins with a simple 1H-NMR 
spectrum, which provides an idea of the overall complexity of the structure. At this early 
stage, it is possible to recognize certain NP classes or characteristic structural features. For 
known compounds, such tentative structural assignments can be easily confirmed by 
comparison with reported NMR data. For unknown compounds, the next step usually consists 
of acquisition of 2D NMR spectra. Four different types of 2D NMR experiments are the most 
common [28]: 
• (1H,1H)-COSY or TOCSY are used for the characterization of proton spin systems. 
COSY spectra show only directly coupled protons, whereas TOCSY may show 
crosspeaks for further protons belonging to the same spin system.  
• (1H,13C)-HSQC and HMQC serve to identify proton-bearing carbons and to associate 
these carbon atoms with their attached protons. Multiplicity-edited HSQC versions 
offer the added benefit of distinguishing CH3, CH2, and CH groups. 
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• (1H,13C)-HMBC provides long-range correlations between protons and carbons – 
mostly for those being two or three bonds apart from each other. It allows the 
identification of quaternary carbons and the linkage between separate structural 
fragments obtained from analysis of COSY/TOCSY and HSQC/HMQC.  
• (1H,1H)-NOESY and ROESY provide information about spatial proximity of protons 
that are separated by up to 5 Å, which can be used to determine relative configuration. 
 
For most organic small molecules, acquisition of 1D 13C-NMR spectrum is not required when 
well-resolved HSQC and HMBC spectra are available. For NPs that cannot be sufficiently 
characterized by routine 2D NMR spectroscopy, as in the case of highly unsaturated 
compounds, (13C,13C)-INADEQUATE experiments are an option. However, due to the low 
natural abundance of 13C, sensitivity of this method is extremely low and therefore, it 
requires a large amount of sample [28]. 
 
Although NOESY and ROESY experiments provide stereochemical information, only 
relative configuration can be extracted from these spectra. Thus, the complete spatial 
arrangement of a chiral molecule, or absolute configuration, needs to be proven by different 
methods. Determination of the absolute configuration of chiral NPs is essential, for it 
conditions their stereoselective interaction with biological targets and thus, their biological 
activity [29]. 
 
Although NMR techniques can be used for the determination of absolute configuration, 
complex experimental procedures are required. Spectroscopic measurement of chiroptical 
properties such as optical rotation (OR), optical rotatory dispersion (ORD), and circular 
dichroism (CD), allow the rapid and unambiguous differentiation between stereoisomers 
without major experimental efforts, using sub-µg amounts of sample [30]. 
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2.2. Traditional medicine in drug-discovery: contributions and challenges 
 
 
“Trees are sanctuaries. Whoever knows how to speak to them, 
whoever knows how to listen to them, can learn the truth” 
 
Hermann Hesse in Bäume. Betrachtungen und Gedichte (1984) 
  
The role of ethnopharmacology in drug discovery 
When screening for biologically active plant constituents, selection of the plant species to be 
studied is a crucial factor for the success of the investigation. Focused plant libraries can be 
assembled on the basis of ethnopharmacological, chemotaxonomic, ecological, or 
phylogenetic considerations, among others. Although some successful results in drug 
discovery have been accomplished with random (also known as biodiversity-based) 
screening, as in the case of taxol, the search based on ethnopharmacology is considered as 
one of the most effective approaches in the discovery of novel potential drug leads from 
plants [1–3].  
 
Ethnobotany, also referred to as ethnopharmacology, is defined as the science of people’s 
interaction with plants, including those used with therapeutic purposes [4]. The use of 
medicinal plants in traditional medicine represents a sort of preexisting clinical testing and a 
shortcut to biologically active compounds. Analyses of bioactivity databases such as the US 
National Cancer Institute (NCI) list of active plants, have revealed that species with an 
ethnopharmacological record are 2-5 times more likely to generate active extracts than those 
with no traditional use in medicine [3,5]. However, the translation of ethnobotanical 
knowledge into commercialized products is not easy. Many traditional medicines take 
holistic approaches and include in their treatments intangible elements that cannot be 
translated into molecular terms. Further complications can arise from insufficient validation 
and standardization, sustainability of the source, or intellectual property issues [5]. 
 
Ethnobotanical surveys and the study of written records on traditional medicine of cultures 
around the world have been the basis for the discovery of important therapeutic agents. A 
famous example is the discovery of the cardiac glycoside digoxin from foxglove (Digitalis 
purpurea), a European plant known as cardiotonic since centuries. Digoxin is nowadays used 
in the treatment of arrhythmia and congestive hearth failure. Moreover, the study of the 
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pharmacology of this drug has led to an understanding of the biochemical pathways involved 
in the development of heart conditions. Galanthamine, a drug currently used in the treatment 
of Alzheimer’s disease, constitutes another example of therapeutic agents isolated from 
European species (in this case, Galanthus spp.) [5–7].  
 
Traditional medicine in other cultures has also guided the discovery of plenty of useful NPs. 
Ethnopharmacological knowledge on the North American plant Podophyllum peltatum led to 
the discovery of podophyllotoxin, whose derivatives etoposide and teniposide are potent 
cytotoxic agents used nowadays in the chemotherapy of several types of cancer. 
Catharanthus roseus, a species from Madagascar known for its hypoglycemic properties, 
yielded the so called vinca alkaloids (e.g. vinblastine and vincristine), also used to date in 
oncology treatments. The study of plants used in traditional Chinese medicine (TCM) such as 
Camptotheca acuminata and Artemisia annua, has allowed the discovery of camptothecin 
and artemisinin, respectively. Semisynthetic derivatives of Camptothecin (i.e. topotecan and 
irinotecan) and artemisinin (i.e. artesunate and artemether) are nowadays used in clinic as 
chemotherapeutic agents for the treatment of cancer and malaria [5,6]. 
 
These examples above constitute just few of the many contributions of traditional medicine to 
drug discovery. However, medicinal plants are not only useful as the source of pure, 
chemically defined active principles. Being an essential component in the healthcare systems 
of many cultures worldwide1, medicinal plants are commonly used as complex mixtures 
containing a broad range of constituents (infusions, tincture, extracts, among other 
preparations) [8,9]. Due to the rising interest on herbal medicines around the world, a brief 
description of challenges and perspectives of complex herbal products is provided in the next 
sections. Owing to the worldwide increasing impact and recognition of TCM as an alternative 
medicine modality, emphasis has been made on this traditional healthcare system.  
 
Traditional Chinese Medicine 
TCM is a holistic medical system for disease prevention, diagnosis, and treatment. It has a 
long history of development and application in China and, recently, is beginning to play a 
role in western healthcare as a complementary and alternative medicine modality. The overall 
                                                      
1 According to the World Health Organization (WHO), traditional medicines represent the primary healthcare 
system for 60% of the world’s population [2]. 
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treatment concept of TCM differs greatly from that of western medicine, for patients are 
treated in an integral way that combines physical, emotional, and spiritual elements. Based on 
the Chinese philosophy of Yin-Yang balance2, TCM uses experience-based therapies such as 
acupuncture and herbal medicine. Preventive approaches such as dietary advice, physical 
exercises, meditation, and massages, are also common in TCM [10,11]. 
 
Medicines prescribed in accordance with the principles and theories of TCM are generally 
designated as Chinese Materia Medica (CMM). They consist mostly of plants, although 
animals and minerals can also be used with therapeutic purposes. Prescription and processing 
of CMM constitute unique and critical aspects in the application of TCM. Prescriptions 
usually consist of complex mixtures of multiple components, chosen based on differentiation 
of symptoms and signs including yin, yang, exterior, interior, cold, heat, deficiency, and 
excess. In such formulations the balance and interaction of all components are more 
important than the effect of any individual element [10,11]. Processing is a common practice 
in TCM, in which CMM are subjected to specific treatments before their use, with the aim of 
enhancing the efficacy and/or reducing the toxicity of crude drugs. These treatments can go 
from cleaning and cutting, to boiling, steaming, soaking in vinegar, frying, or roasting, 
among many others. Fifteen CMM processing methods have been clearly listed in the 
Chinese Pharmacopoeia (2010 edition), which also comprises the most commonly used TCM 
drugs, listed as i) materia medica and prepared slices of Chinese crude drugs, ii) vegetable 
oils, fats, and extracts, iii) patented prescriptions, and iv) single preparations. Information on 
purity standards, testing, dosage, precautions, storage, and strength is provided for each drug 
[12–14].  
 
Over the past two decades, governmental and non-governmental efforts within and outside 
China have been made to promote TCM practice, teaching, research, and development. As a 
result, new international organizations like the International Society for Chinese Medicine, 
the Modernized Chinese Medicine International Association, and the World Federation of 
Chinese Medicine Societies have been created. Existing organizations have also taken actions 
into the matter. In 2009, the International Organization for Standardization (ISO) set up 
specialized committees dedicated to TCM. In 2010, the WHO set up a program to standardize 
                                                      
2 Yin-Yang: In Chinese philosophy and religion there are two primal, opposite principles. One negative, dark, 
and feminine (yin) and one positive, bright, and masculine (yang). From their interaction, all things are produced 
and dissolved [10]. 
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terms used in TCM and its derivatives (e.g. the Japanese herbal medicine Kampo), aiming for 
the creation of an international platform to harmonize information exchange on traditional 
medicines. In 2011, the UNESCO inscribed Ben Cao Gang Mu (Compendium of Materia 
Medica) and Huang Di Nei Jing (Yellow Emperor’s Inner Cannon) in the Memory of the 
World Register [11].   
 
Herbal medicines: the quality issue 
Herbal medicinal products (HMPs) are widely used around the world, increasingly so in 
western nations. Although HMPs are considered to be safer than synthetic drugs, there has 
been more recognition of the potential risks associated with this type of products as their use 
increases. Potential harm can come from diverse sources, most of them involving purity and 
identity issues. Purity of HMPs may be compromised by the presence of dirt, pesticides, 
heavy metals, microorganisms or toxins, residual solvents, processing impurities, among 
others. Identity issues include species substitution, misidentification or adulteration with 
foreign plant material or synthetic drugs that resemble/mimic the expected action of a given 
HMP (e.g. addition of benzodiazepines to herbal sleep aids, sildenafil to herbal treatments of 
erectile dysfunction, etc.) [15,16]. 
 
In the case of herbs used in TCM, quality issues can arise from poor authentication of CMM 
due to similarities in nomenclature. Common Chinese names of CMM are often a source of 
confusion, since some herbs have more than one name and in occasions, these names are used 
for more than one herb. Even just similar common names can lead to misidentification and 
confusions as in the case of Panax notoginseng (Sanqi ) and Tupistra chinensis 
(Chuansanqi ). These two herbs are commonly confused, although they belong to 
different families and have different therapeutic effects [13,17]. A well known and tragic case 
of such confusion is the mistaken use of Aristolochia species as a substitute for herbs with 
similar common name in some slimming preparations, which resulted in the widely reported 
fatal incidents of “Aristolochic acid nephropathy” [15,18,19].  
 
Morphological similarities between herbal drugs, commonly consisting of dried or processed 
plant parts, can also be a source of confusion in authentication of CMM. In China, herb 
authentication in CMM markets is based on the macroscopic evaluation of properties such as 
shape, size, color, texture, odor, taste, and reaction to water and fire. Being the simplest and 
fastest method for CMM, authentication by macroscopic inspection relies solely on personal 
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experience and can be misleading, since organoleptic properties of herbs depend on a number 
of factors such as growing, harvesting, and processing conditions. Moreover, closely related 
herbal drugs (e.g. species from the same genus) can be hard to distinguish by the naked 
senses [20].  
 
An additional complication with quality and safety of Chinese herbs comes from CMM 
processing. Crude and processed forms of the same herb often have different properties and 
must be used as such. However, differently processed herbs can be misused as the same drug, 
resulting in treatment failure or even poisoning. A common example is the misuse of 
different forms of Semen Strychni, a CMM derived from the seeds of Strychnos nux-vomica. 
In this case, while the processed drug (Zhimaqianzi ) is used in the treatment of 
rheumatic conditions, while the crude seeds (Shengmaqianzi ) are highly toxic [12,13].  
 
Authentication and standardization of CMM are urgent tasks to ensure the safety and efficacy 
of their use. Macroscopic authentication must be confirmed by taxonomic, microscopic, and 
physicochemical analyses [13,17]. TLC and HPLC fingerprinting are the most widely used 
techniques in chemical authentication and have been adopted in many pharmacopoeias as 
identification methods [21–23]. Information obtained from chemical fingerprinting allows 
reliable confirmation of herb identity and detection of some non-chemically-related 
contaminants. Furthermore, the quality of different samples of the same herb can be assessed, 
based on the variable content of active or toxic constituents due to environmental, processing, 
and storage conditions [13].  
 
Genomic and metabolomic approaches are also being applied in the identification, 
authentication, and quality control of medicinal herbs. Metabolic fingerprinting allows 
differentiation between individual species of the same genus and identification of the exact 
geographic origin of certain species [15,24]. On the other hand, genetic tools provide highly 
reliable data for the authentication of herbs at the DNA level, which is particularly useful in 
the case of those herbs that are substituted or adulterated with morphologically and/or 
chemically similar material. DNA technology provides consistent results that do not depend 
on the age, tissue origin, physiological conditions, environmental factors, harvest, storage, or 
processing of the samples. With little amounts of sample, plants can be unequivocally 
identified up to their species, subspecies, and variety [25]. 
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International regulation and actions on herbal drugs 
Increasing discussions on the safety assessment of herbs used in both food and medicines 
around the world, have resulted in the development of protocols and guidance documents for 
the assurance of continuing quality of herbal drugs. Examples include the Dietary 
Supplement Health and Education Act (DSHEA) in United States, the Natural Health 
Products Regulations (NHPR) in Canada, and the Therapeutics Goods Act in Australia. In the 
European Union, the Committee on Herbal Medicinal Products (HMPC), part of the 
European Medicines Agency (EMEA), regulates the use of herbal medicines and publishes 
herbal monographs for quality control. The WHO has also published guidelines on the 
quality of HMPs, and specifications for the quality of a number of herbal drugs are set out in 
pharmacopeias such as the Unites States Pharmacopoeia (USP), the British Pharmacopoeia 
(BP), and the European Pharmacopoeia (EP) [15]. 
 
In the particular case of TCM, due to its globalized use, potential impact on healthcare, and 
opportunities for new drug development, special international actions have been started up. 
Two years ago, a new era for modernization of TCM was launched with the successful 
completion of the Good Practice in Traditional Chinese Medicine Research in the Post-
genomic Era (GP-TCM) project, under the European Union’s 7th Framework Program (FP7). 
This project brought together a large collaborative network of over 200 Chinese and 
European scientists, 107 institutions, and 24 countries to work on the analysis of current 
status, challenges, priorities, and future directions of TCM research. Multiple aspects were 
covered, i.e. quality control, toxicology, pharmacology, regulatory issues, and acupuncture 
and moxibustion. As a result of the three-year project, a series of guidelines and technical 
notes were developed for the harmonization of international TCM research through standard 
protocols and methodologies [11,26,27]. 
 
In April 2012, a consortium called GP-TCM Research Association was founded to develop, 
refine, and disseminate the results generated from the GP-TCM project. One essential point is 
the application of good practice in authentication, quality control, safety assessment, and 
sustainable use of TCM drugs. Likewise, agricultural, manufacturing, commercial, and 
clinical practices must incorporate good practices into their protocols and actions. Beyond 
quality assessment, efficacy and mechanistic studies have also been defined as priorities on 
TCM research. In this context, omics (genomics, proteomics, metabolomics, etc) and systems 
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biology technologies are expected to provide a more holistic approach to the study of 
complex TCM drugs [11,27,28]. 
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2.3. The GABAA receptor  
 
“(…) and if you take more of those, you will get an overdose. 
No more running for the shelter of a mother’s little helper. 
They just helped you on your way, through your busy dying day” 
 
The Rolling Stones about barbiturates in their song Mother’s little helper (1966) 
 
 
Definition and structural features of GABAA receptors 
Neuronal activity results from the interplay between synaptic excitation and inhibition. In the 
brain, excitation is mainly generated by the neurotransmitter glutamate, while inhibition is 
primarily produced by gamma-aminobutyric acid (GABA) [1], synthesized from glutamate 
by the enzyme glutamic acid decarboxylase [2]. Being the major inhibitory neurotransmitter 
in the central nervous system (CNS), GABA regulates many physiological and psychological 
processes through activation of ionotropic GABAA receptors (GABAARs) and metabotropic 
GABAB receptors (GABABRs), both of which are involved in the modulation of emotions, 
cognition, pain, and muscle tone. While GABABRs are G-protein-coupled receptors 
mediating slow inhibitory neurotransmission, GABAARs are chloride channels that mediate 
the major form of fast synaptic inhibition in the CNS3 [5–7]. GABA-induced activation of 
GABAARs triggers a conformational change in the protein and consequent opening of the ion 
channel [8], which results in increased chloride conductance, hyperpolarization of 
postsynaptic neurons, and subsequent inhibition of further action potentials. Therefore, 
impaired GABAergic neurotransmission is often associated with a number of CNS conditions 
like epilepsy, anxiety, mood disorders, and neurodevelopmental disorders such as autism and 
schizophrenia [9]. 
 
GABAARs belong to the gene superfamily of Cys-loop ligand-gated ion channels (LGICs), 
heteropentameric proteins that work as transducers of chemical messages into electric signals 
[8]. Receptor activation involves three major stages: agonist binding, transduction of the 
binding signal down the channel (coupling), and opening of the ion channel (gating) [10]. 
Five membrane-spanning subunits surround the central chloride-selective pore, each of them 
consisting of a large N-terminal extracellular hydrophilic domain, four transmembrane 
regions, and a relatively short extracellular C-terminal domain. The interface between 
                                                      
3 GABAARs are excitatory receptors in embryonic life and inhibitory in the developed nervous system [3]. This 
switch is essential for structural and functional maturation of neurons [4]. 
38
adjacent extracellular domains constitutes the neurotransmitter binding site, whereas the 
membrane-spanning domains form the ion channel (Figure 2.3) [2,10]. Nineteen different 
GABAAR subunit isoforms have been identified so far in mammals, and are divided into 
eight subunit families on the basis of their sequence homology (Figure 2.4): α1– 6, β1–3, γ1–3, δ, 
ε, θ, π, and ρ1– 3, the later of which can form homopentamers previously known as GABAC 
receptors4.  
 
 
 
 
 
 
 
 
Figure 2.3. Structure of the nicotinic acetylcholine receptor (nAChR) illustrates the general 
structure of Cys-loop receptors. Left: Side view of the receptor embedded in the cell membrane, 
showing extracellular and membrane-spanning domains. Right: View from the top of the receptor. 
The subunits are labeled according the GABAAR nomenclature and the most abundant receptor 
subtype is displayed. The approximate locations of the GABA and benzodiazepine (BZD) binding 
sites are noted (reproduced from D’Hulst et al., 2009 [2]). 
 
 
Different subunit combinations result in a large number of structurally and functionally 
distinct GABAAR subtypes. Furthermore, structural diversity is increased by the alternative 
exon splicing of some receptor subunits, primarily γ2 and β2. However, despite the vast 
potential for receptor diversity, only 11 subtypes have been identified as reasonably abundant 
in the brain and 15 more subtypes are likely to exist although to a much lesser extent 
[5,11,12]. Explanations include differential gene expression by specific neuronal subtypes, 
preferential co-assembly of particular subunits [13], and receptor trafficking regulation5 [4].  
 
The nature, stoichiometry, arrangement, and localization of the subunits involved determine 
the biophysical and pharmacological profile of the assembled receptor [2,5,9]. GABAARs 
                                                      
4 GABACRs were originally described based on their distinctive pharmacology. However, they are now 
designated as part of the GABAAR family and therefore, the use of this nomenclature is discouraged [5].  
 
5 GABAARs are assembled in the endoplasmic reticulum (ER). Misfolded or in any way immature receptors 
cannot exit the ER and are subsequently degraded in a proteasome. Only a limited number of the theoretically 
possible subunit combinations can actually reach the neuronal cell surface. [11]. 
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with stoichiometry 2α:2β:1γ are predominant in the brain [5,14], and show the concatenation 
pattern α-β-α-γ-β [15]. This arrangement provides two GABA-binding sites at the β-α 
interfaces, normally containing β2 or β3 subunits, and a benzodiazepine (BZD) binding site at 
the α-γ interface, most commonly comprising γ2 and α1, α2, α3, or α5. Approximately 60% of 
all GABAARs have the subunit combination α1β2γ2. Following in abundance are the receptor 
subtypes α2β3γ2 (15-20% approx), α3βnγ2 (10-15% approx), and α4βnγ or α4βnδ (5% approx). 
Other combinations such as α5β2γ2 and α6β2/3γ2 constitute less than 5% of the total GABAARs 
in the CNS [14,15].    
 
 
 
 
 
Figure 2.4. Dendrogram of the 19 genes for human 
GABAARs. Distances along each line are 
proportional to the degree of sequence identity 
between homologous subunits. Greek letters 
designate subunit families of high (>70%) identity. 
The scale bar corresponds to 20% sequence 
divergence (reproduced from Simon et al., 2004 
[16]). 
 
 
 
 
 
 
According to the PDB (Protein Data Bank) website, to date there is no available high-
resolution structure of the GABAAR [17]. Electron micrographs of nAChRs in the electric 
ray Torpedo marmorata, members of the same gene superfamily, have provided the most 
complete structure of a Cys-loop receptor so far [10]. Although structural information of 
GABAAR is much less complete, homology in topography and structure of the functional 
domain allows comparative modeling of the binding sites of GABAAR based on the nAChR 
structure [15,18]. However, low sequence identity between target (GABAAR) and template 
(nAChR) can result in potential inaccuracy and uncertainty of such models, limiting rational 
drug design of GABAAR ligands [19,20]. 
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Pharmacology of GABAA receptors 
GABAARs serve as molecular target for a number of drugs, used both clinically and as 
research tools. The list of chemically diverse GABAAR ligands includes agonists like 
muscimol, antagonists like bicuculline, channel blockers like picrotoxin, and receptor 
modulators such as BZDs, non-benzodiazepines, barbiturates, neurosteroids, ethanol, and 
some general anesthetics like etomidate and propofol (Figure 2.5) [2,5,18].  
 
Figure 2.5. Examples of GABAAR ligands. Compounds binding at the α-β interface can be direct 
agonists (e.g. muscimol) or direct antagonists (e.g. bicuculline). Compounds binding at the α-γ 
interface are allosteric modulators. This modulation, achieved by stabilizing different 
conformations of the receptor, can be positive, negative, or neutral. Positive and negative allosteric 
modulators (also referred as BZD-site agonists and inverse agonists, respectively) enhance or 
reduce the GABA-induced chloride ion influx. Neutral allosteric modulators (or BZD-site 
antagonists) do not influence the chloride influx but are able to competitively inhibit the action of 
positive and negative allosteric modulators. Prototypic examples for positive, negative, and neutral 
GABAAR allosteric modulators are diazepam, β-CCM (methyl β-carboline-carboxylate), and 
flumazenil, respectively [5,12,14]. Picrotoxin is a channel blocker. The binding sites for other 
ligands like barbiturates, general anesthetics, and neurosteroids have not been identified yet 
[12,21,22].  
 
 
The interaction of BZDs with GABAARs has been most extensively investigated [18]. Unlike 
barbiturates, BZDs are allosteric modulators of GABAARs. They mediate their actions via an 
alternative binding site also known as BZD binding site. Consequently, they do not activate 
the receptors in the absence of GABA and thus, modulation is self-limiting: the conductance 
of the channel in the presence of GABA and BZDs is never higher than the conductance 
induced by GABA alone [14]. BZDs have been prescribed since 1960, when 
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chlordiazepoxide (Librium®) was first introduced. Due to their improved therapeutic index 
over barbiturates, they became the most prescribed drugs in the 1960s and 70s [23]. A 
number of clinical uses have been approved for BZDs, including the treatment of sleep 
disturbances, anxiety disorders, epilepsy, and muscular spasms [12]. However, as a 
consequence of non-selective binding to GABAARs containing α1, α2, α3, or α5 subunits, 
these pharmacological effects are not clearly separated by dosing and thus, BZDs induce a 
number of side effects including residual sedation, anterograde amnesia, tolerance, physical 
dependence, and addiction liability [14]. 
 
BZDs have been used as research tools to elucidate the functions of individual GABAAR 
subtypes in mutated mouse lines, in which specific receptors have been rendered insensitive 
to diazepam (Figure 2.6). Histidine-to-arginine point mutations at a conserved residue of 
subunits α1, α2, α3, and α5 abolish binding of diazepam, whereas the action of the 
physiological neurotransmitter GABA is preserved [14]. Comparison of diazepam-induced 
behavioral responses in the mutated and wild-type mice, have revealed that BZD-induced 
sedation, anterograde amnesia, and anticonvulsant effects are mediated by α1-containing 
GABAARs, while receptors with α2 mediate the anxiolytic action and to a large degree the 
myorelaxant effects. Subunits α3 and α5 are also involved in myorelaxant action of BZDs 
[18,21]. The addictive properties of BZDs have been correlated to α1-containing GABAARs 
by a mechanism that involves changes in synaptic plasticity of dopaminergic neurons at the 
brain’s VTA (ventral tegmental area) [12]. The development of tolerance to the sedative 
properties of diazepam has been associated with α1 and α5 subunits, which explains why the 
partially selective hypnotic Zolpidem (which does not bind to the α5-containing GABAAR) 
shows less dependence liability than non-selective BZDs [23]. 
   
 The identification of physiological and pharmacological functions of GABAAR subtypes 
defined by their α subunit composition has renewed the interest in the target for the 
development of drugs with improved therapeutic profile over BZDs. A number of compounds 
with receptor subtype selectivity have been identified and evaluated in preclinical and clinical 
studies. However, further development of such compounds has stopped due to unfavorable 
pharmacokinetic properties or toxicity issues [14,24]. Non-benzodiazepines (also known as 
Z-drugs) like zolpidem, zaleplon, and zopiclone, are the only GABAAR modulators on the 
market with preferential binding to α1-containing receptors [25]. However, BZD-like side 
effects are still being reported for these drugs [26]. 
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Figure 2.6. Pharmacological effects and distribution of GABAAR α subunits in the mouse brain. 
The pie chart represents the approximate abundance of GABAAR subtypes that are known to exist 
in vivo. α1 is expressed in cortex, thalamus, pallidum, and hippocampus. α2 is expressed in 
hippocampus, cortex, striatum, and nucleus accumbens. α3 occurs in the cortex and the reticular 
nucleus of the thalamus, and α5 in the hippocampus and deep layers of the cortex (adapted from 
Rudolph and Knoflach, 2011 [14]). 
 
 
GABAA receptor modulators: current challenges and perspectives 
GABAAR ligands are well known agents in the history of neuropharmacology. It all began in 
1911, when barbiturates hit the market with Bayer’s Veronal® (barbital) and Luminal® 
(phenobarbital). Barbiturates were extensively used as sedative/hypnotic, antiepileptic, and 
anesthetic drugs until the end of the 1950s [27], when it became evident that high doses of 
barbiturates lead to pulmonary arrest and death, outcomes that gained further notoriety with 
the deaths of celebrities like Marilyn Monroe and Jimi Hendrix. The 1960s brought new hope 
with the introduction of the much safer BZDs, but they too fell out of favor when long-term 
treatments induced residual sedation, memory impairment, and addiction. Z-drugs came into 
the picture in the 1990s and have been the hypnotics of choice ever since. However, despite 
their improved therapeutic profile and partial receptor selectivity, complications such as 
dependence and “confusional arousals” are still reported [26,28]. 
 
Recurrent failure in the development of subtype selective GABAAR modulators seems to 
have discouraged pharmaceutical companies from the search of new GABAergic drugs [24]. 
However, it appears that the problems observed during preclinical and clinical studies are 
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unrelated to the mechanism of the developed leads and thus, further efforts should be directed 
towards improving the pharmacokinetics and toxicity of such compounds [12].  
 
In the absence of receptor-selective GABAAR modulators, new targets are now being 
explored. Serotonin (5-HT), neuropeptide, glutamate, and endocannabinoid systems stand 
now as the principal focus of anxiolytic drug discovery research [24]. On the other hand, dual 
orexin receptor antagonists (DORAs) are rendering promising results in the management of 
insomnia with a better safety profile [26]. Suvorexant, an orexin receptor-antagonist, was 
submitted by Merck & Co. for US FDA approval in 2012 [28]. Approval still depends on the 
results of further safety and manufacturing studies requested by the FDA in 2013. If 
approved, this would be the first DORA in the market for the treatment of insomnia [29]. 
Nevertheless, GABAARs remain an important target in the development of improved 
therapeutics for the management of anxiety, epilepsy, insomnia, and cognitive disorders 
[3,19]. Moreover, the identification of separable key functions of particular GABAAR 
subtypes has provided valuable information about novel possible indications of GABAAR 
modulators, such as chronic pain, depression, schizophrenia, and stroke [14]. Although the 
complexity and large structural diversity of GABAARs poses a challenge to drug 
development, it offers plenty of possibilities for fine tuned pharmacological interventions 
[19]. Further efforts must be directed to the elucidation of the structure of GABAARs. 
Together with functional studies, it would provide a clearer picture of the role of these 
receptors in neurotransmission and the way structural variations between receptor subtypes 
impart their unique characteristics, facilitating the design of novel and improved therapeutics 
for the treatment of neurological disorders [10]. 
 
In vitro assessment of GABAergic activity: two-microelectrode voltage-clamp assay 
Measurement of ion influx across the cell membrane can be achieved using several 
techniques such as radioactivity-based ion influx assays, fluorescence-based assays, or 
microphysiometry studies. However, these techniques do not allow the membrane potential to 
be controlled. As a consequence, the electrochemical gradients that drive the flow through 
ion channels can get disrupted, leading to false readouts. Further disadvantages of these 
methods include artifact formation during fluorescence measurements and accumulation of 
ligands in the cells due to the lack of continuous perfusion systems [30,31]. 
 
44
Electrophysiological techniques offer a better alternative for the study of ion channels. In this 
case, electrical changes upon receptor activation are measured directly and quantitatively 
while the membrane potential is controlled (i.e. clamped). Automated patch-clamp systems 
demand stable cell lines expressing the target of interest and highly specialized consumables, 
which makes them time-consuming and labor-intensive techniques for electrophysiological 
measurements. The more flexible two-electrode voltage-clamp (TEVC) technique, a robust 
electrophysiological technique using Xenopus oocytes for expression of the target of interest, 
in this case GABAARs, circumvents some of the disadvantages of the automated patch-clamp 
systems. In this method, cell membrane is clamped at a fixed value and the whole cell 
currents produced in response to receptor activation are measured in terms of the current 
required to maintain the voltage clamp. Two electrodes, one controlling membrane potential 
(VE) and one measuring the current (CE), impale the oocyte during the experiments. By 
means of a feedback system, the CE provides the current needed to maintain membrane 
potential. The current flowing though the CE provides a measurement of the current flowing 
though the ion channels (Figure 2.7) [31,32].   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7. Schematic representation of the TVEC recordings workflow using Xenopus oocytes, 
for the study of ion channels. Oocytes are surgically removed from adult female Xenopus laevis, 
defolliculated by enzymatic means, and injected with cRNA (transcripted from cDNA) of the 
desired receptor subunits. Incubation allows expression of the molecular target. The oocytes with 
the expressed receptors are used for TEVC recordings (reproduced from Kvist et al. 2011[31]) 
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Xenopus oocytes, the immature egg cells of the South African clawed frog Xenopus laevis, 
are a reliable and powerful system for the transient expression of multi-subunit proteins 
derived from exogenously introduced RNA or DNA. These cells are easy to handle due to 
their robustness and large size (1 – 1.2 mm diameter), which make them tolerant to repeated 
impalement with RNA injection pipettes and microelectrodes used in electrophysiological 
techniques (Figure 2.8). The relative scarcity of endogenous ion channels in the oocyte 
membrane makes it a versatile tool for the study of a wide range of ion channel proteins, 
including members of the LGIC family such as GABAARs .  
 
 
 
 
 
 
 
 
 
Figure 2.8. Photograph of a Xenopus oocyte impaled during TEVC recordings (Picture D. Rueda, 
Vienna) 
 
 
Activation and gating of ligand-gated ion channels is characterized by complex kinetics. Fast 
(“concentration jump”) application of neurotransmitter or drug samples during TEVC 
experiments is crucial for screening on GABAAR. Slow perfusion rates and consequent slow 
sample application leads to slow channel activation and substantial receptor desensitization 
during chamber perfusion. As a result, peak current values induced by neurotransmitters or 
drugs may be underestimated. Therefore, fast perfusion of oocytes is key for the acquisition 
of reproducible data with the TEVC technique. In order to fulfill these conditions and 
standardize drug application to the oocytes, a medium-throughput automated system for fast 
perfusion has been implemented by Professor Hering and coworkers at the University of 
Vienna. In this optimized system, the oocytes are placed in a small bath chamber and 
perfused in a vertical direction at a very fast rate (up to 600 µL/s), while compound delivery 
is controlled by a programmable pipetting workstation. Figure 2.9 provides detailed 
descriptions of the system [33]. 
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Figure 2.9. Cross-section view (a) and top view (b) of the oocyte perfusion chamber of the 
automated two- microelectrode voltage clamp assay as implemented by the Hering group in 
Vienna [33]. Two microelectrodes (1 and 2) are inserted via the sloping access inlets (8) through a 
glass cover plate (7) into the small (∼ 15 µL) oocyte chamber (c). Samples are applied by the tip of 
an automated liquid handling arm (3) to a funnel reservoir made of quartz (6) surrounding the 
microelectrode access holes. Perfusion of the oocyte (10) that is placed on a cylindrical holding 
device (15) is enabled by means of the syringe pump (9) connected to the chamber body (11) via 
the outlet (12). Residual solution is removed from the funnel before drug application via the funnel 
outlets (4 and 5). In addition to the ground reference electrode (13), the cylindrical holder for the 
oocyte contains a reference electrode (14) that serves as an extracellular reference for the potential 
electrode. Salt bridges can be inserted into the side outlet for the ground electrode (13). (c) 
Schematic drawing of the solution flow inside the perfusion chamber and in the annular gap 
around the cylinder with oocyte. (d) Photo of the oocyte perfusion chamber. An oocyte (10) is 
placed on a cylinder and impaled with two microelectrodes (1,2) surrounded by the funnel (6) 
(reproduced from Baburin et al. 2006 [33]). 
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2.4. GABAA receptor modulators of natural origin: structural and 
physicochemical considerations 
 
Structural scaffolds for GABAA receptor modulators from nature  
Plant secondary metabolites are produced as the result of the interaction of plants with their 
surrounding environment. Some of these compounds are used to attract pollinating insects, 
provide defense against natural predators or pathogens, or control signaling processes. 
However, the functions of this sophisticated chemical arsenal are more complex and have not 
been fully elucidated yet. The biosynthetic pathways for the production of these compounds 
are often long and involve complex enzymatic reactions. Owing to the interaction with their 
biosynthetic enzymes, plant secondary metabolites possess the inherent ability to recognize 
and interact with protein surfaces, which allows them to act on animal targets such as 
cholinergic, adrenergic, dopaminergic, or GABAergic systems [1,2]. 
 
In recent years, a large number of NPs have been identified as GABAAR ligands. In fact, 
many of the compounds first used to study GABAARs are plant secondary metabolites. The 
list includes the receptor antagonist bicuculline (from Dicentra cucullaria), the agonist 
muscimol (from Amanita muscaria), and the channel blocker picrotoxin (from Anamirta 
cocculus) (Figure 2.10) [3]. NPs with GABAergic activity belong mainly to the flavonoid, 
terpenoid, and alkaloid families, according to a compilation of plant-derived GABAAR 
modulators provided by Zaugg in 2011 [4]. Some new natural scaffolds have been reported in 
the period 2011-2014, including lignans and piperamides. An overview of the diverse natural 
scaffolds for GABAARs is provided in the next sections. 
 
 
 
 
 
 
Figure 2.10. Natural products used for the study of GABAARs, with no clinical application. An 
equimolar mixture of the sesquiterpene lactones picrotoxinin and picrotin constitutes the 
convulsant terpenoid picrotoxin [4]. 
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i) Flavonoids 
Among all plant-derived GABAAR modulators, flavonoids have been the most thoroughly 
studied. A number of flavones (e.g. chrysin, ororylin A, quercetin, and apigenin) and 
biflavones (e.g. amentoflavone), have been reported to modulate GABAARs via the BZD-
binding site [5]. Structure-activity relationship (SAR) studies on the flavonoid scaffold have 
revealed that substitution at the 6- and/or 3’- positions with electronegative moieties 
increases affinity towards the BZD-binding site of GABAARs, which has led to the synthesis 
of high-affinity derivatives such as 6,3’-dinitroflavone. The relatively rigid structure of 
flavonoids makes them valuable scaffolds for medicinal chemistry. Combinatorial libraries 
have yielded flavones acting as BZD-site agonists (e.g. 6-bromoflavone) and antagonists 
(e.g. 6-chloro-3’-nitroflavone) [6]. Recent studies have identified flavonoids with partially 
selective GABAAR modulatory activity (e.g. 6-hydroxyflavone, 3-hydroxy-2’-methoxy-6-
methylflavone), showing significant preference for α2 or α4-containing receptors [7]. In vitro 
and in vivo studies on the mechanism for GABAAR modulation have revealed that certain 
flavonoids like apigenin and quercetin are able to enhance the actions of other GABAAR 
modulators such as diazepam, through an alternative modulatory mechanism called second 
order modulation or metamodulation. An alternative low-affinity flumazenil-insensitive 
binding site has been suggested to be involved in this mechanism [3]. The structures of some 
representative flavonoids are displayed in Figure 2.11. 
 
 
 
 
 
Figure 2.11. GABAAR modulators with flavonoid scaffold. 
 
ii) Isoflavones 
Although biogenetically related to flavonoids, isoflavonoids constitute a distinctly separate 
class of secondary metabolites, differing by the position of the phenolic ring B [8]. 
Isoflavones, the main subclass among isoflavonoids, had been associated with GABAARs 
ever since some of them were found to displace [3H] diazepam binding in rat brain 
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membranes [9]. However, it was only until 2011 that they were reported as positive 
GABAAR modulators by Gavande et al. [10], as a result of a study on a series of synthetic 
isoflavone derivatives. The study, conducted in Xenopus oocytes expressing receptors of the 
subtype α1β2γ2L, showed that modulation of GABAARs by isoflavones is flumazenil-
insensitive, suggesting that these compounds might not bind the BZD-site. Figure 2.12 
displays the most potent isoflavones of this report, with potencies ranging from 9 to 16 µM 
and efficiencies between 250 and 1079%.  
 
 
 
 
 
 
Figure 2.12. GABAAR modulators with isoflavone scaffold. 
 
iii) Terpenoids 
Diverse scaffolds for GABAAR modulators have been identified among terpenoids. Aside 
from picrotoxin (Figure 2.10), the sesquiterpene valerenic acid is a well known example. It 
has been described as a partially specific GABAAR modulator with preference for β2/3–
containing receptors, able to induce anxiolytic-like effects in mice. Valerenic acid served as a 
scaffold for medicinal chemistry to develop derivatives with enhanced GABAergic activity 
[11,12]. 
 
Among diterpenes, miltirone from the Chinese herb Salvia miltiorrhiza has been reported to 
induce anxiolytic-like behavior in animal models, although the mechanism on GABAARs 
remains unclear [4]. Two new diterpene scaffolds for GABAAR modulators have been 
recently identified: pimarane and labdane diterpenes. Zerumin A, a labdane diterpene from 
Curcuma kwangsiensis, showed positive GABAAR modulatory activity in receptors of the 
subtype α1β2γ2S expressed in Xenopus oocytes [13]. Pimarane diterpenes are exemplified by 
sandaracopimaric acid from Biota orientalis, which showed non-selective positive 
GABAAR modulatory activity in Xenopus oocytes expressing different receptors subtypes. 
The modulatory activity of sandaracopimaric acid was not affected by the absence of γ 
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subunit in the receptors, which indicates that the compound interacts with a non-BZD binding 
site. In behavioral experiments using mice, the compound reduced the locomotor activity 
[14]. The structures of some relevant terpenoids with GABAergic properties are displayed in 
Figure 2.13. 
          
Figure 2.13. GABAAR modulators with terpenoid scaffold. 
 
iv) Alkaloids 
In contrast to the nitrogen-bearing BZDs or nonbenzodiazepines, most natural alkaloids with 
identified GABAergic activity are direct antagonists of GABAARs and therefore, possess 
convulsant properties. It is the case of bicuculline (Figure 2.10), which is devoid of clinical 
application and used only in basic research on GABAARs. Alkaloids of the β-carboline type 
such as harmane have been found to act as full, partial or mixed agonists, antagonists, or 
inverse antagonists at the GABAA receptor. The β-carboline scaffold has been used for the 
development of anxiolytic compounds [4].  
 
Recently, a new alkaloid scaffold was reported by Zaugg et al. [15]. By means of an HPLC-
based activity profiling approach, piperine, isolated from Piper nigrum, was identified as a 
positive allosteric GABAAR modulator targeting a BZD-independent site. Structurally related 
piperamides such as trichostachine and piperlonguminine, isolated along with piperine, were 
inactive in the oocyte assay, suggesting that the piperidine ring is essential for the activity of 
piperamides. However, Khom et al. [16] reported SCT-66, a piperine derivative in which the 
piperidine ring has been replaced with a N,N-diisobutyl residue, as a GABAAR modulator 
with enhanced in vitro and in vivo activity over piperine. Both piperine and SCT-66 induce 
anxiolytic-like effects in rodent models. The structures of some representative piperamides 
are displayed in figure 2.14. 
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 Figure 2.14. GABAAR modulators with piperamide scaffold. 
 
v) Lignans 
The neolignans honokiol and magnolol from Magnolia officinalis have been shown to act as 
partially selective GABAAR modulators in binding studies, and have been used in medicinal 
chemistry to study the potential role of the acetamido group in subunit-dependent receptor 
modulation. Animal behavior models have revealed that honokiol induces anxiolytic-like 
effects after oral administration [17]. Lignans such as arisantetralones A-D and acyclic 
lignans like saururenin were recently identified as GABAAR modulators with comparative 
potency in receptors of the subtype α1β2γ2S. Arisantetralones showed a mechanism of action 
that combines partial agonistic activity, positive modulation, and possibly channel block at 
high concentrations [18]. Figure 2.15 displays the structures of some lignans with 
GABAergic properties. 
 
 
 
 
 
Figure 2.15. GABAAR modulators with lignan scaffold. 
 
Reaching the target: “drug-likeness” and permeation of blood-brain barrier 
In addition to high potency and selectivity towards the biological target, any drug candidate 
must be able to reach the target tissue in sufficient concentration to achieve therapeutic 
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efficacy. ADME properties play a pivotal role in defining the availability of a molecule to 
reach the target in vivo. The recognition that poor ADME properties are one of the major 
reasons for the failure of drug candidates in the pre-clinical or clinical phases of development 
has driven a revolution in drug discovery research in the last decades. From the mid-1990s, a 
battery of in vitro ADME screens was implemented almost universally in research programs 
for the screening of intestinal absorption and metabolic stability. In parallel to these in vitro 
technologies, considerable efforts were also invested in the development of computational (or 
in silico) approaches to the prediction of ADME properties [19,20]. 
 
Owing to the preference for oral administration, much of the attention of both in vitro and in 
silico approaches is focused on the prediction of a compound’s intestinal absorption and 
tissue distribution. However, an additional kinetic process, i.e. blood-brain barrier (BBB) 
penetration, comes into play when designing CNS drugs [19,20]. A brief description of the 
general requirements for oral absorption and BBB permeation of drugs is provided here. 
 
i) Oral absorption 
The ability of drugs to cross the gastrointestinal epithelium is conditioned by specific 
physicochemical properties such as molecular size, charge, hydrogen-bonding potential, and 
lipophilicity [21].  
 
After analyzing the calculated physicochemical properties of several thousands of clinical 
candidates reaching Phase II trials (or further), in 1997 Lipinski et al. [22] came up with a 
series of parameters to predict a compound’s likelihood of undergoing oral absorption 
(considering solubility and permeability as the only factors affecting oral bioavailability of 
drugs). The Rule of 5 (RO5), as the group of parameters is called, establishes that good 
absorption or permeability are more likely when  
- Number of H-bond donors (expressed as the sum of OHs and NHs) < 5 
- cLogP (calculated 1-octanol – water partition coefficient) < 5 
- Molecular weight < 500 Da 
- Number of H-bond acceptors (expressed as the sum of Ns and Os) < 10 
 
In general, the RO5 properties are interrelated and thus, if two of them are out of the range, 
poor oral absorption can be expected. Although some orally active drugs lie outside the 
parameter cutoffs in the rule (i.e. antibiotics, antifungals, vitamins, and cardiac glycosides), 
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90% of orally active drugs that have achieved phase II clinical status comply with these rules. 
Thus, compounds with physicochemical properties among the ranges dictated by the RO5 are 
considered drug-like molecules [22].  
 
However, passing the RO5 does not ensure drug-likeness. On the one hand, the RO5 says 
nothing about structural features defining drugs or non-drugs. Molecular flexibility for 
example, has been found to influence oral absorption, with more than 10 rotable bonds 
decreasing oral bioavailability. On the other hand, the meaning of drug-like is dependent on 
the administration route and target location. For instance, the number of H-bond acceptors (N 
+ O atoms) for oral drugs intended to act at the CNS must be less than or equal to 5, instead 
of 10 [23,24].  
 
ii) Blood-brain barrier permeation 
The BBB is a dynamic and complex interface that strictly controls the exchanges between 
bloodstream and brain. It is composed of brain capillary microvascular endothelial cells, 
supported by other cell types such as pericytes, astrocytes, and neurons (Figure 2.16). Brain 
microvascular endothelial cells form a tightly sealed monolayer, characterized by the absence 
of fenestrations, a low number of pinocytic vesicles, high metabolic activity, and complex 
tight junctions between adjacent endothelial cells. Altogether, the BBB acts as a physical and 
metabolic barrier that maintains homeostasis in the brain and protects it from xenobiotics, 
neurotoxic metabolites, and pathogens circulating in the bloodstream [5,25,26]. 
 
 
 
 
 
 
 
 
Figure 2.16. Schematic representation the BBB, showing the main cell types. Pericytes are 
enclosed within the endothelial basal lamina and form the closest associations with the 
endothelium. The endfeet of astrocytic glial cells are placed in the outer surface of the basal lamina 
(reproduced from Abbott et al., 2006 [27]) 
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Despite the relative impermeability of the BBB, a number of specific transport processes 
occur across the barrier, primarily aimed to transport polar nutrients into the brain and to 
excrete waste products and potential toxicants out of the CNS. Due to the tight junctions 
between endothelial cells, most molecular traffic across the BBB occurs through transcellular 
mechanisms, namely i) passive diffusion, ii) carrier-mediated uptake, iii) endocytosis, and iv) 
active efflux (Figure 2.17). Small gaseous molecules such as O2 and CO2 can diffuse freely 
through the lipid membranes of endothelial cells, which is also the route of access for small 
lipophilic agents including drugs like barbiturates and ethanol. The transcellular traffic of 
essential polar nutrients is regulated by carrier systems which are specific for small peptides, 
hexoses, monocarboxylic acids, amino acids, neurotransmitters, and organic ions. Such 
transporters can be uni- or bidirectional, making it possible for certain molecules to go into or 
out of the brain depending on the concentration gradient across the BBB. Endocytosis, which 
occurs via receptor-mediated or adsorptive processes, is the main route of access for high-
molecular weight molecules (e.g. peptides and proteins) into the brain. Alternatively, 
molecules can be pumped back from the brain into the blood by an active transfer process, 
mainly through p-glycoprotein, using an ATP efflux mechanism [27–29]. 
 
It has been estimated that 98% of all small molecules are not able to cross the BBB. Hence, 
BBB permeation is a major challenge in the development of drugs acting in the CNS, where 
penetration into the brain is essential to achieve therapeutic effects, except for those drugs 
intended to be delivered by invasive or intranasal routes [20,25,28]. In early drug discovery 
and development, NCEs are now screened for their ability to cross the BBB. For this purpose, 
a wide range of in silico, in vivo (e.g. in situ brain perfusion), and cell-based in vitro BBB 
models for early prediction of brain permeability of compounds have been developed and 
established [25]. In silico prediction methods are typically based on in vivo experimental 
data. The increasing computational possibilities and development of sophisticated modeling 
algorithms have resulted in accurate prediction of BBB permeability. In general, such 
predictions seem to correlate well with brain drug penetration in vivo. However, 
computational approaches are only able to predict passive permeation across the BBB [26].  
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Figure 2.17. Molecular traffic across the BBB. (a) Polar solute transport is severely restricted by 
tight junctions. (b) Lipophilic or amphiphilic solutes may passively diffuse through the large 
surface of the lipid cell membrane. (c) Many essential polar molecules (e.g. glucose) can be can be 
transported into the CNS via carrier-mediated uptake. Active efflux carriers may intercept some of 
these molecules (e.g. Cyclosporin A and Vinca alkaloids) and pump them out of the endothelial 
cells. (d) Receptor-mediated transcytosis can transport macromolecules such as proteins and 
particles across the endothelium (e.g. insulin, cytokines, and viruses such as Herpes simplex). (e) 
Adsorptive transcytosis appears to be nonspecifically induced by positively charged 
macromolecules. Most CNS active agents enter via route (b) (reproduced from Lalatsa et al., 2011 
[28]).  
 
 
Computational quantitative SAR (QSAR) studies on CNS drugs such as BZDs, barbiturates, 
and anesthetics, have revealed that lipophilicity, molecular weight, hydrogen bonding, polar 
surface area (PSA), molecular flexibility, and molecular charge determine diffusion of small 
molecules across the BBB. In addition to these physicochemical features, some 
pharmacokinetic properties such as metabolic stability, oral absorption, and protein binding 
determine the success of BBB permeation, by affecting the concentration at which drugs 
reach the barrier. In short, for a drug to be able to cross the BBB and hence to elicit 
therapeutic effects, it should possess the following attributes [19,20,28]: 
- Potent activity 
- High selectivity 
- Molecular weight < 450 Da 
- Minimal hydrophobicity (cLogP) < 5 
- Number of H-bond donor < 3 
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- Number of H-bond acceptor < 7 
- Number of rotable bonds < 8 
- PSA < 90 Å2 
- pKa 7.5-10.5 (neutral or basic nature) 
- Metabolic stability, with > 80% remaining after 1 h 
- P450 enzyme inhibition > 50% at 30 µM 
- Low CYP2D6 metabolism 
- Low CYP3A4 inducing properties 
- Low affinity for serum albumin (Kd < 10 µM) 
- Aqueous solubility > 60 µg/mL 
- Intestinal permeability > 1 × 10-6 cm/sec 
 
In general terms, compared to non-CNS drugs, CNS drugs tend to be more lipophilic, less 
polar (decreased hydrogen bonding and lower PSA), more rigid (reduced number of rotable 
bonds), and smaller (lower molecular weight). 
 
Pharmacokinetics of GABAA receptor modulators from nature 
Pharmacokinetic studies on most plant-derived scaffolds for GABAAR modulators are rather 
limited. Sandaracopimaric acid and piperine have shown CNS effects in rodent models, but 
their pharmacokinetic behavior has not been studied yet. Recent in vivo studies on valerenic 
acid have revealed that this compound possesses reasonably good oral bioavailability 
(33.7%), fast tissue distribution (half-life 6-12 min), and slow elimination (half-life 6-46 h) in 
rats [30]. In the course of in vitro studies, valerenic acid has shown BBB permeation [31]. 
However, BBB penetration of valerenic acid remains to be confirmed in animal models [30].  
 
Numerous in vitro and in vivo studies have demonstrated that flavonoids are able to cross 
gastrointestinal and blood-brain barriers [29,32,33]. Most flavonoids are usually present in 
plants as glycosides. Prior to absorption into systemic circulation, flavonoids undergo 
deglycosylation in the intestinal lumen, which is mainly mediated by the enzymes lactase, 
phloridzin hydrolase, and β-glucosidase. After deglycosylation, aglycones can passively 
diffuse across the intestinal membrane, from the intestinal lumen to the bloodstream. Once 
absorbed, the flavonoid aglycones are subjected to three main types of conjugation: 
methylation, sulfation, and glucuronidation. Thus, flavonoids are present in the plasma 
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almost exclusively in a conjugated form [5,34]. 
 
Flavonoids, both as aglycones and in the conjugated form, cross the BBB. During 
permeation, conjugates may be metabolized back to the parent aglycones, which then enter 
the CNS. In the brain, flavonoids act on different systems such as GABAA or 5-HT receptors, 
thus exerting sedative, anxiolytic, anticonvulsant, antidepressant, or neuroprotective effects, 
among others [5]. 
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3.1. Discovery of GABAA receptor modulator aristolactone in a commercial 
sample of the Chinese herbal drug “Chaihu” (Bupleurum chinense roots) 
unravels adulteration by nephrotoxic Aristolochia manshuriensis roots 
 
Diana C. Rueda, Janine Zaugg, Melanie Quitschau, Eike Reich, Steffen Hering, and Matthias 
Hamburger. Planta Med 2012; 78: 207 – 210 (doi: 10.1055/s-0031-1298171) 
 
 
 
 
 
 
 
 
 
 
The germacranolide aristolactone, isolated from a commercial sample of the traditional 
Chinese herbal drug Chaihu (Bupleurum chinense DC. roots), was identified as a low-
potency GABAA receptor modulator by HPLC-based activity profiling coupled with a 
functional assay in Xenopus oocytes. However, the presence of aristolactone in the sample 
suggested possible adulteration with Aristolochia species. The commercial sample of Chaihu 
was proved to be adulterated with roots of the nephrotoxic herb Aristolochia manshuriensis, 
using a validated HPTLC protocol for detection of aristolochic acids and macroscopic 
inspection of the drug. 
 
 
 
Extraction of the plant material for isolation, HPLC-based activity profiling, isolation of 
aristolactone, bioactivity assessment of fractions and aristolactone in Xenopus oocytes, 
oocyte preparation, recording and interpretation of analytical data for structure elucidation 
(UV, HRMS, NMR spectra), writing of the manuscript draft, and preparation of the figures 
(except for Figure 3) were my contributions to this publication. NRM analysis was assisted 
by M. Quitschau. TLC analyses were performed at CAMAG laboratory, under the 
supervision of E. Reich. 
Diana C. Rueda 
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bChinese Materia Medica (CMM) is a general termcovering medicines, mostly of botanical origin,prescribed in accordance with the principles andtheories of traditional Chinese medicine (TCM)[1,2]. In recent years, the use of CMM has enor-mously increased worldwide, and so has the in-ternational attention regarding its safe and effec-tive use [2–4]. Similarities in morphology and no-menclature can lead tomisidentification and con-
fusion [2,5], which may result in poisoning inci-
dents. A case in point has been the aristolochic ac-
id (AA) nephropathy caused by a slimming tea
which contained Aristolochia due to mistaken
identity of CMM, and consequent misuse of Aris-
tolochia species in some herbal preparations [2,
5–8]. Aristolochia species (Aristolochiaceae) have
been used in TCM as anti-inflammatory herbs.
However, their use is no longer permitted in
many countries due to their content of AA shown
to be nephrotoxic, carcinogenic, and mutagenic
[2,6].
In recent years we have been successfully identi-
fying new structural scaffolds for GABAA receptor
modulators [9–11] by an extract library-based ap-
proach and HPLC-based activity profiling [12,13],
using an automated functional two–microelec-
trode voltage clamp assay with Xenopus laevis oo-
cytes that transiently express the GABAA receptor
subtype α1β2γ2s [14]. One of the active samples in
the library was a petroleum ether extract of a
commercial sample labelled as “Chaihu” (poten-
tiation of IGABA by 156% ± 22% when tested at
100 µg/mL). The Chinese herbal drug Chaihu (Bu-
pleuri Radix) refers to the dried roots of Bupleu-
rum chinense DC. (Bei-chaihu) or B. scorzonerifo-
lium Willd. (Nan-chaihu) (Apiaceae) [15,16]. It is
awell-knownTCM drug claimed to posses, among
others, sedative properties [17]. It is widely used
in TCM as the principal ingredient of many multi-
herb remedies due to its broad spectrum of tradi-
tional uses [16,18].
By means of HPLC-based activity profiling [13], a
major peak of activity could be located in fraction
11 (potentiation of IGABA by 212% ± 14%)
(l" Fig. 1). We isolated the peak contained in this
fraction by semipreparative HPLC. A molecular
formula C15H20O2 of compound 1 was derived
from the accurate mass obtained by LC-TOFMS
analysis. A database search with this molecular
formula gave no entries for B. chinense [19]. For
Abstract
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HPTLC protocol for detection of aristolochic acids
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ple was confirmed to be a mixture of Aristolochia
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This finding was corroborated by macroscopic in-
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commercialized in Europe.
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bthe entire genus Bupleurum, there was only one entry with thismolecular formula, corresponding to saikodiyne A. However, the1H NMR and 2DNMR spectra did not match with this polyacety-lenic compound. Detailed analysis of the spectra finally led toidentification of 1 as aristolactone (l" Fig. 2A; spectroscopic datain Supporting Information). Concentration dependent GABAA re-ceptor modulation of 1was tested in the oocyte assay, at concen-trations between 0.1 and 1000 µM. Aristolactone (1) potentiatedIGABA in a concentration-dependent manner, with an EC50 of56.0 µM± 5.1 µM and a maximum potentiation of 70.7% ± 2.6%(l" Fig. 2B). No significant direct activation of GABAA receptors
was observed (l" Fig. 2C), but concentrations lower than 100 µM
induced inhibition of IGABA. This may indicate a high potency neg-
ative modulation binding site interfering with a low potency pos-
itive modulation, since concentrations in the range of 100 µM to
1mM induced moderate enhancement of IGABA (l" Fig. 2B and
2C).
Aristolactone is a characteristic marker for the genus Aristolochia.
Due to its unexpected presence in the extract, we suspected adul-
teration of B. chinense roots with an Aristolochia species. There-
fore, we subjected the commercial herb sample to HPTLC analysis
using a validated protocol for detection of AA [20]. The presence
of AAwas confirmedwith the aid of reference solutions, whereas
an authentic sample of Bupleurum chinense roots was devoid of
AA (l" Fig. 3). Further HPTLC fingerprint analyses and macro-
scopic inspection revealed that the sample was a mixture (ap-
prox. 1 :1) of B. chinense roots and A. manshuriensis roots (Fig. 2S,
Supporting Information).
The case described here highlights an apparent gap in appropri-
ate control of TCM herbal drugs imported in Europe. In principle,
wholesale distributors importing bulk herbal drugs are legally
bound to ensure proper quality control measures using the re-
spective pharmacopoeia monographs. Massive adulteration of a
widely used and safe drug, Bupleuri radix (Chaihu), with highly
toxic AA-containing Aristolochia species represents a serious risk
for consumer safety [5]. It is worrying to see that almost two dec-
ades after the discovery of AA nephropathy [7,8], AA-containing
drugs and herbal products are still on the market across the
world [21,22], and that certain populations are at a measurable
risk of getting AA-related cancer [23]. At this point we can only
speculate about the reasons for this case of adulteration. Howev-
er, root samples often possess few distinctive macroscopic fea-
tures, especially in their commercial form of cut drugs, and this
fact lends to either accidental or intentional adulteration. The
rather similar visual appearance of the two drugs in question
visibly led to a situation which was only uncovered by chance.
Thus, regulatory bodies should be aware of the specific issues re-
lated to TCM herbal drugs, so that proper quality and safety can
be ensured. For authentication of TCM herbs, a broad range of
methods is available, such as chromatographic and spectroscopic
techniques [24,25], as well as DNA fingerprinting and genomic
approaches [26,27]. Yet, methods such as HPTLC fingerprinting
and macroscopic and microscopic inspection [2,28] remain im-
Fig. 2 A Chemical structure of compound 1. B Concentration-response
curve for 1 on GABAA receptors of the subunit composition α1β2γ2S, using a
GABA EC5–10. C Typical traces for modulation of IGABA for compound 1. The
flat segments in the currents indicate the absence of direct activation of
the receptors.
Fig. 1 HPLC-based activity profiling of a petroleum ether extract of a
commercial sample labelled as B. chinense DC. roots, for GABAA receptor
modulatory activity. B HPLC chromatogram (210 nm) of a semipreparative
separation of 10mg of extract. The 27 time-based fractions collected, 90 s
each, are indicated with dashed lines. A Potentiation of the IGABA by each
fraction.
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bportant. The specific case discussed here highlights the high in-formation content of HPTLC fingerprints.Materials and Methods!Aristolochia reference samples were provided and identified bythe European Directorate for the Quality of Medicines & Health-Care (EDQM), and Bupleurum reference samples by the AmericanHerbal Pharmacopoeia. The herbal drug labelled as “Chaihu”(dried roots of Bupleurum chinense DC.) was purchased in 2002from the Institute of Chinese Medicine, PeterWeinfurth, Ennepe-tal, Germany. Prior to extraction for the extract library in 2002,the drug was submitted to macroscopic and microscopic analysisin comparison with the respective monograph of the ChinesePharmacopoeia [29]. A voucher specimen (00 363) is depositedat the herbarium of the Division of Pharmaceutical Biology, Uni-versity of Basel.Microfractionation of the extract for activity profiling was per-formed as previously described [11,13], with minor modifica-
tions (see Supporting Information). A total of 27 time-based mi-
crofractions of 90 s each were collected for assessment of GABAA
receptor modulatory activity, as previously described [10,11,14].
Details of the bioassay are given in the Supporting Information.
The peak in the active time window was isolated by means of
semipreparative HPLC. LC‑PDA-ESITOFMS and microprobe NMR
were used for structure elucidation. For details, see Supporting
Information.
Detection of AA in the commercial sample was performed by
HPTLC, according to the PhEur Test for Aristolochic Acids in Herbal
Drugs (2.8.21), method A [30]. HPTLC fingerprint analyses were
performed as previously described [20], with minor modifica-
tions specified in the Supporting Information. Macroscopic in-
spection was carried to complement the information about the
composition and purity of the sample obtained from HPTLC anal-
ysis. By visual comparison to an authentic reference drug, 60% of
the sample was found to be different or questionable.
Supporting information
Detailed description of the experimental conditions, NMR spec-
troscopic data of aristolactone (1), and HPTLC evidence of adul-
teration of the commercial sample of B. chinense roots with
A. manshuriensis roots are available as Supporting Information.
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Experimental details 
 
General procedures 
High resolution mass spectra were obtained on a microTOF ESI-MS system (Bruker Daltonics) 
connected via a T-splitter (1:10) to an HP 1100 system (Agilent), consisting of a degasser, a 
binary mixing pump, autosampler, column oven, and a diode array detector (G1315B). Data 
acquisition and processing was performed on Hystar 3.0 software (Bruker Daltonics). Semi-
preparative HPLC separations for activity profiling and off-line microprobe NMR were 
performed with an HP 1100 series system (Agilent) consisting of a quaternary pump, column 
oven, and diode array detector (G1315B). SunFire™  C18  (3.5  μm,  3.0×150  mm)  and  SunFire™  
Prep  C18  (5  μm, 10×150 mm) columns (Waters) were used for analytical and semi-preparative 
HPLC analysis, respectively. Parallel evaporation of semi-preparative HPLC fractions was 
performed with a Genevac EZ-2 plus vacuum centrifuge (Avantec). 1D and 2D NMR spectra 
were measured at room temperature on a Bruker Avance III spectrometer operating at 500.13 
Mz. A 1mm TXI probe was used. Spectra were analyzed by TopSpin 2.1 software (Bruker). 
HPLC grade methanol (Scharlau Chemie S.A.) and water were used for HPLC separations. NMR 
spectra were recorded in d3-chloroform (Armar Chemicals). Technical grade solvents purified by 
distillation were used for extraction. 
 
Extraction 
For preparation of the extract library, an aliquot of the drug was extracted sequentially with 
petroleum ether, ethyl acetate and methanol using pressurized liquid extraction (2 cycles of 5 
min each for each solvent; pressure 120 bar; temperature 70oC). Extracts were formatted as 
© Georg Thieme Verlag KG · DOI 10.1055/s-0031-1298171 · Planta Med · Rueda DC et al.
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DMSO stock solutions (10 mg/mL) and stored at -80oC in 2D-barcoded MatrixR storage plates. 
Initial screening and HPLC based activity profiling was carried out with an aliquot from the 
extract library. For isolation of aristolactone, an aliquot (approximately 50g) of milled drug was 
extracted by maceration with petroleum ether (4 x 500 mL, 1 h each, rt). The solvent was 
evaporated at reduced pressure, and the extract was stored at 2-8 ºC until use.  
 
Microfractionation 
Microfractionation for GABAA receptor activity profiling was performed as previously described 
[10-11, 13], with minor modifications: separation was done on a semipreparative HPLC column 
with methanol (solvent A) and water (solvent B), using a gradient from 50 to 100% A in 30 min, 
hold for 15 min. The flow rate was  4  mL/min,  and  100  μL  of  extract  (100  mg/mL  in  DMSO) 
were injected. A total of 27 time-based microfractions of 90 s each were collected and 
evaporated in parallel. The dry films were redissolved in1 mL of methanol, and aliquots of 0.5 
mL were dispensed in two vials, dried under N2 gas, and submitted to bioassay.  
 
HPLC-PDA-ESI-TOF-MS 
The petroleum ether extract of the commercial sample of Chaihu was analyzed with methanol 
(solvent A) and water (solvent B), both containing 0.1% formic acid, with gradient elution of 50 
to 100% A in 30 min, hold for 10 min at a flow rate of 0.4 mL/min. The sample was dissolved in 
DMSO at a concentration of 10 mg/mL; the injection volume was 5  μL.  Spectra  were  recorded  in  
the range of m/z 100-800 in positive mode. Nitrogen was used as a nebulizing gas at a pressure 
of 2.0 bar, and as a drying gas at a flow rate of 9.0 L/min (dry gas temperature 240 °C). Capillary 
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voltage was set at 4500 V, hexapole at 250.0 Vpp. Instrument calibration was performed using a 
reference solution of sodium formiate 0.1% in 2-propanol/water (1:1) containing 5 mM NaOH. 
 
Semi-preparative HPLC and Off-Line Microprobe NMR 
For isolation of the active peak, the extract was submitted to semi-preparative HPLC using the 
same solvent system and gradient elution as for HPLC-TOFMS. The flow rate was set at 4 
mL/min. The sample was dissolved in DMSO at a concentration of 100 mg/mL, and the injection 
volume  was  100  μL.  The peak in fraction 11 was collected, evaporated, and redissolved in d1-
chloroform (10 µL). The following parameters were used for measurements of NMR spectra: 
128 scans for 1H spectra; 8 scans for 1H1H-COSY spectra using the cosygpqf pulse program; 32 
scans and 256 increments to record HSQC experiments using the hsqcedetgp pulse program; the 
HMBC spectrum was recorded with 64 scans and 128 increments, using the Hmbcgp pulse 
program. 
 
HPTLC fingerprint analyses 
HPTLC screening test for aristolochic acids on the commercial sample was carried out according 
PhEur 7 (2.8.81) [30], with minor modifications: the powdered drug (0.5 g) was sonicated with 
methanol (5 mL) for 10 min. 
 
For detection of Bupleurum in the sample, a developing system of ethyl acetate-methanol-water 
(80:20:10) was used on HPTLC silica gel 60F254 (MERCK) in a saturated chamber over a 
distance of 60 mm. The plate was derivatized with anisaldehyde reagent and evaluated under 
white light. 
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 Expression of GABAA Receptors  
Stage V-VI oocytes from Xenopus laevis were prepared, and cRNA was injected as previously 
described [13]. Female Xenopus laevis (NASCO, Fort Atkinson, WI) were anesthetized by 
exposing them for 15 min to a 0.2% MS-222 (methanesulfonate salt of 3-aminobenzoic acid 
ethyl, Sigma) solution before surgically removing parts of the ovaries. Follicle membranes from 
isolated oocytes were enzymatically digested with 2 mg/mL collagenase from Clostridium 
histolyticum (Type 1A, Sigma). Synthesis of capped runoff poly(A+) cRNA transcripts was 
obtained from linearized cDNA templates (pCMV vector). Directly after enzymatic isolation, the 
oocytes were injected with 50 nL of DEPC-treated water (Sigma) containing different cRNAs at 
a concentration of approximately 300-3000 pg/nL per subunit. The amount of injected cRNA 
mixture was determined by means of a NanoDrop ND-1000 (Kisker Biotech). To ensure 
expression of the gamma subunit in α1β2γ2S receptors, rat cRNAs were mixed in a 1:1:10 ratio. 
Oocytes were then stored at 18 °C in ND96 solution containing 1% of penicillin-streptomycin 
solution (Sigma-Aldrich). Voltage clamp measurements were performed between days 1 and 5 
after cRNA injection.  
 
Positive control 
Diazepam (7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one, Sigma, purity 
not less than 98%) was used as positive control. At 1 µM diazepam enhanced IGABA up to 231.3 
r 22.6% (n=3). See also Fig S1. 
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Two-Microelectrode Voltage Clamp Studies 
 Electrophysiological experiments were performed by the two-microelectrode voltage clamp 
method making use of a TURBO TEC 03X amplifier (npi electronic GmbH) at a holding 
potential of -70 mV and pCLAMP 10 data acquisition software (Molecular Devices). Currents 
were low-pass-filtered at 1 kHz and sampled at 3 kHz. The bath solution contained 90 mM NaCl, 
1 mM KCl, 1 mM MgCl2, 1 mM CaCl2, and 5 mM HEPES (pH 7.4). Electrode filling solution 
contained 2 M KCl. Oocytes with maximal current amplitudes > 3 μA were discarded to exclude 
voltage clamp errors. 
 
Fast Solution Exchange during IGABA Recordings  
Test  solutions  (100  μL)  were  applied  to  the  oocytes  at  a  speed  of  300  μL/s  by  means  of  the  
ScreeningTool automated fast perfusion system [9]. In order to determine GABA EC5-10 
(typically  between  3  and  10  μM  for  receptors  of  subunit  composition  α1β2γ2s), a dose-response 
experiment  with  GABA  concentrations  ranging  from  0.1  μM  to  1  mM  was  performed.  Stock  
solution of the petroleum ether extract (10 mg/mL in DMSO) was diluted to a concentration of 
100  μg/mL  with  bath  solution  containing  GABA  EC5-10 according to a validated protocol [13]. 
As previously described, microfractions collected from the semipreparative HPLC separations 
were dissolved in  30  μL  of  DMSO  and  subsequently  mixed  with  2.97  mL  of  bath  solution  
containing GABA EC5-10 [13]. A stock solution of compound 1 (100 mM in DMSO) was diluted 
to concentrations of 0.1, 0.3, 1.0, 3.0, 10, 30, 100, 300, 500, and 1000 μM  with  bath  solution  for 
measuring direct activation, or with bath solution containing  GABA EC5-10 for measuring 
modulation of GABAA receptors. The final DMSO concentration in all the samples including the 
GABA control samples was adjusted to 1% to avoid solvent effect at the GABAA receptor.  
© Georg Thieme Verlag KG · DOI 10.1055/s-0031-1298171 · Planta Med · Rueda DC et al.
73
 Data Analysis  
Enhancement of the IGABA was defined as I(GABA+Comp)/IGABA - 1, where I(GABA+Comp) is the current 
response in the presence of a given compound, and IGABA is the control GABA-induced chloride 
current. Data were analyzed using the ORIGIN 7.0 SR0 software (OriginLab Corporation) and 
are  given  as  mean  ±  S.E.  of  at  least  two  oocytes  and  ≥2  oocyte  batches. 
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Fig. S1.  Diazepam  (1  µM)  enhanced  IGABA  through  α1β2γ2S GABAA receptors and was 
therefore used as positive control for the assay. Currents in the presence of GABA (EC5-10, single 
bar, control) and during co-application of GABA and diazepam (1 µM, double bar) are shown. 
At 1 µM diazepam enhanced IGABA up to 231.3 r 22.6% (n=3). 
 
 
 
 
 
 
Figure S2: HPTLC fingerprints confirming and identifying the adulteration of a commercial 
sample labelled as B. chinense DC. roots.  
A: detection of B. chinense in the commercial sample. Developing system: ethyl acetate-
methanol-water (80:20:10). Derivatization: anisaldehyde. Samples: 1. Authentic B. chinense; 2. 
Commercial sample of B. chinense roots; 3. Blank; 4. A. manshuriensis; 5. A. fangii; 6. A. 
serpentaria; 7. saikosaponin D; 8. Saikosaponin A. Bands corresponding to saikosaponins A and 
D, markers of Bupleurum species, are only evident for the authentic sample of B. chinense, and 
the commercial sample studied.  
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B: identification of A. manshuriensis as the adulterant in the commercial sample. Developing 
system: water, formic acid, ehtyl acetate, toluene (1:1:10:20). Derivatization: tin chloride 
reagent. Visualization: UV 366 nm. Samples: 1. B. bicaule; 2-8. Authentic B. chinense; 9. 
Commercial sample of B. chinense roots; 10. A. manshuriensis; 11. A. serpentaria; 12. AA I/II. 
The analysis of several B. chinense samples and different Aristolochia species confirms the 
absence of AA in B. chinense and indicates the presence of A. manshuriensis in the commercial 
sample.  
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NMR spectroscopic data for compound (1) 
Table S1: NMR spectroscopic data (500.13 MHz, CDCl3) for aristolactone (1)  
CAS Nr. 6790-85-8  
 
 
 
 
 
Position GCa GH (I, m, J in Hz) 
1 132.6 - 
2 25.1 2.21 (CH2, ddd, 13.0, 10.8, 7.8) 
3 24.2 2.19 (CH2, m) 
4 128.8 4.57 (CH, dbr. 12.5) 
5 136.7 - 
6 40.8 1.89 (CH2, dd, 12.0, 12.0) 
7 26.3 1.50 (CH2, ddbr, 15.1, 10.8) 
8 52.5 2.40 (CH, dbr, 11.0) 
9 82.3 4.96 (CH, sbr) 
11 173.5 - 
12 152.3 6.60 (CH, sbr) 
1’ 150.3 - 
2’ 110.3 4.70 (CH2, m) 
3’ 20.2 1.81 (CH3, sbr) 
4’ 15.5 1.47 (CH3, sbr) 
a chemical shifts derived from HMBC spectrum 
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3.2. Identification of dihydrostilbenes in Pholidota chinensis as a new 
scaffold for GABAA receptor modulators 
 
Diana C. Rueda, Angela Schöffmann, Maria De Mieri, Melanie Raith, Evelyn A. Jähne, 
Steffen Hering, and Matthias Hamburger. Bioorg Med Chem 2014; 22(4): 1276 – 84  
(doi: 10.1016/j.bmc.2014.01.008) 
 
 
 
 
 
 
 
 
 
 
The dihydrostilbene batatasin III was identified as a very efficient, non-selective GABAAR 
modulating compound in P. chinensis stems and roots by HPLC-based activity profiling. 
Two structurally related non-flexible stilbenes, coelonin and pholidotol D, were also isolated 
from the extract but they were inactive in the oocyte assay. Structural flexibility of stilbenes 
was proved to be crucial for modulation of GABAA receptors by testing 13 commercially 
available stilbenes and their corresponding semisynthetic dihydrostilbenes in the oocyte 
assay.  
 
 
 
Extraction of the plant material for isolation, HPLC-based activity profiling, isolation of 
pure compounds, biological assessment of pure compounds at a single concentration, 
recording and interpretation of analytical data for structure elucidation (UV, HRMS, NMR 
spectra), bioactivity assessment of synthetic stilbenes and their semisynthetic dihydro 
derivatives in Xenopus oocytes, writing of the manuscript draft, and preparation of the 
figures (except for Figure 4) were my contributions to this publication. A. Schöffmann 
performed concentration-response experiments with compounds (1-3) and subunit specificity 
tests. Semisynthesis of dihydrostilbenes from commercial stilbenes was carried out by M. De 
Mieri. Structure elucidation of compounds 1-3 was assisted by M. Raith.   
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a b s t r a c t
A dichloromethane extract of stems and roots of Pholidota chinensis (Orchidaceae) enhanced
GABA-induced chloride currents (IGABA) by 132.75 ± 36.69% when tested at 100 lg/mL in a two-micro-
electrode voltage clamp assay, on Xenopus laevis oocytes expressing recombinant a1b2c2S GABAA recep-
tors. By means of an HPLC-based activity profiling approach, the three structurally related stilbenoids
coelonin (1), batatasin III (2), and pholidotol D (3) were identified in the active fractions of the extract.
Dihydrostilbene 2 enhanced IGABA by 1512.19 ± 176.47% at 300 lM, with an EC50 of 52.51 ± 16.96 lM,
while compounds 1 and 3 showed much lower activity. The relevance of conformational flexibility for
receptor modulation by stilbenoids was confirmed with a series of 13 commercially available stilbenes
and their corresponding semisynthetic dihydro derivatives. Dihydrostilbenes showed higher activity in
the oocyte assay than their corresponding stilbenes. The dihydro derivatives of tetramethoxy-piceatannol
(12) and pterostilbene (20) were the most active among these derivatives, but they showed lower effi-
ciencies than compound 2. Batatasin III (2) showed high efficiency but no significant subunit specificity
when tested on the receptor subtypes a1b2c2s, a2b2c2s, a3b2c2s, a4b2c2s, a5b2c2s, a1b1c2s, and a1b3c2s.
Dihydrostilbenes represent a new scaffold for GABAA receptor modulators.
! 2014 Elsevier Ltd. All rights reserved.
1. Introduction
GABAA receptors are ligand-gated chloride channels physiolog-
ically activated by GABA, the major inhibitory neurotransmitter in
the brain. Structurally, they are heteropentameric assemblies
forming a central chloride-selective channel. Up to now 19 differ-
ent subunits (a1–6, b1–3, c1–3, d, e, h, p, q1–3) have been identi-
fied. Depending on the nature, stoichiometry, and arrangement of
these subunits, the receptor subtypes exhibit distinct pharmaco-
logical profiles providing the potential for rational drug therapy
in several disorders related with impaired GABAergic function,
such as epilepsy, insomnia, anxiety, and mood disorders.1–3 GABAA
receptors are the target for many clinically important drugs such as
benzodiazepines (BDZs), barbiturates, neuroactive steroids, anes-
thetics, and certain other CNS depressants. Due to their lack of
subunit specificity, these drugs show a number of adverse side ef-
fects. Hence, there is a need for subtype-selective drugs devoid of
the side effects of the classical BDZs. Despite the availability of
experimental subunit-specific GABAergic drugs for more than a
decade, no subtype-selective GABAA receptor modulators have
been introduced into clinical practice.3,4
In a search for new natural product-derived GABAA receptor
modulators, we screened a library of 880 fungal and plant extracts
in an automated functional two-microelectrode voltage clamp as-
say on Xenopus oocytes5 transiently expressing GABAA receptors
of the a1b2c2S subtype, the most abundant subunit combination
in the human brain.2 In this screening the dichloromethane extract
of stems and roots of Pholidota chinensis LINDL (Orchidaceae)
showed promising activity.
Orchidaceae is the largest family of flowering plants, with
around 25,000 species in over 800 genera. The family shows world-
wide distribution, with greatest diversity in tropical and subtropi-
cal climate zones. Apart from their ornamental value, many orchids
have been used as medicinal plants. In traditional Chinese medi-
cine we find the earliest written records for medicinal uses of orch-
ids.6–8 In Chinese folk medicine, the whole plant of P. chinensis (shi
xian tao) has long been used in the treatment of diverse conditions,
such as hypertension, headache, gastroenteritis, and bronchitis.
Previous pharmacological studies on P. chinensis reported sedative
and anticonvulsant activities.9–12 The genus Pholidota comprises
approximately 30 species distributed from tropical Asia to tropical
0968-0896/$ - see front matter ! 2014 Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.bmc.2014.01.008
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Australia. Phytochemical studies on the genus showed the pres-
ence of triterpenes, steroids, lignans, benzoxepines, and stilbe-
noids.10 Stilbenoids exhibit a limited but heterogeneous
distribution in the plant kingdom, and have been most widely re-
ported from the Orchidaceae family. Dihydrostilbenes and 9,10-
dihydrophenanthrenes have been previously identified in the
genus Pholidota.13–17
In this study, batatasin III (2) isolated from a DCM extract of
P. chinensis was identified as a positive GABAA receptor modulator
by means of HPLC-based activity profiling,18 a miniaturized
approach for the rapid identification of new bioactive natural com-
pounds,19–22 that we have been successfully applying in the discov-
ery of GABAA receptor ligands of natural origin.23–27 The subunit
selectivity of 2 was assessed at GABAA receptor subtypes a2b2c2s,
a3b2c2s, a4b2c2s, a5b2c2s, a1b1c2s, and a1b3c2s. Furthermore,
dihydrostilbenes were established as a new scaffold for GABAA
receptor modulators, by comparison of the performance of a series
of commercially available stilbenes and their semisynthetic
dihydro derivatives on the oocyte assay.
2. Experimental
2.1. General procedures
1D and 2D NMR spectra were measured at room temperature
on a Bruker Avance III 500 MHz spectrometer (Bruker BioSpin,
Fällanden, Switzerland) operating at 500.13 MHz. Spectra were re-
corded at 291.2 K with a 1 mm TXI probe with z-gradient. The fol-
lowing settings were used: 128 scans for 1H spectra; 8 scans for
1H1H-COSY spectra (cosygpqf pulse program); 32 scans and 256
increments for HSQC experiments (hsqcedetgp pulse program); 64
scans and 128 increments for HMBC spectra (hmbcgp pulse pro-
gram). Spectra were analyzed by TopSpin 3.0 software (Bruker).
High resolution mass spectra (HPLC–ESITOFMS) were recorded in
positive mode, m/z range 100–800, on a Bruker microTOF ESIMS
system (Bruker Daltonics, Bremen, Germany) connected via a
T-splitter (1:10) to an Agilent HP 1100 system consisting of a deg-
asser, a binary mixing pump, autosampler, column oven, and a
diode array detector (G1315B) (Agilent Technologies, Waldbronn,
Germany). Nitrogen was used as a nebulizing gas at a pressure of
2.0 bar, and as drying gas at a flow rate of 9.0 L/min (dry gas tem-
perature 240 !C). Capillary voltage was set at 45,000 V; hexapole at
230.0 Vpp. Instrument calibration was done with a reference solu-
tion of sodium formate 0.1% in 2-propanol/water (1:1) containing
5 mM NaOH. Data acquisition and processing was performed with
Bruker Daltonics Hystar 3.0 software. Semi-preparative HPLC sep-
arations for activity profiling and purification were performed with
an Agilent HP 1100 series system consisting of a quaternary pump,
autosampler, column oven, and diode array detector (G1315B).
Waters SunFire™ C18 (3.5 lm, 3.0 ! 150 mm) and SunFire™ Prep
C18 (5 lm, 10 ! 150 mm) columns were used for analytical and
semi-preparative HPLC analysis, respectively (Waters, Wexford,
Ireland). Parallel evaporation of semi-preparative HPLC fractions
was performed with a Genevac EZ-2 plus vacuum centrifuge (Gen-
evac Ltd, Ipswich, United Kingdom). Flash chromatography was
performed with pre-packed Buchi Sepacore" silica flash cartridges
(40–63 lm, 40 ! 150 mm) on a Buchi Sepacore" system consisting
of two C-605 pumps, a C-620 control unit, and a C-660 fraction col-
lector (Buchi, Flawil, Switzerland). Sample introduction was car-
ried out with a Buchi Prep Elut adapter filled with the sample
adsorbed onto silica gel. The separation was monitored by TLC. Pre-
parative HPLC separations were performed with a Waters SunFire
Prep C18 OBD column (5 lM, 30 ! 150 mm) connected to a
Shimadzu LC-8A preparative HPLC with SPD-M10A VP diode array
detector. HPLC-grade MeOH (Scharlau Chemie S.A.), acetonitrile
(Scharlau Chemie S.A.) and water were used for HPLC separations.
For analytical separations, HPLC solvents contained 0.1% of HCO2H.
NMR spectra were recorded in methanol-d4 (Armar Chemicals). For
extraction and flash chromatography, distilled technical grade sol-
vents were used. Silica gel (63–200 lm, Merck) was used for open
column chromatography.
2.2. Plant material
Shi Xian Tao (dried stems/roots of P. chinensis Lindl.) was pur-
chased in 2008 from a local herbal market in Kunming and authen-
ticated by Dr. X. Yang (previously Pharmaceutical Biology,
University of Basel, now Kunming Institute of Botany, Chinese
Academy of Science, Kunming, PR China). A voucher specimen
(463) is deposited at the Division of Pharmaceutical Biology, Uni-
versity of Basel.
2.3. Extraction
The plant material was frozen with liquid nitrogen and ground
with a ZM1 ultracentrifugal mill (Retsch). The DCM extract for
screening and HPLC-based activity profiling was prepared with
an ASE 200 extraction system with solvent module (Dionex, Sun-
nyvale CA). Three extraction cycles (5 min each) were performed,
at an extraction pressure of 120 bar and a temperature of 70 !C.
For preparative isolation, 293 g of ground plant material was mac-
erated with DCM (4 ! 1 L, 3 h each, permanent magnetic stirring).
The solvent was evaporated at reduced pressure to yield 10.3 g of
extract. The extracts were stored at 2–8 !C until use.
2.4. Microfractionation for activity profiling
Time-based microfractionation for GABAA receptor activity pro-
filing was performed as previously described,23,27,28 with minor
modifications: separation was done on a semi-preparative HPLC
column with MeOH (solvent A) and water (solvent B), using a gra-
dient from 50% A to 80% A in 30 min, followed by 80% A to 100% A
in 2 min. The flow rate was 4 mL/min, and 10 mg of extract (in
200 lL of DMSO) were injected. A total of 24 microfractions of
90 s each were collected. After parallel evaporation of solvents,
the dry films were redissolved in 1 mL of methanol, and aliquots
of 0.5 mL were dispensed in two vials, dried under N2 gas, and sub-
mitted to bioassay.
2.5. Isolation
An aliquot of the DCM extract (450 mg) was dissolved in CHCl3
and adsorbed onto silica gel (3 g), prior to packing into a Buchi Prep
Elut adapter. Separation was performed on a Sepacore" silica gel
cartridge eluted with an n-hexane (solvent A) and EtOAc (solvent
B) gradient: 0% B to 30% B in 90 min, followed by 30% B to 50% B
in 30 min, and 50% B to 80% B in 30 min. The flow rate was set at
15 mL/min. Fractions of 15 mL were collected and later combined
into 18 fractions (1–18) on the basis of a TLC analysis (detection
at 254, 366, and at daylight after staining with anisaldehyde–sulfu-
ric acid reagent). Fractions 1–18 were submitted to analytical
HPLC–PDA–ESIMS with MeOH (solvent C) and water (solvent D),
using a gradient from 50% C to 100% C in 30 min, hold for
15 min. The flow rate was 0.4 mL/min, and 10 lg of each fraction
(in 10 lL of DMSO) were injected. Fractions 13 and 14 were found
to contain the compounds of interest and were submitted to semi-
preparative HPLC using solvents C and D as eluents. A gradient of
50% C to 60% C in 30 min was used for fraction 13, and isocratic
conditions (50% C, 30 min) for fraction 14. The flow rate was
4 mL/min. Stock solutions in DMSO (50 mg/mL) were prepared
and repeatedly injected in portions of 50–100 lL. A portion
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(17 mg) of fraction 13 (25 mg) afforded compounds 1 (2.3 mg) and
2 (6.5 mg). Compound 3 (2 mg) was isolated from 10 mg of fraction
14 (16 mg).
Compounds 1–3 were identified by comparison of their physio-
chemical data (NMR, ESI-TOFMS, and UV–vis) with published val-
ues.14,29–31 The purity was >95% (purity check by 1H NMR).
2.5.1. Coelonin (1)
1H NMR (methanol-d4, 500.13 MHz) dH (ppm): 8.13 (1H, d,
J = 8.4 Hz, H-5), 6.62 (1H, dd J = 8.3 and 2.7 Hz, H-6), 6.61 (1H, d,
J = 2.6 Hz, H-8), 6.30 (1H, d, J = 2.5 Hz, H-3), 6.26 (1H, d,
J = 2.5 Hz, H-1), 3.67 (3H, s, 4-OCH3), 2.59 (4H, s, H-9 and H-10);
13C shifts (derived from multiplicity-edited HSQC and HMBC spec-
tra), dC (ppm): 158.3 (C, C-4), 155.4 (C, C-2), 154.8 (C, C-7), 139.8 (C,
C-8a), 138.7 (C, C-10a), 128.6 (CH, C-5), 125.2 (C, C-4b), 114.8 (C,
C-4a), 113.8 (CH, C-8), 112.2 (CH, C-6), 104.8 (CH, C-1), 100.1
(CH, C-3), 54.2 (4-OCH3), 30.8 (CH2, C-10) 30.1 (CH2, C-9).
HR-ESIMS m/z 243.1016 [M+H]+ (calcd for C15H15O3, 243.1016).
2.5.2. Batatasin III (2)
1H NMR (methanol-d4, 500.13 MHz) dH (ppm): 7.03 (1H, dd,
J = 7.9 and 7.5 Hz, H-50), 6.64 (3H, m, H-20, H-40, and H-60), 6.29
(1H, br s, H-2), 6.23 (2H, m, H-4 and H-6), 3.63 (3H, s, 5-OCH3),
2.75 (4H, m, H-a and H-b); 13C shifts (derived from multiplicity-
edited HSQC and HMBC spectra), dC (ppm): 160.9 (C, C-5), 157.6
(C, C-3), 156.7 (C, C-30), 144.9 (C, C-1), 143.3 (C, C-10), 129.0 (CH,
C-50), 119.8 (CH, C-60), 115.3 (CH, C-20), 112.4 (CH, C-40), 108.1
(CH, C-2), 105.5 (CH, C-6), 98.7 (CH, C-4), 54.3 (CH3, 5-OCH3),
37.6 (CH2, C-b), 37.0 (CH2, C-a). HR-ESIMS m/z 245.1176 [M+H]+
(calcd for C15H17O3, 245.1172).
2.5.3. Pholidotol D (3)
1H NMR (methanol-d4, 500.13 MHz) dH (ppm): 7.17 (1H, dd,
J = 7.9 and 7.8 Hz, H-50), 7.00–6.95 (4H, m, H-20, H-60, H-a and H-
b), 6.69 (1H, dd, J = 8.2 and 2.2 Hz, H-40), 6.58 (2H, m, H-2 and H-
6), 6.31 (1H, t, J = 2 Hz, H-4), 3.76 (3H, s, 5-OCH3); 13C shifts (de-
rived from multiplicity-edited HSQC and HMBC spectra), dC
(ppm): 160.8 (C, C-5), 157.7 (C, C-3), 156.0 (C, C-30), 139.7 (C, C-
1), 138.5 (C, C-10), 129.4 (CH, C-50), 128.6 (CH, C-b), 128.4 (CH, C-
a), 117.8 (CH, C-60), 114.4 (CH, C-40), 112.4 (CH, C-20), 105.8 (CH,
C-2), 103.4 (CH, C-6), 100.3 (CH, C-4), 54.4 (CH3, 5-OCH3). HR-
ESIMS m/z 243.1017 [M+H]+ (calcd for C15H15O3, 243.1016).
Further purification of compound 2 for subunit specificity tests
was achieved by separating a portion of the extract (7.3 g) by open
column chromatography (6 ! 69 cm, 700 g of silica gel), using a
step gradient of n-hexane–EtOAc (100:0, 95:5, 90:10, 85:15,
80:20, 75:25, 70:30, 65:35, 60:40, 55:45, 50:50, 40:60, 30:70,
20:80, 10:90, 0:100, 1 L each) and washing in the end with MeOH
100% (1.5 L). The flow rate was ca. 50 mL/min. The effluent was
combined to 15 fractions (1–15) based on TLC patterns. After
HPLC–PDA–MS analysis, fractions 7 and 8 were selected for isola-
tion of compound 2 by preparative HPLC, with acetonitrile (solvent
A) and water (solvent B), using a gradient from 40% A to 50% A in
30 min, followed by 50% A to 100% A in 5 min, hold for 10 min.
The flow rate was 20 mL/min. Stock solutions in THF (100 mg/
mL) were prepared and repeatedly injected in portions of 300–
400 lL. The separation of fractions 7 (129 mg) and 8 (132 mg),
yielded compound 10.8 mg of 2.
2.6. Synthesis of dihydrostilbenes
2.6.1. Stilbenes
Compounds 4–7, 9, 11, 13, 15, 17, and 19 were purchased from
TCI Europe N.V. Compounds 21 and 25 were purchased from Sig-
ma–Aldrich Co. Compound 23 was purchased from Santa Cruz Bio-
technology, Inc.
2.6.2. General procedure
Dihydro derivatives of compounds 7, 9, 11, 13, 15, 17, 19, 21,
and 23 were prepared by hydrogenation of corresponding stilb-
enes. A standard protocol was followed,32 with minor modifica-
tions. Solutions of each stilbene (10 mg) in absolute EtOH (5 ml)
were stirred under H2 for 3 h in the presence of 10% Pd/C. The reac-
tion mixtures were filtered over Celite to remove the catalyst, and
evaporated to dryness. The resulting residues were purified by
flash column chromatography, using a hexane/EtOAc gradient, to
afford target compounds 8, 10, 12, 14, 16, 18, 20, 22, and 24,
respectively, in yields of 85–95%. The spectroscopic data of com-
pounds were in agreement with the literature, except for com-
pound 24, for which no report was found (1H NMR spectrum is
provided as Supporting information).32–41
2.6.3. trans-2-Fluoro-40-methoxy-dihydrostilbene (24)
1H NMR (chloroform-d4, 500.13 MHz) dH (ppm): 7.26–7.08 (4H,
m), 7.08–7.98 (2H, m), 6.90–6.80 (2H, m), 3.81 (3H, s), 3.05–2.84
(4H, m). HRESI-MS m/z 253.1589 [M+Na]+ (calcd formula weight
for C15H15FO, 230.2774).
2.7. Expression of GABAA receptors
Stage V–VI oocytes from Xenopus laevis were prepared, and
cRNA injected as previously described.23 Female Xenopus laevis
(NASCO, Fort Atkinson, WI) were anesthetized by exposing them
for 15 min to a 0.2% MS-222 (methanesulfonate salt of 3-amino-
benzoic acid ethyl, Sigma) solution before surgically removing
parts of the ovaries. Follicle membranes from isolated oocytes were
enzymatically digested with 2 mg/mL collagenase from Clostridium
histolyticum (Type 1A, Sigma). Synthesis of capped runoff poly(A+)
cRNA transcripts was obtained from linearized cDNA templates
(pCMV vector). Directly after enzymatic isolation, the oocytes were
injected with 50 nL of DEPC-treated water (Sigma) containing dif-
ferent cRNAs at a concentration of approximately 300–3000 pg/nL
per subunit. The amount of injected cRNA mixture was determined
by means of a NanoDrop ND-1000 (Kisker Biotech). To ensure
expression of the gamma subunit in a1b2c2S receptors, rat cRNAs
were mixed in a 1:1:10 ratio. Oocytes were then stored at 18 !C
in ND96 solution containing 1% of penicillin–streptomycin solution
(Sigma–Aldrich). Voltage clamp measurements were performed
between days 1 and 5 after cRNA injection.
2.8. Positive control
Diazepam (7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-
benzodiazepin-2-one, Sigma, purity not less than 98%) was used
as positive control. At 1 lM diazepam enhanced IGABA up to
231.3 ± 22.6% (n = 3). See also Figure S1, Supporting information.
2.9. Two-microelectrode voltage clamp studies
Electrophysiological experiments were performed by the two-
microelectrode voltage clamp method making use of a TURBO
TEC 03X amplifier (npi electronic GmbH) at a holding potential
of "70 mV and pCLAMP 10 data acquisition software (Molecular
Devices). Currents were low-pass-filtered at 1 kHz and sampled
at 3 kHz. The bath solution contained 90 mM NaCl, 1 mM KCl,
1 mMMgCl2, 1 mM CaCl2, and 5 mM HEPES (pH 7.4). Electrode fill-
ing solution contained 2 M KCl. Oocytes with maximal current
amplitudes >3 lA were discarded to exclude voltage clamp errors.
2.10. Fast solution exchange during IGABA recordings
Test solutions (100 lL) were applied to the oocytes at a speed of
300 lL/s by means of the ScreeningTool (npi electronic, Tamm,
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Germany) automated fast perfusion system.5 In order to determine
GABA EC3–10 (typically between 3 and 10 lM for receptors of sub-
unit composition a1b2c2s), a dose–response experiment with GABA
concentrations ranging from 0.1 lM to 1 mMwas performed. Stock
solution of the DCM extract (10 mg/mL in DMSO) was diluted to a
concentration of 100 lg/mL with bath solution containing GABA
EC3–10 according to a validated protocol.23 As previously described,
microfractions collected from the semi-preparative HPLC separa-
tions were dissolved in 30 lL of DMSO and subsequently mixed
with 2.97 mL of bath solution containing GABA EC3–10.23 A stock
solution of each pure compound tested (100 mM in DMSO) was di-
luted to concentrations of 0.1, 1.0, 3.0, 10, 30, 100, 300, and 500 lM
with bath solution for measuring direct activation, or with bath
solution containing GABA EC3–10 for measuring modulation of
GABAA receptors. The final DMSO concentration in all the samples
including the GABA control samples was adjusted to 1% to avoid
solvent effect at the GABAA receptor.
2.11. Data analysis
Enhancement of the IGABA was defined as I(GABA+Comp)/IGABA ! 1,
where I(GABA+Comp) is the current response in the presence of a given
compound, and IGABA is the control GABA-induced chloride current.
Data were analyzed using the ORIGIN 7.0 SR0 software (OriginLab
Corporation) and are given as mean ± SE of at least two oocytes and
P2 oocyte batches.
3. Results and discussion
3.1. Isolation and structure elucidation of active compounds
Screening for GABAA modulating activity was performed with
Xenopus laevis oocytes transiently expressing GABAA receptors of
the subtype a1b2c2s. In an automated fast-perfusion system used
for two-microelectrode voltage clamp measurements,5 a dichloro-
methane extract (100 lg/mL) of P. chinensis roots enhanced the
GABA-induced chloride ion current (IGABA) by 132.8 ± 36.7%. To
track the activity in the extract, we used HPLC-based activity pro-
filing with a validated protocol.23 The chromatogram (210–
700 nm) of a semipreparative HPLC separation (10 mg of extract)
and the corresponding activity profile of the time-based fraction-
ation (24 microfractions of 90 s each) are shown in Figure 1B and
A, respectively. The major peak of activity was found in fraction
9, which potentiated IGABA by 119.1 ± 19.1%. Fraction 8 showed
marginal activity (enhancement of IGABA by 26.5 ± 4.7%). All the
remaining fractions showed minimal activity and were not consid-
ered further.
Isolation of the active compounds was achieved by flash chro-
matography and subsequent purification by semi-preparative
HPLC. Compounds were tracked with the aid of TLC and HPLC–
ESIMS. The three structurally related stilbenoids coelonin (1),
batatasin III (2), and pholidotol D (3) (Fig. 2) were identified by
ESI-TOF-MS, 1D and 2D microprobe NMR, and comparison with
published data.14,29–31 The Z configuration in compound 3was cor-
roborated by proton NMR, using the chemical shifts and coupling
constant of the two olefinic protons at dH 6.95 (2H, d, J = 6.0 Hz,
H-b and a), which discards the presence of the trans-stereoisomer
thunalbene. Detailed spectroscopic data of compounds 1–3 are
available as Supporting information.
Stilbenoids are the major secondary metabolites in the genus
Pholidota,10 and the identification of compounds 1–3 in the ac-
tive fractions of P. chinensis DCM extract was not surprising.
The three compounds have been previously isolated from the
species,10,12,14 but they have not been reported as GABAA recep-
tor modulators.
3.2. Modulation of GABAA receptors
For a preliminary activity profile at GABAARs of the subtype
a1b2c2s, 1–3 were tested at a concentration of 100 lM in the Xeno-
pus oocyte assay. Batatasin III (2) was the most efficient among the
three compounds. It potentiated IGABA by 628.3 ± 87.1%, while com-
pounds 1 and 3 exhibited weaker enhancements (139.5 ± 14.4%
and 192.0 ± 64.1%, respectively) (Fig. 3A). Further concentration–
response experiments on a1b2c2s receptors were performed with
compounds 1–3, at concentrations ranging from 1 to 300 lM
(500 lM for compound 3). As shown in Figure 3B, all stilbenoids
enhanced IGABA at a GABA EC3–10 in a concentration-dependent
manner. The bibenzyl batatasin III (2) displayed strong GABAA
receptor modulatory activity, with an efficiency (maximal stimula-
tion of IGABA) of 1512.9 ± 176.5% and a potency (higher concentra-
tion for half-maximal stimulation of IGABA, or EC50) of
52.5 ± 17.0 lM. The structurally related stilbene pholitodol D (3)
showed much lower activity, with an efficiency of 786.8 ± 72.1%
and potency of 175.5 ± 25.5 lM. The dihydrophenanthrene coelo-
nin (1) showed activity similar to compound 2, but no saturation
of the receptors was reached at the highest concentration tested
(300 lM). None of the compounds induced direct activation of
the receptors when applied prior to GABA, at concentrations lower
than 100 lM. This was indicative of an allosteric modulation of the
receptor with the subunit composition a1b2c2s, rather than direct
agonistic activity (Fig. 3C).
Compared to other natural products tested in the same in vitro
model and GABAA receptor subtype,24,27,28,33 batatasin III (2) exhib-
ited much higher efficiency. The efficiency of 2 in GABAARs of the
Figure 1. HPLC-based activity profiling of a DCM extract of stems and roots of P.
chinensis, for GABAA receptor modulatory activity. (B) HPLC chromatogram (210–
700 nm) of a semipreparative separation of 10 mg of extract. The numbers above
peaks designate compounds 1–3. The 24 time-based fractions of 90 s each are
indicated with dashed lines. (A) Potentiation of the IGABA by each microfraction
(error bars correspond to SE).
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subtype a1b2c2s was also significantly higher than that of classical
BDZs, with a potentiation of IGABA at least fourfold that of triazolam,
clotiazepam, and midazolam.34 However, its EC50 value was signif-
icantly higher than that of BDZs and indicated a much lower bind-
ing affinity.
Despite the small number of compounds, preliminary struc-
ture–activity considerations could be derived. Conformational
flexibility as in batatasin III (2) appeared to be critical for the mod-
ulatory activity of stilbenoids, since introduction of a double bond
Db,a in pholidotol D (3) drastically decreased potency and effi-
ciency. The importance of flexibility was confirmed by the weak
activity of coelonin (1) in which the dihydrophenanthrene ring
conferred additional rigidity to the structure. Although stilbenoids
such as resveratrol have been described as neuroprotective
Figure 3. (A) Potentiation of IGABA by the DCM extract of P. chinensis stems and roots (100 lg/mL), by microfraction 9, and compounds 1–3 (100 lM). (B) Concentration–
response curve for compounds 1–3 on GABAA receptors of the subunit composition a1b2c2S. (C–E) Typical traces for modulation of IGABA by compounds 1–3, respectively. The
flat segments in the currents indicate the absence of direct activation of the receptors. All experiments in A–E were carried out using a GABA EC3–10.
Figure 2. Chemical structures of compounds 1–3.
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agents,17,35–38 none of them has been reported as GABAA receptor
ligand so far. Batatasin III (2) is thus the first representative of a
new scaffold for GABAA receptor modulators. It is noteworthy that
compounds with biosynthetically related scaffolds such as flavo-
noids,25,39 coumarins,24 and lignans40 have been previously shown
to possess GABAA receptor modulatory properties.
3.3. GABAA receptor subtype selectivity
Batatasin III (2) was tested for potential a subunit specificity, by
replacing the a1 subunit in the receptor subtype a1b2c2s with a2,
a3, a4, and a5. Likewise, b subunit specificity was evaluated by
replacing b2 with b1 and b3. Concentration-dependent IGABA modu-
lation of compound 2 was evaluated on receptor subtypes a2b2c2s,
a3b2c2s, a4b2c2s, a5b2c2s, a1b1c2s, and a1b3c2s (Table 1).
As shown in Figure 4 and summarized in Table 1, compound 2
did not exhibit subtype specificity, as reflected by comparable EC50
values with all receptor subtypes studied (p > 0.05). The order of
potency of batatasin III (2) in receptor composed by different a
subunits was a4b2c2s > a5b2c2s > a1b2c2s > a3b2c2s > a2b2c2s. The
lower potency on a2b2c2s receptors compared to a4b2c2s was sta-
tistically significant, while there were no significant differences
in efficiency among the other a-containing receptor subtypes. On
GABAA receptors comprising different b subunits, almost no differ-
ences in potency and efficiency were observed. Thus, batatasin III
(2) was a positive allosteric modulator of GABAARs, devoid of sig-
nificant subtype specificity.
3.4. GABAAR modulatory activity of dihydrostilbenes
Flexibility appeared to be a critical factor for the GABAAR mod-
ulatory activity of stilbenoids. To confirm the influence of the dou-
ble bond Db,a, 13 commercially available stilbenoids and their
corresponding dihydro derivatives (compounds 4–25; Fig. 5) were
tested in the Xenopus oocyte assay. Compounds were initially
tested at a concentration of 100 lM on GABAARs of the subtype
a1b2c2s. As expected, dihydrostilbenes showed higher activity than
the corresponding stilbenes (Table 2, Fig. 6A). These differences in
the activity of stilbenes and their dihydro derivatives were statisti-
cally significant in almost every case, with the exception of the
pairs 4 and 5/6, 9/10, 13/14, and 23/24 (p > 0.05).
Among the stilbenes, tetramethoxy-piceatannol (11), resvera-
trol (13), pterostilbene (19), and resveratrol triacetate (21), dis-
played the highest activity, potentiating IGABA between 100% and
200%. Their corresponding dihydro derivatives showed the highest
activity among dihydrostilbenes, but only compounds 12 and 20
showed efficiencies comparable to that of batatasin III (2)
(544.5 ± 104.4% and 660.6 ± 100.2% respectively). A comparison
of the activity of the dihydrostilbenes at 100 lM revealed that
the bibenzyl scaffold alone (6) does not possess any GABAAR mod-
ulatory activity. In general, substituents at C-3 and C-5 (12, 14, 16,
18, 20, and 22) resulted in an enhancement of the activity. Increas-
ing the lipophilicity by replacing the hydroxy groups at C-3 and C-5
with bulkier oxygenated functions (12, 20, and 22) enhanced the
Figure 4. (A) a-Subunit dependency of batatasin III (2), depicted as concentration–response curves, with GABAA receptors of the subunit compositions a1b2c2s, a2b2c2s,
a3b2c2s, a4b2c2s, and a5b2c2s. (B) b-Subunit dependency of batatasin III (2), depicted as concentration–response curves with GABAA receptors of the subunit compositions
a1b1c2s, a1b2c2s, and a1b3c2s. (C and D) Typical traces for modulation of IGABA by compound 2, in receptors with different a and b subunit composition, respectively. All
experiments were performed using a GABA EC3–10.
Table 1
Potencies and efficiencies of batatasin III (2) for GABAA receptors of different subunit
compositions
Subtype EC50 (lM) Max. potentiation of IGABA
(EC3–10) (Imax) (%)
Hill coeff. (nH) na
a1b2c2s 52.5 ± 17.0 1512.9 ± 176.5 1.4 ± 0.3 5
a2b2c2s 80.8 ± 22.1 1026.5 ± 139.2 1.2 ± 0.1 6
a3b2c2s 67.3 ± 18.6 1694.2 ± 229.0 1.2 ± 0.1 5
a4b2c2s 26.2 ± 3.6 1588.2 ± 97.5 1.5 ± 0.1 6
a5b2c2s 46.7 ± 9.0 1375.7 ± 76.5 1.3 ± 0.1 5
a1b1c2s 66.7 ± 21.0 1251.3 ± 157.0 1.8 ± 0.4 5
a1b3c2s 67.2 ± 10.5 1252.9 ± 79.9 1.4 ± 0.1 5
a Number of experiments.
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activity of dihydrostilbenes. The role of substituents in ring B was
less clear within this compounds series. In the case of compounds
12 and 20, different substitution patterns in ring B did not influ-
ence the activity. In contrast, when comparing compounds 14,
16, and 18, addition of a hydroxy group in C-40 or C-60 led to a sig-
nificant decrease of activity. Introduction of a halogen atom as in
25 induced slight negative receptor modulation, and substitution
at C-4 (compound 10) decreased activity. Since we had only one
pair of cis and trans isomers (4 and 5, both inactive at 100 lM),
the role of geometric isomerism could not be assessed in more
detail.
The dihydro derivatives of tetramethoxy-piceatannol and ptero-
stilbene (compounds 12 and 20, respectively) were submitted to
further concentration–response experiments on a1b2c2s receptors.
Both compounds enhanced IGABA at a GABA EC3–10 in a concentra-
tion-dependent manner (Fig. 6B). Compounds 12 and 20 had lower
efficiency than the natural dihydrostilbene 2 (Table 3), with max-
imal stimulations of IGABA of 870.7 ± 106.8% and 694.2 ± 86.0%,
respectively. In terms of potency, 20 was comparable to 2 (EC50
54.5 ± 13.4 lM), whereas 12 was twice as potent (EC50 20.2 ±
Figure 5. Chemical structures of compounds 4–25.
Table 2
Potentiation of IGABA in a1b2c2s receptors by compounds 4–25, at a test concentration
of 100 lM
Stilbenes Dihydrostilbenes
Compound Max. potentiation
of IGABA
na Compound Max. potentiation
of IGABA
na
4 12.6 ± 9.2 3 6 8.3 ± 22.9 3
5 !11.3 ± 12.3 3
7 !7.3 ± 0.1 3 8 51.6 ± 1.1 3
9 !24.8 ± 4.8 3 10 !20.9 ± 3.7 3
11 101.3 ± 0.9 3 12 544.5 ± 140.4 3
13 121.9 ± 21.8 3 14 162.2 ± 17.5 3
15 !35.4 ± 9.8 3 16 86.3 ± 9.9 3
17 !19.7 ± 3.9 3 18 44.1 ± 19.7 3
19 212.4 ± 10.9 3 20 660.6 ± 100.2 3
21 122.8 ± 18.6 3 22 227.7 ± 1.3 2
23 !22.9 ± 7.5 3 24 !16.8 ± 7.9 3
Diazepamb
(1 lM)
231.3 ± 22.6 3 25 !12.9 ± 0.4 3
a Number of experiments.
b Positive control.
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6.4 lM). This suggests that increased lipophilicity of ring B may
have a positive effect on the potency of dihydrostilbenes. However,
further studies with a larger series of compounds are needed for
confirmation. None of the compounds induced direct activation
of the receptors when applied prior to GABA, at concentrations
lower than 100 lM (Fig. 6C).
Stilbenoids have attracted significant attention in recent years
due to their wide range of useful properties, including applications
in optics, biochemistry, and chemotherapy.13,41 The stilbenoid
scaffold can be considered as a priviledged structure.42,43 However,
there have been no reports on GABAA receptor modulatory activity
of stilbenoids up to now, despite a significant number of publica-
tions on biological activities of natural stilbenoids, and in particu-
lar, on resveratrol. Dihydrostilbenes such as 2 may thus be an
interesting starting point for the synthesis of new GABAA receptor
modulators.
4. Conclusions
With the aid of an HPLC-based profiling approach, we identified
batatasin III (2) as the major compound responsible for GABAAR
modulatory activity of the dichloromethane extract of P. chinensis.
This dihydrostilbene showed allosteric modulation in a1b2c2s
GABAA receptors with a higher efficiency than any other natural
products tested up to now, but its EC50 value was significantly
higher than that of BDZs. Dihydrostilbenes represent a new scaf-
fold for GABAA receptor modulators.
The conformational flexibility of dihydrostilbenoids appeared
critical for GABAAR modulatory properties. For a further explora-
tion of this scaffold, conformationally restricted derivatives should
be synthesized in order to explore in more detail the optimal ori-
entation of the aromatic rings and substituents.
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Fig. S1.  Diazepam (1 µM) enhanced IGABA through α1β2γ2S GABAA receptors and was therefore used as positive 
control for the assay. Currents in the presence of GABA (EC5-10, single bar, control) and during co-application of 
GABA and diazepam (1 µM, double bar) are shown. At 1 µM diazepam enhanced IGABA up to 231.3 ± 22.6% (n=3). 
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Fig. S2.  Analytical HPLC chromatogram of a dichloromethane extract of P. chinensis. A. UV trace (210-700 nm). 
B. ELSD trace (45°C, N2 2.8 L/min). Compounds 1-3 appear as the major constituents of the extract. Separation was 
performed with MeOH (solvent A) and water (solvent B), using a gradient from 50% A to 80% A in 40 min, 
followed by 80% A to 100% A in 5 min. The flow rate was 0.4 mL/min, and 50 µg of extract (in 10 µL of DMSO) 
were injected. 
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Fig. S3.  1H NMR spectrum of compound 24 
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Table S1: NMR spectroscopic data (500.13 MHz, methanol-d3) for coelonin (1)  
Molecular formula: C15H14O3; Formula weight: 242.26986; CAS Nr. 82344-82-9   !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! 
 
 
 
  
Position  δCa δH (I, m, J in Hz) 
1 104.8 6.26 (CH, d, 2.5) 
2 155.4 - 
3 100.1 6.30 (CH, d, 2.5) 
4 158.3 - 
4a 114.8 - 
4b 125.2 - 
5 128.6 8.13 (CH, d, 8.4) 
6 112.2 6.62 (CH, dd, 8.3, 2.7) 
7 154.8 - 
8 113.8 6.61 (CH, d, 2.6)  
8a 139.8 - 
9 30.1  2.59 (CH2, s) 
10 30.8  2.59 (CH2, s) 
10a 138.7 - 
4-OCH3 54.2 3.67 (CH3, s)  
a chemical shifts  derived from multiplicity-edited HSQC and HMBC spectra. Blue arrows in structural formula 
indicate observed HMBC correlations. 
OH
O
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Table S2: NMR spectroscopic data (500.13 MHz, methanol-d3) for batatasin III (2)  
Molecular formula: C15H16O3; Formula weight: 244.28574; CAS Nr. 56684-87-8 
 
 
 
  
Position  δCa δH (I, m, J in Hz) 
1 144.9 - 
2 108.1 6.29 (CH, br s) 
3 157.6 -  
4 98.7 6.23 (CH, m)  
5 160.9 - 
6 105.5 6.23 (CH, m) 
1´ 143.3 - 
2´ 115.3  6.64 (CH, m) 
3´ 156.7 - 
4´ 112.4 6.64 (CH, m) 
5´ 129.0 7.03 (CH, dd, 7.9, 7.5) 
6´ 119.8 6.64 (CH, m)  
α 37.0 2.75 (CH2, m)  
β 37.6 2.75 (CH2, m) 
5-OCH3 54.3 3.63 (CH3, s) 
a  chemical shifts  derived from multiplicity-edited HSQC and HMBC spectra. Blue arrows in structural formula 
indicate observed HMBC correlations. 
OH
O
OH
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Table S3: NMR spectroscopic data (500.13 MHz, methanol-d3) for pholidotol D (3)  
Molecular formula: C15H14O3; Formula weight: 242.26986; CAS Nr. 1006380-82-0 
 
 
 
 
Position  δCa δH (I, m, J in Hz) 
1 139.7 - 
2 105.8 6.58 (CH, m) 
3 157.7 - 
4 100.3 6.31 (CH, t, 2.0)   
5 160.8 - 
6 103.4 6.58 (CH, m) 
1´ 138.5 - 
2´ 112.4 7.00-6.65 (CH, m)  
3´ 156.0 - 
4´ 114.4 7.00-6.65 (CH, m) 
5´ 129.4 7.17 (CH, dd, 7.9, 7.8) 
6´ 117.8 6.69 (CH, dd, 8.2, 2.2) 
α 128.4 7.00-6.65 (CH, m) 
β 128.6 7.00-6.65 (CH, m) 
5-OCH3 54.4 3.76 (CH3, s) 
a  chemical shifts  derived from multiplicity-edited HSQC and HMBC spectra. Blue arrows in structural formula 
indicate observed HMBC correlations. 
OH
O
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3.3. HPLC-based activity profiling for GABAA receptor modulators 
in Adenocarpus cincinnatus  
 
Diana C. Rueda, Maria De Mieri, Steffen Hering, and Matthias Hamburger. J Nat 
Prod 2014. Published online (doi: 10.1021/np500016z) 
 
 
 
 
 
 
 
HPLC-based activity profiling enabled the isolation of 15 flavonoid and isoflavonoid 
derivatives, including 8 new natural products, from A. cincinnatus roots and tubers. 
Structure elucidation was achieved by high-resolution mass spectroscopy, microprobe 
NMR, ECD, and polarimetry. All compounds were tested at 100 µM in the oocyte 
assay and the most active one were submitted to concentration-response experiments. 
Two pterocarpans and one isoflavone showed remarkably higher potency than other 
natural products previously isolated in our group (EC50 below 10 µM).  
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ABSTRACT: In a two-microelectrode voltage clamp assay
with Xenopus laevis oocytes, a dichloromethane extract of
Adenocarpus cincinnatus roots and tubers (Leguminosae)
enhanced the GABA-induced chloride current (IGABA) through
receptors of the subtype α1β2γ2s by 126.5 ± 25.1% when tested
at 100 μg/mL. By means of HPLC-based activity profiling, 15
flavonoid and isoflavonoid derivatives, including eight new
compounds, were identified in the active fractions of the
extract. Isoflavone 11 and pterocarpans 2 and 8 showed
promising activity in the oocyte assay, with EC50 values
between 2.8 ± 1.4 and 18.8 ± 2.3 μM. Maximal potentiation of
IGABA ranged between 490% and 640%. This is the first report
of pterocarpans as GABAA receptor modulators.
GABAA receptors (GABAARs) are ligand-gated chloridechannels that mediate the major form of fast inhibitory
neurotransmission in the CNS. They are heteropentamers
assembled from 19 known subunits (α1−6, β1−3, γ1−3, δ, ε, θ, π,
ρ1−3), forming an integral chloride-selective channel. GABA-
induced chloride influx hyperpolarizes the postsynaptic
neurons, inhibiting further action potentials, and thus, impaired
GABAergic function results in CNS disorders such as epilepsy,
insomnia, anxiety, and mood disorders.1−3 A number of
clinically important drugs such as benzodiazepines (BDZs),
barbiturates, neuroactive steroids, anesthetics, and certain other
CNS depressants bind GABAARs. However, these drugs lack
subunit specificity and, therefore, exhibit a number of unwanted
side effects.4 Hence, there is a need for GABAAR modulators
with new structural scaffolds.
In recent years, a large number of natural products have been
identified as GABAAR ligands. Among these, flavonoids have
been extensively studied as first- and second-order GABAAR
modulators interacting with the BDZ binding site and with
alternative BDZ-insensitive sites of the receptor.5−7 Recently,
isoflavones have also been identified as GABAA receptor
modulators.8 Although biogenetically related to flavonoids,
isoflavonoids represent a structurally distinct scaffold.
In the search for new GABAA receptor modulators, we
screened a library of 880 fungal and plant extracts in an
automated two-microelectrode voltage clamp assay in Xenopus
oocytes9 expressing GABAARs of the subtype α1β2γ2s, the most
abundant one in the human brain.1 The dichloromethane
extract of the roots and tubers of Adenocarpus cincinnatus (Ball)
Maire (Fabaceae) potentiated the GABA-induced chloride
current by 126.5 ± 25.1% when tested at 100 μM. A.
cincinnatus, native to Morocco,10,11 is one of the ca. 25 species
of the genus Adenocarpus, subfamily Papilionoideae. Quinoli-
zidine, pyrrolizidine, and bipiperidyl alkaloids, flavonoids, and
isoflavonoids have been described as chemosystematic markers
for the genus.11,12 However, information available on the
species is very limited.
We here describe the identification of 15 flavonoid and
isoflavonoid derivatives from the active extract of A. cincinnatus
by means of HPLC-based activity profiling13 and report
pterocarpans as a new scaffold for GABAA receptor modulators.
Eight new natural products were identified in the extract, while
the remaining seven are reported for the species for the first
time.
■ RESULTS AND DISCUSSION
Isolation and Structure Elucidation of Active Com-
pounds. The activity in the extract was tracked by means of
HPLC-based activity profiling using a previously validated
protocol.14 The chromatogram (210−700 nm) of a semi-
preparative HPLC separation (10 mg of extract) and the
corresponding activity profile of the time-based fractionation
(24 microfractions of 90 s each) are shown in Figure 1B and A,
respectively. The GABAA receptor modulatory activity of the
extract was localized in microfractions 7 to 13. Fractions 9 and
10 potentiated IGABA by 334.15 ± 113.12% and 245.43 ±
141.70%, while fractions 7, 8, and 13 potentiated IGABA between
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170% and 213%. Fractions 11 and 12 enhanced IGABA by 146.51
± 70.60% and 126.76 ± 29.40%, respectively. Owing to the
occurrence of unresolved peaks in the active time window of
the chromatogram, a single-step purification of active
compounds by means of semipreparative or preparative
HPLC was not possible.
Preparative isolation was started with open column
chromatography on silica gel, and 19 fractions (A−S) were
collected on the basis of TLC patterns. HPLC-ESIMS analysis
under optimized separation conditions (Figure 1C) revealed
that the extract was significantly more complex than suggested
by the time-based fractionation (Figure 1B). Peaks with
retention times fitting active microfractions 7−13 were detected
in fractions G−M. Active compounds were isolated from
fractions G, I, and K−M (Figure 1C) with the aid of preparative
and semipreparative HPLC. A total of 15 flavonoid and
isoflavonoid derivatives (1−15) were isolated from the active
time window of the extract, including eight new natural
products: 2, 4, 6, 7, 8, 9, 11, and 12 (Figure 2). Structure
elucidation was achieved by means of ESITOFMS and 1D and
2D microprobe NMR spectroscopy, and absolute configuration
was established by electronic circular dichroism (ECD)
spectroscopy.
The NMR data of compounds 1, 5, 9, and 15 showed
resonances of two vicinal oxygenated methines (H-2 and H-3),
a carbonyl function (C-4), and a set of aromatic protons
suggesting a 7-hydroxydihydroflavonol scaffold. Compound 1
had a molecular formula of C15H12O4 based on HRESIMS (m/
z 279.0626 [M + Na]+) and 13C NMR data. Its structure was
established by NMR spectroscopic data as 7-hydroxydihydro-
flavonol. The compound had been previously isolated from
Virgilia oroboides (Fabaceae), but was identified only as its 3,7-
diacetate.15 Compounds 5 and 15 were identified as lespecyrtin
A1
16 and lespeflorin B2,
17 respectively. The large 3JH,H coupling
constant (∼11.8 Hz) between H-2 and H-3 indicated trans
configurations for 1, 5, and 15 (S5, Supporting Information). In
agreement with previous reports,15−17 the three compounds
showed a 2R,3R absolute configuration. Their ECD spectra
(Figure 3A) exhibited the typical pattern of (2R,3R)-
dihydroflavonols, with a positive CE at 320−303 nm and
negative CE at 270−290 nm, due to n→π* and π→π*
transitions, respectively.18,19 It is noteworthy that the original
report of the (2R,3R)-lespecyrtin (5)16 describes a CD
spectrum with positive CEs for both transitions. However,
such data would contradict the expected behavior, and we
Figure 1. HPLC-based activity profiling of a dichloromethane extract
of roots and tubers of Adenocarpus cincinnatus, for GABAA receptor
modulatory activity. (B) HPLC chromatogram (210−700 nm) of a
semipreparative separation of 10 mg of extract. The 24 time-based
fractions of 90 s each are indicated with dashed lines. (A) Potentiation
of the IGABA by each microfraction (error bars correspond to SE). (C)
Optimized analytical HPLC traces (210−700 nm) of open column
fractions G, I, and K−M. The first trace at the top corresponds to the
crude extract. The numbers above peaks designate compounds 1−15.
The active time window from the HPLC-based activity profile (time-
based fractions 7−13) is indicated between dashed lines.
Figure 2. Flavonoid and isoflavonoid derivatives isolated from A.
cincinnatus.
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assume our experimental data are proper indicators of the
2R,3R absolute configuration of this compound.
Compound 9 has a molecular formula of C25H30O6 based on
HRESIMS (m/z 449.2087 [M + Na]+) and 13C NMR data.
Strong similarities with the NMR data of 15 indicated that 9
was also a 7,4′-dihydroxydihydroflavonol. The only major
difference in the 1H NMR spectrum of 9 (Table 1) was seen
with resonances at δH 2.67 (2H, m, H-α), δH 1.73 (2H, m, H-
β), and δH 1.26 (6H, s, H-δ and -ε). These data were indicative
of a 3-hydroxy-3-methylbutyl moiety, which was corroborated
by the corresponding 13C NMR resonances of C-α−C-ε (δC
25.9, 44.6, 71.6, 29.43, and 29.41, respectively). The attachment
of the side chain at C-6 (δC 117.5) was established via the
NOESY (H-5/H-α, H-β) and HMBC (H-α/C-5, C-7)
correlations. The absolute configuration was established as
2R,3R based on the ECD spectrum (Figure 3A). Hence, the
structure of compound 9 was established as (2R,3R)-7,4′-
dihydroxy-6-(3-hydroxy-3-methylbutyl)-8-(3-methylbut-2-en-1-
yl)dihydroflavonol.
The UV and NMR spectra of compounds 2, 3, 7, 8, and 14
showed distinctive features of the pterocarpan scaffold.19,20 The
absolute configuration of the five pterocarpans was confirmed
as 6aR,11aR by ECD spectra (Figure 3B) and specific rotation
values.19 Compounds 3 and 14 were identified as
(−)-(6aR,11aR)-maackiain21 and (−)-(6aR,11aR)-isoneoraute-
nol,22,23 by comparison with published NMR spectroscopic
data (S6, Supporting Information).
Compound 2 had a molecular formula of C20H22O5 based on
HRESIMS (m/z 365.1324 [M + Na]+) and 13C NMR data. A
set of 1H NMR aliphatic resonances at δH 4.20 (dd, J = 10.9
and 5.0 Hz), δH 3.57 (dd, J = 10.7 and 10.7 Hz), δH 3.45 (ddd, J
= 10.5, 7.0, and 5.0 Hz), and δH 5.40 (d, J = 7.0 Hz) was
assigned to protons of the heterocyclic B and C rings (Table
2).19,20 The coupling constant between H-6a and H-11a (7.0
Hz) indicated a cis-junction of the fused B/C ring system.
Likewise, the 13C NMR shifts of C-6, C-6a, and C-11a of 2
(Table 2) were in agreement with values reported for the cis-
pterocarpan scaffold.20 With the aid of COSY, HMBC (H-1/C-
11a), and NOESY (H-1/H11a) correlations the three aromatic
protons at δH 7.31 (d, J = 8.5 Hz), δH 6.54 (dd, J = 8.5 and 2.5
Hz), and δH 6.36 (d, J = 2.5 Hz) were assigned to the A-ring
spin system. 1H and 13C NMR data indicated the presence of
two hydroxy groups, which were located at C-3 (δC 160.1) and
C-9 (δC 157.1) through HMBC correlations (H-1, H-2, H-4/C-
3; H-7, H-10, H-α/C-9) and comparison of 13C NMR data for
other 3,9-dihydroxy-cis-pterocarpans such as erylysin C.24 A 3-
hydroxy-3-methylbutyl group was indicated by the aliphatic
resonances at δH 1.24 (6H, s), δH 2.64 (2H, m), and δH 1.70
Figure 3. (A) ECD spectra of dihydroflavonols 1, 5, 9, and 15. (B) ECD spectra of pterocarpans 2, 3, 7, 8, and 14.
Table 1. 1H and 13C NMR Spectroscopic Data for
Compound 9 (Methanol-d4, 500 MHz for
1H and 125 MHz
for 13C NMR, δ in ppm)
position δH (J in Hz) δC, type
2 4.93 (d, 11.9) 85.6, CH
3 4.46 (d, 11.9) 74.8, CH
4 195.4, C
4a 113.5, C
5 7.49 (s) 126.2, CH
6 117.5, C
7 161.1, C
8 115.7, C
8a 161.9, C
1′ 130.0, C
2′ 7.37 (d, 8.4) 130.5, CH
3′ 6.83 (d, 8.4) 116.2, CH
4′ - 159.2, C
5′ 6.83 (d, 8.4) 116.2, CH
6′ 7.37 (d, 8.4) 130.5, CH
R1 at C-6
α 2.67 (m) 25.9, CH2
β 1.73 (m) 44.6, CH2
γ 71.6, C
δ 1.26 (s) 29.43, CH3
a
ε 1.26 (s) 29.41, CH3
a
R2 at C-8
α′ 3.28 (m) 23.3, CH2
β′ 5.13 (tsp, 7.3, 1.3) 123.2, CH
γ′ 132.7, C
δ′ 1.61 (s) 26.1, CH3
ε′ 1.52 (s) 18.1, CH3
aInterchangeable within the same column.
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(2H, dd, J = 9.6 and 7.3 Hz) and was attached at C-8 (δC
124.5) based on HMBC (H-α/C-7, C-8, and C-9; H-β/C-8)
and NOESY (H-7/H-β) correlations. Thus, the structure of
compound 2 was established as (−)-(6aR,11aR)-3,9-dihydroxy-
8-(3-hydroxy-3-methylbutyl)pterocarpan.
Compound 7 had a molecular formula of C17H12O4 based on
its HRESIMS (m/z 303. 1141 [M + Na]+) and 13C NMR data.
Its NMR data (Table 2) were similar to those of compound 3,
the only difference being the substituents at C-8 and C-9. An
AX system (δH 7.56, CH, d, J = 2.3 Hz; δH 6.70, CH, d, J = 2.1
Hz) indicated the presence of a furan ring fused at C-8 and C-9.
The structure of 7 was thus established as (−)-(6aR,11aR)-3-
hydroxyfuro[3′,2′:8,9]pterocarpan.
For compound 8, a molecular formula of C20H20O5 was
deduced from HRESITOFMS (m/z 363.1187 [M + Na]+) and
13C NMR data. The UV spectrum was similar to that of 2 (λmax
290 nm), and analysis of the 1H NMR data (Table 2) revealed
that compounds 2 and 8 were closely related. An upfield shift of
H-1 in 8 (δH 6.87, d, J = 8.4 Hz) was attributed to the positive
mesomeric effect induced by a second hydroxy moiety located
at C-4. The substitution pattern was corroborated by diagnostic
changes in the 13C NMR chemical shifts (Table 2) of C-1 (δC
124.7 in 8; 133.4 in 2), C-3 (δC 147.2 in 8; 160.1 in 2), C-4 (δC
134.5 in 8; 104.3 in 2), and C-4a (δC 145.9 in 8; 158.1 in 2). An
isoprenyl residue (δH 3.26, 2H, d, J = 7.1 Hz; 5.35, 1H, tsp, J =
7.3 and 1.3 Hz; 1.76, 3H, s; 1.77, 3H, s) was attached at C-8
(δC 121.9) based on HMBC correlations (H-α/C-7, C-8, and
C-9; H-β/C-8). Compound 8 was thus characterized as
(−)-(6aR,11aR)-3,4,9-trihydroxy-8-(3-methylbut-2-en-1-yl)-
pterocarpan.
Compound 4 had a molecular formula of C16H16O4 based on
HRESIMS (m/z 295.0941 [M + Na]+) and 13C NMR data, and
the UV spectrum showed absorption maxima at 210, 284, and
319 nm. 1D and 2D NMR data (Table 3) displayed resonances
attributable to a monosubstituted (δH 7.10−7.21, 5H, m) and a
1,2,4-trisubstituted aromatic ring, based on the ABX system at
δH 6.32, d, J = 2.2 Hz; 6.36, dd, J = 8.7 and 2.2 Hz; and 7.78, d,
J = 8.7 Hz. Two hydroxy functions were evidenced by two
quaternary 13C NMR resonances at δC 167.6 and 167.2. The
remaining resonances in the 1H and 13C NMR spectra
indicated the presence of a 2-methoxypropan-1-one moiety
(δH 3.26, 3H, s; 3.00, 2H, m; 4.75, 1H, dd, J = 7.5 and 5.4 Hz;
δC 40.3, 58.2, 85.2, and 204.2). HMBC correlations from H-3′
and H-6′ to the carbonyl carbon and from the CH2-β to H-2/6
were indicative of a dihydrochalcone.25,26 C-α (R) absolute
configuration was determined by comparison of the specific
rotation of 4 ([α]25D +47; c 0.1, MeOH) with reported
values26,27 and was confirmed by a positive Cotton effect (CE)
around 300 nm in the ECD spectrum.27 Thus, compound 4
was identified as (+)-(αR)-α-methoxy-2′,4′-dihydroxydihydro-
chalcone.
The molecular formula of compound 12 (C16H14O4; m/z
293.0798 [M + Na]+) differed from that of 4 by 2 mass units.
1H and 13C NMR spectra of compound 12 closely resembled
those of 4 (Table 3), except for the absence of the aliphatic
resonances. An additional olefinic proton resonance at δH 6.18
(1H, s) in 12 was assigned to H-β and permitted definition of
the structure of 12 as α-methoxy-2′,4′-dihydroxychalcone.
Compound 6 had a molecular formula of C20H20O5 based on
the HRESIMS (m/z 363.1311 [M + Na]+) and 13C NMR data.
The NMR spectroscopic data showed strong similarities to
those of 5-deoxykievitone (10),28 which indicated an
isoflavanone scaffold. This was confirmed by the 1H NMR
resonances for H-2a (δH 4.39, dd, J = 11.0 and 5.4 Hz), H-2b
Table 2. 1H and 13C NMR Spectroscopic Data for Compounds 2, 7, and 8 (Methanol-d4, 500 MHz for
1H and 125 MHz for 13C
NMR, δ in ppm)
2 7 8
position δH (J in Hz) δC, type δH (J in Hz) δC, type δH (J in Hz) δC, type
1 7.31 (d, 8.5) 133.4, CH 7.28 (d, 8.3) 133.5, CH 6.87 (d, 8.4) 124.7, CH
1a 113.3, C 113.0, C 114.2, C
2 6.54 (dd, 8.5, 2.5) 110.9, CH 6.51 (dd, 8.3, 2.3) 111.0, CH 6.59 (d, 8.4) 110.6, CH
3 160.1, C 160.5, C 147.2, C
4 6.36 (d, 2.5) 104.3, CH 6.33 (d, 2.1) 104.4, CH 134.5, C
4a 158.1, C 158.3, C 145.9, C
6 4.20 (dd, 10.9, 5.0) 68.0, CH2 4.23 (dd, 10.0, 4.0) 67.7, CH2 4.33 (dd, 10.8, 4.8) 68.2, CH2
3.57 (dd, 10.7, 10.7) 3.58 (dd, 10.0, 10.0) 3.64 (dd, 10.6, 10.6)
6a 3.45 (ddd, 10.5, 7.0, 5.0) 41.4, CH 3.60 (ddd, 10.0, 6.0, 4.0) 41.3, CH 3.50 (m) 41.3, CH
7a 119.4, C 125.8, C 119.1, C
7 7.01 (s) 126.6, CH 7.42 (s) 117.9, CH 7.01 (s) 126.3, CH
8 124.5, C 122.9, C 121.9, C
9 157.1, C 157.4, C 157.0, C
10 6.33 (s) 98.5, CH 6.87 (s) 94.6, CH 6.35 (s) 98.6, CH
10a 159.8, C 159.2, C 159.9, C
11a 5.40 (d, 7.0) 80.0, CH 5.49 (d, 6.0) 80.5, CH 5.46 (d, 7.0) 80.1, CH
α 2.64 (m) 26.1, CH2 3.26 (d, 7.1) 29.1, CH2
β 1.70 (dd, 9.6, 7.3) 45.5 CH2 5.35 (tsp 7.3, 1.3) 122.3, CH
γ 71.8, C 132.5, C
δ 1.24 (s) 29.1, CH3
a 1.76 (s) 26.1, CH3
ε 1.24 (s) 29.2, CH3
a 1.77 (s) 18.1, CH3
O-CH2-O
1′ 7.56 (d, 2.3) 145.6, CH
2′ 6.70 (d, 2.1) 107.8, CH
aInterchangeable within the same column.
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(δH 4.54, dd, J = 10.9 and 10.9 Hz), and H-3 (δH 4.09, dd, J =
11.0 and 5.4 Hz), typical for ring C of isoflavanones (Table
4).29 The presence of a 3-methylbut-2-en-1-yl (isoprenyl)
group in 6 at C-6 (δC 125.0) was established via the HMBC
correlation between H-α (δH 3.23, d, J = 7.3 Hz) and C-5 and
C-7 (δC 129.1 and 164.4, respectively). Compound 6 was
therefore identified as 7,2′,4′-trihydroxy-6-(3-methylbut-2-en-1-
yl)isoflavanone. The ECD spectra of compounds 6 and 10 were
devoid of CEs in the 200−450 nm region. This is reminiscent
of racemates, since it is known that racemization occurs in
isoflavanones even under mild conditions.19 The absolute
configuration of 5-deoxykievitone (10) and structurally similar
isoflavanones has not been established. However, the absolute
configuration of other prenylated isoflavanones has been
determined by ECD.30
Compound 11 had a molecular formula of C20H18O5 based
on its HRESIMS (m/z 361.1067 [M + Na]+) and 13C NMR
data. Its UV and NMR data (Table 4) were similar to those of
8-prenyldaidzein (13)31 (S7, Supporting Information). Differ-
ences in the NMR data of 11 and 13 were observed for
resonances attributable to ring B. The 1H NMR spectrum of 11
displayed an ABX system due to a hydroxy group attached to
C-2′. The assignment was supported by the HMBC correlation
of H-3′/C-2′, C-4′ and 13C NMR data (Table 4). The structure
of compound 11 was thus established as 2′,4′,7-trihydroxy-8-(3-
methylbut-2-en-1-yl)isoflavone.
Modulation of GABAA Receptors. Compounds 1−15
were tested at an initial concentration of 100 μM in the Xenopus
oocyte assay (Figure 4A, Table 5). In α1β2γ2s receptors,
isoflavone 11 enhanced IGABA by 560.34 ± 387.06%, while 8-
prenyldaidzein (13), differing only by the substituent at C-2′,
modulated IGABA to a lower extent (192.35 ± 47.30%).
Pterocarpans 2 and 8 enhanced IGABA by 488.57 ± 268.62%
and 453.87 ± 141.03%, respectively, while 3 and 7 exhibited
lower efficiency. This suggested that an additional five-
membered ring attached to C-8 and C-9 had a negative
influence in the GABAAR modulatory activity of pterocarpans.
In contrast, a six-membered ring fused at the same position as
in isoneorautenol (14) (IGABA potentiation by 388.50 ±
47.30%) did not negatively affect activity. Among dihydro-
flavonols, lespecyrtin A1 (5) and lespeflorin B2 (15)
significantly enhanced IGABA (272.42 ± 132.19% and 287.35
± 60.59%, respectively), whereas 1 was essentially inactive. In
the case of chalcone derivatives 4 and 12, which potentiated
IGABA by 88.82 ± 28.94% and 227.81 ± 48.14%, respectively,
increased conformational flexibility appeared to have a negative
effect on potency.
Concentration−response curves were recorded for com-
pounds 2, 8, 11, and 14, which potentiated IGABA by more than
380% at the initial concentration of 100 μM (Figure 4B).
Isoflavone 11 displayed the highest potency (EC50 of 2.84 ±
1.37 μM), followed by pterocarpans 2 (8.60 ± 1.64 μM) and 8
(18.83 ± 2.34 μM). Isoneorautenol (14) displayed a much
lower potency (EC50 of 40.74 ± 4.08 μM), although it showed
the highest efficiency (Emax), enhancing IGABA by 771.09 ±
57.94% (Table 6).
No direct receptor activation was observed at concentrations
lower than 100 μM (Figure 4C−F). This suggested allosteric
modulation rather than direct agonistic activity on the
receptors. A strong decrease in IGABA enhancement was
observed with pterocarpans 2, 8, and 14 at 300 μM (Figure
4B, C, D, and F). This reduced modulation at high
concentrations suggests that the mechanism of action of
pterocarpans may combine modulation of GABAARs and low-
affinity open channel block, as in the case of valerenic acid, a
β2/3 subunit-specific modulator of the receptor.
32 In the case of
Table 3. 1H and 13C NMR Spectroscopic Data for
Compounds 4 and 12 (Methanol-d4, 500 MHz for
1H and
125 MHz for 13C NMR, δ in ppm)
4 12
position δH (J in Hz) δC, type δC, type
δH (J in
Hz)
1 138.5, C 135.5, C
2 7.10−7.21 (m) 130.5, CH 131.0, CH 7.76 (dd,
7.3, 1.2)
3 7.10−7.21 (m) 129.4, CH 129.6, CH 7.37 (dd,
7.5, 7.3)
4 7.10−7.21 (m) 127.7, CH 129.4, CH 7.30 (tt,
7.3, 1.3)
5 7.10−7.21 (m) 129.4, CH 129.6, CH 7.37 (dd,
7.5, 7.3)
6 7.10−7.21 (m) 130.5, CH 131.0, CH 7.76 (dd,
7.3, 1.2)
α 4.75 (dd, 7.5, 5.4) 85.2, CH 154.2, C
β 3.00 (m) 40.3, CH2 120.4. CH 6.18 (s)
CO 204.2, C 195.8, C
1′ 113.0, C 113.7, C
2′ 167.6, C 168.3, C
3′ 6.32 (d, 2.2) 104.0, CH 104.2, CH 6.33 (d,
1.5)
4′ 167.2, C 167.5, C
5′ 6.36 (dd, 8.7, 2.2) 109.9, CH 110.0, CH 6.37 (dd,
8.6, 1.5)
6′ 7.78 (d, 8.7) 133.6, CH 135.8, CH 7.84 (d,
8.6)
β-OCH3 3.26 (s) 58.2, CH3 58.7, CH3 3.66 (s)
Table 4. 1H and 13C NMR Spectroscopic Data for
Compounds 6 and 11 (Methanol-d4, 500 MHz for
1H and
125 MHz for 13C NMR, δ in ppm)
6 11
position δH (J in Hz) δC, type δC, type δH (J in Hz)
2 4.39 (dd, 11.0, 5.4) 72.2, CH2 156.9, CH 8.17 (s)
4.54 (dd, 10.9,
10.9)
3 4.09 (dd, 11.0, 5.4) 48.8, CH 123.9, C
4 195.2, C 179.9, C
4a 115.3, C 118.0, C
5 7.60 (s) 129.1, CH 125.7, CH 7.92 (d, 8.8)
6 125.0, C 116.0, CH 6.96 (d, 8.8)
7 164.4, C 162.3,C
8 6.35 (s) 103.0, CH 117.0, C
8a 164.2, C 157.7, C
1′ 114.7, C 112.4, C
2′ 157.8, C 158.2, C
3′ 6.36 (d, 2.3) 103.8, CH 105.0, CH 6.42 (d, 2.2)
4′ 159.0, C 160.4, C
5′ 6.26 (dd, 8.3, 2.3) 107.9, CH 108.7, CH 6.38 (d, 8.2, 2.2)
6′ 6.81 (d, 8.3) 131.8, CH 133.2, CH 7.05 (d, 8.2)
α 3.23 (d, 7.3) 28.5, CH2 23.0, CH2 3.55 (d, 7.0)
β 5.29 (tsp, 7.3, 1.3) 123.4, CH 123.0, CH 5.25 (tsp, 7.3,
1,3)
γ 133.6, C 133.4, C
δ 1.72 (s) 25.9, CH3 26.3, CH3 1.68 (s)
ε 1.68 (s) 17.8, CH3 18.2, CH3 1.82 (s)
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isoflavone 11, potentiation of IGABA did not drop significantly at
high test concentrations, in agreement with the simple
modulation mechanism recently proposed for isoflavones acting
at this biological target.8
We compared the potency and efficiency of 2, 8, 11, and 14
to other natural products identified as GABAA receptor
modulators33−36 (Figure 5). Compounds 11 and 2 exhibited
remarkably higher potency, with EC50 values below 10 μM,
indicating higher binding affinity toward the receptor. The
efficiencies of the compounds on α1β2γ2s GABAARs were higher
than that of BDZs such as triazolam, clotiazepam, and
midazolam.37
Pterocarpans are the second largest subclass of isoflavonoids
after isoflavones. They are known as phytoalexins, and a range
of other biological activities,20,38,39 but no GABAergic proper-
ties, have been reported for these compounds. Compounds 2,
8, and 14 thus represent a new scaffold for GABAA receptor
modulators. In vivo studies show that certain flavonoids are
absorbed after oral administration, cross the blood−brain
barrier (BBB), and bind to GABAA receptors, resulting in
sedation, anxiolytic, or anticonvulsant effects.40,41 Being
biosynthetically and structurally related, a similar behavior
could be expected from pterocarpans. Their physicochemical
properties are favorable for a possible BBB permeation (Table
6) (cLogP ≤ 5, MW ≤ 450, and topological polar surface area
(tPSA) ≤ 90 Å2).42,43 Hence, they expand the spectrum of
known GABAA receptor modulators among flavonoids beyond
flavones and isoflavones.8,44 Behavioral studies in rodents are
needed to evaluate the in vivo activity of these pterocarpans.
Using an HPLC-based activity profiling approach, we
identified 15 dihydroflavonols, isoflavones, isoflavanones,
chalcones, and pterocarpans from a lipophilic extract of A.
cincinnatus. Among these were eight new natural products (2, 4,
6, 7, 8, 9, 11, and 12); known compounds 1, 3, 5, 10, 13, and
Figure 4. (A) Potentiation of IGABA by compounds 1−15 (100 μM). Data obtained from three oocytes (two different batches). (B) Concentration−
response curves for compounds 2, 8, 11, and 14 recorded with GABAA receptors of the subunit composition α1β2γ2s. Data points represent means ±
SE from four oocytes (three different batches). (C−F) Typical traces for modulation of IGABA by compounds 2, 8, 11, and 14, respectively. The flat
segments in the currents indicate the absence of direct activation of the receptors. All experiments in A−F were carried out using a GABA EC5−10.
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14 have not been previously isolated from A. cincinnatus. We
identified pterocarpans as a new scaffold for GABAA receptor
modulators. Further pharmacological studies on subunit
specificity, binding properties, and in vivo activity are needed
to further explore the potential of this scaffold.
■ EXPERIMENTAL SECTION
General Experimental Procedures. Optical rotations were
measured with a Perkin-Elmer 341 polarimeter using a 10 cm
microcell and MeOH (1 mg/mL) as solvent. UV and ECD spectra
were recorded in MeOH (120 μg/mL) on a Chirascan CD
spectrometer and analyzed with Pro-Data V2.4 software. NMR spectra
were recorded on a Bruker Avance III spectrometer operating at
500.13 for 1H and 125.77 MHz for 13C. 1H NMR, COSY, HSQC,
HMBC, and NOESY spectra were measured at 18 °C in a 1 mm TXI
probe with a z-gradient, using standard Bruker pulse sequences. 13C
NMR/DEPT spectra were recorded at 23 °C in a 5 mm BBO probe
with a z-gradient. Spectra were analyzed by Bruker TopSpin 3.0
software. ESITOFMS spectra were recorded in positive mode on a
Bruker microTOF ESIMS system. Nitrogen was used as a nebulizing
gas at a pressure of 2.0 bar and as drying gas at a flow rate of 9.0 L/min
(dry gas temperature 240 °C). Capillary voltage was set at 45 000 V,
and hexapole at 230.0 Vpp. Instrument calibration was done with a
reference solution of 0.1% sodium formate in 2-propanol/water (1:1)
containing 5 mM NaOH.
HPLC-PDA-ESIMS spectra were obtained in positive mode on a
Bruker Daltonics Esquire 3000 Plus ion trap MS system, connected via
T-splitter (1:10) to an Agilent HP 1100 system consisting of a
degasser, binary mixing pump, autosampler, column oven, and diode
array detector (G1315B). Data acquisition and processing was
performed with Bruker Daltonics Hystar 3.0 software. Semipreparative
HPLC separations were carried out with an Agilent HP 1100 series
system consisting of a quaternary pump, autosampler, column oven,
and diode array detector (G1315B). Preparative HPLC separations
were performed on a Shimadzu LC-8A preparative HPLC system with
an SPD-M10A VP diode array detector. Waters SunFire C18 (3.5 μm,
3.0 × 150 mm i.d.), SunFire Prep C18 (5 μm, 10 × 150 mm i.d.), and
SunFire Prep C18 OBD (5 μM, 30 × 150 mm i.d.) columns were used
for analytical, semipreparative, and preparative separations, respec-
tively. HPLC-grade MeOH (Scharlau Chemie S.A.) and water were
used for HPLC separations. HPLC solvents contained 0.1% of
HCO2H for analytical and semipreparative separations. NMR spectra
were recorded in methanol-d4 (Armar Chemicals). Technical grade
solvents purified by distillation were used for extraction and open
column chromatography. Silica gel (63−200 μm, Merck) was used for
open column chromatography.
Plant Material. Dried roots and tubers of A. cincinnatus were
collected in 2005 in Beni Tajjite, Morocco, by Thomas Friedrich. The
identity of the plant material was confirmed at the Division of
Pharmaceutical Biology, University of Basel, where a voucher
specimen (092) is deposited.
Extraction. The plant material was frozen with liquid N2 and
ground with a ZM1 ultracentrifugal mill (Retsch). The DCM extract
for screening and HPLC-based activity profiling was prepared with an
ASE 200 extraction system with solvent module (Dionex Sunnyvale,
CA, USA). In total, three extraction cycles (5 min each) were
performed, at a pressure of 120 bar and a temperature of 70 °C. For
preparative isolation, 304 g of ground plant material was macerated
with DCM (4 × 1 L, 3 h each, permanent magnetic stirring). The
solvent was evaporated at reduced pressure to yield 8.5 g of extract.
The extracts were stored at 2−8 °C until use.
Microfractionation for Activity Profiling. Time-based micro-
fractionation of the extract for GABAA receptor activity profiling was
performed as previously described,14 with minor modifications:
separation was done on a semipreparative HPLC column with
MeOH (solvent A) and H2O (solvent B), using a gradient from 50% A
to 100% A in 30 min, hold for 15 min. The flow rate was 4 mL/min,
and 10 mg of extract (in 100 μL of DMSO) was injected. A total of 24
time-based microfractions of 90 s each were collected and evaporated
in parallel. The dry films were redissolved in 1 mL of MeOH, and
aliquots of 0.5 mL were dispensed in two vials, dried under N2 gas, and
submitted to bioassay.
Isolation. A portion of the extract (7 g) was separated by open
column chromatography (6 × 69 cm, 700 g of silica gel), using a step
gradient of n-hexane/EtOAc (100:0, 95:5, 90:10, 85:15, 80:20, 75:25,
70:30, 65:35, 60:40, 55:45, 50:50, 30:70, 0:100, 1 L each), and washing
in the end with MeOH 100% (1.5 L). The flow rate was ca. 50 mL/
min. The effluent was combined to 19 fractions (A−S) based on TLC
patterns (detection at 254 nm and at daylight after staining with
vanillin−sulfuric acid reagent). Fractions A−S were subjected to
analytical HPLC-PDA-ESIMS with MeOH (solvent A) and H2O
(solvent B), using an optimized gradient of 50% A to 100% A in 50
min, hold for 10 min. The flow rate was 0.4 mL/min, and 50 μg of
each fraction (in 5 μL of DMSO) was injected. Fractions G−M were
found to contain the compounds of interest. Therefore, fractions G, I,
and K−M were submitted to preparative HPLC using solvents A and
B as eluents, with a flow rate of 20 mL/min. Stock solutions in THF
(100 mg/mL) were prepared and repeatedly injected in portions of
300−400 μL. Fraction G (314 mg) was separated into 12 fractions
(G1−G12), using a gradient of 50% A to 60% A in 30 min, followed
Table 5. Potentiation of IGABA in α1β2γ2s Receptors by
Compounds 1−15, at a Test Concentration of 100 μM
compound max. potentiation of IGABA (%)
a
1 11.73 ± 2.97
2 488.57 ± 268.62
3 237.75 ± 28.56
4 88.82 ± 28.94
5 272.42 ± 132.19
6 198.60 ± 66.39
7 212.56 ± 61.40
8 453.87 ± 141.03
9 −26.01 ± 9.03
10 361.45 ± 224.48
11 560.34 ± 387.06
12 227.81 ± 48.14
13 192.35 ± 47.30
14 388.50 ± 47.30
15 287.35 ± 60.59
aModulation measured in three oocytes from two different batches.
Table 6. Potency and Efficiency of Compounds 2, 8, 11, and 14 as Positive Modulators of GABAA Receptors of α1β2γ2s Subunit
Composition, Calculated log P, and Topological Polar Surface Area
compound Emax (%)
a EC50 (μM)
a nH
b ClogPc tPSA (Å2)c
2 640.02 ± 53.56 8.6 ± 1.6 1.56 ± 0.22 2.58 79.15
8 490.97 ± 22.34 18.8 ± 2.3 2.42 ± 0.43 3.76 79.15
11 552.73 ± 84.07 2.8 ± 1.4 1.00 ± 0.46 3.07 86.99
14 771.09 ± 57.94 40.7 ± 4.08 1.57 ± 0.10 4.41 47.92
aModulation measured in four oocytes from three different batches. bHill coefficient. Indicates the slope of the concentration−response curve at the
EC50 point.
cClogP and topological polar surface area (tPSA) calculated with ChemBioDraw Ultra 12.0 software (CambridgeSoft).
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by 60% A to 100% A in 20 min, hold for 10 min. Fraction I (889 mg)
was separated into 14 fractions (I1−I14), with a gradient of 50% A to
80% A and 80% A to 100% A in 50 and 5 min, respectively (hold for
10 min). Separation of fraction K (376 mg) yielded 14 fractions (K1−
K14) with a gradient of 50% A to 70% A in 50 min, followed by 70% A
to 100% A in 5 min, hold for 10 min. The same gradient was used for
the separation of fractions L (185 mg) and M (270 mg), which were
separated into 16 fractions each (L1−L16 and M1−M16,
respectively). Owing to the complexity of the fractions, separation
by preparative HPLC did not yield any pure compounds. Thus,
preparative HPLC fractions selected on the basis of their LC-MS
profiles were submitted to further purification by semipreparative
HPLC, using solvents A and B as eluents. The flow rate was 4 mL/
min. Stock solutions in DMSO (100 mg/mL) were prepared and
repeatedly injected in portions of 40 to 70 μL. Fraction G1 (11 mg)
was separated under isocratic conditions of 55% A for 25 min to yield
5.8 mg of (−)-6aR,11aR-maackiain (3). Separation of fraction G2
(32.4 mg) under the same conditions yielded compounds 4 (10 mg)
and 7 (2.5 mg). Fractions G4 (4.4 mg) and G5 (4.9 mg) were
separated with a gradient of 60% A to 75% A in 35 min to obtain
compounds 12 (2.7 mg) and 14 (2.1), respectively. A gradient of 50%
A to 80% A in 50 min was used to obtain compound 1 (3.2 mg) from
fraction I1 (5.1 mg). Fraction I11 (28.6 mg) was separated with a
gradient of 65% A to 80% A in 40 min, to yield 11.5 mg of lespeflorin
B2 (15). Compound 11 (2.3 mg) was obtained from separation of
fraction K10 (5.6 mg) with a gradient of 65% A to 75% A in 40 min.
Fractions L6 (3.2 mg) and L7 (12.7) were separated with a gradient of
60% A to 80% A in 40 min to obtain 1.4 mg of compound 5 and 6.5
mg of compound 6, respectively. The same conditions were used for
the separation of fractions M4 (17.8 mg), M8 (10.1 mg), M9 (6.2 mg),
and M10 (5.3 mg), which yielded compounds 2 (9.5 mg), 8 (7.2 mg),
9 (2.7 mg), and 10 (3.4 mg), respectively. Separation of fraction L13
(12.8 mg) with a gradient of 65% A to 80% A in 40 min resulted in 7.9
mg of 8-prenyldaidzein (13). The purity of all compounds was >95%
(purity check by 1H NMR).
(−)-(2R,3R)-7-Hydroxydihydroflavonol (1): [α]25D −4 (c 0.1,
MeOH); UV (MeOH) λmax (log ε) 211 (4.43), 276 (4.04), 312
(3.88) nm; ECD (MeOH, c = 4.9 × 10−4 M, 1 cm path length) λmax
(Δε) 217 (+18.47), 302 (−7.60), 331 (+4.13) nm; 1H and 13C NMR
data, see S5 (Supporting Information); HRESIMS m/z 279.0626 [M +
Na]+ (calcd for C15H12NaO4, 279.0628). NMR spectra of 1 are
available as Supporting Information.
(−)-(6aR,11aR)-3,9-Dihydroxy-8-(3-hydroxy-3-methylbutyl)-
pterocarpan (2): [α]25D −135 (c 0.1, MeOH); UV (MeOH) λmax (log
ε) 288 (3.78) nm; ECD (MeOH, c = 3.6 × 10−4 M, 1 cm path length)
λmax (Δε) 236 (−12.04), 289 (+3.90) nm; 1H and 13C NMR data, see
Table 2; HRESIMS m/z 365.1324 [M + Na]+ (calcd for C20H22NaO5,
365.1359). NMR spectra of 2 are available as Supporting Information.
(+)-(αR)-α-Methoxy-2′,4′-dihydroxydihydrochalcone (4): [α]25D
+47 (c 0.1, MeOH); UV (MeOH); λmax (log ε) 210 (4.23), 233
(sh) (3.82), 284 (4.03), 319 (3.84) nm; ECD (MeOH, c = 9.2 × 10−4
M, 1 cm path length) λmax (Δε) 283 (+1.91) nm; 1H and 13C NMR
data, see Table 3; HRESIMS m/z 295.0941 [M + Na]+ (calcd for
C16H16NaO4, 295.0941). NMR spectra of 4 are available as Supporting
Information.
7,2′,4′-Trihydroxy-6-(3-methylbut-2-en-1-yl)isoflavanone (6): UV
(MeOH) λmax (log ε) 279 (4.10), 319 (3.80) nm;
1H and 13C NMR
data, see Table 4; HRESIMS m/z 363.1311 [M + Na]+ (calcd for
C20H20NaO5, 363.1203). NMR spectra of 6 are available as Supporting
Information.
(−)-(6aR,11aR)-3-Hydroxyfuro[3′,2′:8,9]pterocarpan (7): [α]25D
−211 (c 0.1, MeOH); UV (MeOH) λmax (log ε) 206 (4.83), 245
(4.10), 253 (4.09), 295 (3.92) nm; ECD (MeOH, c = 4.5 × 10−4 M, 1
cm path length) λmax (Δε) 207 (−45.28), 229 (−18.19), 290 (+4.27)
nm; 1H and 13C NMR data, see Table 2; HRESIMS m/z 303.1141 [M
+ Na]+ (calcd for C17H12NaO4, 303.1137). NMR spectra of 7 are
available as Supporting Information.
(−)-(6aR,11aR)-3,4,9-Trihydroxy-8-(3-methylbut-2-en-1-yl)-
pterocarpan (8): [α]25D −132 (c 0.1, MeOH); UV (MeOH) λmax (log
ε) 207 (4.67), 290 (3.71) nm; ECD (MeOH, c = 3.7 × 10−4 M, 1 cm
path length) λmax (Δε) 204 (+14.32), 215 (−22.93), 237 (−11.14),
290 (+2.05) nm; 1H and 13C NMR data, see Table 2; HRESIMS m/z
363.1187 [M + Na]+ (calcd for C20H20NaO5, 363.1203). NMR spectra
of 8 are available as Supporting Information.
Figure 5. Overview of GABAA receptor modulatory efficiency and potency of selected plant-derived natural products, at the α1β2γ2s GABAA receptor.
Compounds in gray correspond to compounds previously isolated from Piper nigrum fruits,33 Acorus calamus roots,35 Biota orientalis leaves and
twigs,36 and Kadsura longipedunculata fruits.34 Reference data of benzodiazepines (triazolam, midazolam, clotiazepam) are taken from Khom et al.,
2006.37 Etomidate and alphaxalone values were measured by Pau et al., 2003.45 Pentobarbitone was investigated by Thompson et al., 1996,46 using a
GABA EC20, meaning that its efficiency is underestimated compared to the rest. (Adapted from Zaugg, 2011.
47)
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(−)-(2R,3R)-7,4′-Dihydroxy-6-(3-hydroxy-3-methylbutyl)-8-(3,3-
dimethylallyl)dihydroflavonol (9): [α]25D −2 (c 0.1, MeOH); UV
(MeOH) λmax (log ε) 224 (4.38), 284 (4.01), 323 (sh) (3.68) nm;
ECD (MeOH, c = 2.9 × 10−4 M, 1 cm path length) λmax (Δε) 220
(+11.91), 238 (+4.54), 307 (−6.46), 339 (+4.48) nm; 1H and 13C
NMR data, see Table 1; HRESIMS m/z 449.2087 [M + Na]+ (calcd
for C25H30NaO6, 449.2087). NMR spectra of 9 are available as
Supporting Information.
7,2′,4′-Trihydroxy-8-(3-methylbut-2-en-1-yl)isoflavone (11): UV
(MeOH) λmax (log ε) 251 (4.17), 291 (3.85) nm;
1H and 13C NMR
data, see Table 4; HRESIMS m/z 361.1067 [M + Na]+ (calcd for
C20H18NaO5, 361.1046). NMR spectra of 11 are available as
Supporting Information.
α-Methoxy-2′,4′-dihydroxychalcone (12): UV (MeOH) λmax (log
ε) 244 (4.06), 297 (sh) (4.07), 347 (4.18) nm; 1H and 13C NMR data,
see Table 3; HRESIMS m/z 293.0798 [M + Na]+ (calcd for
C16H14NaO4, 293.0784). NMR spectra of 12 are available as
Supporting Information.
Expression of GABAA Receptors. Stage V−VI oocytes from
Xenopus laevis were prepared, and cRNA was injected as previously
described.14 Female Xenopus laevis (NASCO, Fort Atkinson, WI, USA)
were anesthetized by exposing them for 15 min to a 0.2% MS-222
(methanesulfonate salt of 3-aminobenzoic acid ethyl, Sigma) solution
before surgically removing parts of the ovaries. Follicle membranes
from isolated oocytes were enzymatically digested with 2 mg/mL
collagenase from Clostridium histolyticum (Type 1A, Sigma). Synthesis
of capped runoff poly(A+) cRNA transcripts was obtained from
linearized cDNA templates (pCMV vector). Directly after enzymatic
isolation, the oocytes were injected with 50 nL of DEPC-treated water
(Sigma) containing different cRNAs at a concentration of approx-
imately 300−3000 pg/nL per subunit. The amount of injected cRNA
mixture was determined by means of a NanoDrop ND-1000 (Kisker
Biotech). To ensure expression of the gamma subunit in α1β2γ2s
receptors, rat cRNAs were mixed in a 1:1:10 ratio. Oocytes were then
stored at 18 °C in ND96 solution containing 1% of penicillin−
streptomycin solution (Sigma-Aldrich). Voltage clamp measurements
were performed between days 1 and 5 after cRNA injection.
Positive Control. Diazepam (7-chloro-1,3-dihydro-1-methyl-5-
phenyl-2H-1,4-benzodiazepin-2-one, Sigma, purity ≥98%) was used
as positive control. At 1 μM, diazepam enhanced IGABA up to 231.3 ±
22.6% (n = 3). See also S1, Supporting Information.
Two-Microelectrode Voltage Clamp Studies. Electrophysio-
logical experiments were performed by the two-microelectrode voltage
clamp method making use of a TURBO TEC 03X amplifier (npi
Electronic GmbH) at a holding potential of −70 mV and pCLAMP 10
data acquisition software (Molecular Devices). Currents were low-
pass-filtered at 1 kHz and sampled at 3 kHz. The bath solution
contained 90 mM NaCl, 1 mM KCl, 1 mM MgCl2, 1 mM CaCl2, and 5
mM HEPES (pH 7.4). Electrode filling solution contained 2 M KCl.
Fast Solution Exchange during IGABA Recordings. Test
solutions (100 μL) were applied to the oocytes at a speed of 300
μL/s by means of the ScreeningTool automated fast perfusion
system.9 In order to determine GABA EC5−10 (typically between 3 and
10 μM for receptors of subunit composition α1β2γ2s), a dose−response
experiment with GABA concentrations ranging from 0.1 μM to 1 mM
was performed. Stock solution of the DCM extract (10 mg/mL in
DMSO) was diluted to a concentration of 100 μg/mL with bath
solution containing GABA EC5−10 according to a validated protocol.
14
As previously described, microfractions collected from the semi-
preparative HPLC separations were dissolved in 30 μL of DMSO and
subsequently mixed with 2.97 mL of bath solution containing GABA
EC5−10.
14 A stock solution of each pure compound tested (100 mM in
DMSO) was diluted to concentrations of 0.1, 1.0, 3.0, 10, 30, 100, and
300 μM with bath solution for measuring direct activation or with bath
solution containing GABA EC5−10 for measuring modulation of
GABAA receptors. The final DMSO concentration in all the samples
and the GABA control samples was adjusted to 1% to avoid solvent
effect at the GABAA receptor.
Data Analysis. Enhancement of the IGABA was defined as
I(GABA+Comp)/IGABA − 1, where I(GABA+Comp) is the current response in
the presence of a given compound, and IGABA is the control GABA-
induced chloride current. Data were analyzed using Origin 7.0 SR0
software (OriginLab Corporation) and are given as mean ± SE of at
least two oocytes from ≥2 oocyte batches.
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 2 
S1. Diazepam (1 µM) enhances IGABA through α1β2γ2S GABAA receptors and was therefore used 
as positive control for the assay. Currents in the presence of GABA (EC5-10, single bar, control) 
and during co-application of GABA and diazepam (1 µM, double bar) are shown. At 1 µM 
diazepam enhanced IGABA up to 231.3 ± 22.6% (n=3). 
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 3 
S2. Optimized analytical HPLC traces (210-700 nm) of open column fractions G, I, and K-M. 
The first trace at the top corresponds to the crude extract. The numbers above peaks designate 
compounds 1-15. The active time window from the HPLC-based activity profile (time-based 
fractions 7-13) is indicated between dashed lines. 
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S3. Compounds isolated from A. cincinnatus roots and tubers, DCM extract. 
 
 Trivial Name CAS number Sum 
formula 
MW Structure Ref 
 
1 
 
--- 
 
34198-87-3 
 
C15H12O4 
 
256 
  
15 
 
2 
 
--- 
 
1177129-77-9 
 
C20H22O5 
 
342 
 
 
--- 
 
3 
 
6aR,11aR-
Maackiain 
 
2035-15-6 
 
C16H12O5 
 
284 
 
 
21 
 
4 
 
--- 
 
--- 
 
C16H16O4 
 
272 
 
 
--- 
 
5 
 
2R,3R- 
Lespecyrtin A1 
 
1103683-88-0 
 
C20H20O5 
 
340 
 
 
16 
  
O
OH
O
OH
OOH
O
OH
OH
OOH
O O
O
O
O
OH OH
O
OH
OH
O
OH
111
 5 
 
6 
 
--- 
 
--- 
 
C20H20O5 
 
340 
 
 
--- 
 
7 
 
--- 
 
--- 
 
C17H12O4 
 
280 
 
 
--- 
 
8 
 
--- 
 
1177965-92-2 
 
C20H20O5 
 
340 
 
 
--- 
 
9 
 
--- 
 
--- 
 
C25H30O6 
 
426 
 
 
--- 
 
10 
 
5-Deoxykievitone 
 
74161-24-3 
 
C20H20O5 
 
340 
 
 
28 
  
OH O
O
OH
OH
OOH
O
O
OOH
O
OH
OH
O
OH
O
OH
OH
OH
OH O
O
OH
OH
112
 6 
 
11 
 
--- 
 
--- 
 
C20H18O5 
 
338 
 
 
--- 
 
12 
 
--- 
 
--- 
 
C16H14O4 
 
270 
 
 
--- 
 
13 
 
8-
Prenyldaidzein 
 
135384-00-
8 
 
C20H18O4 
 
322 
 
 
31 
 
14 
 
6aR,11aR-
Isoneorautenol 
 
98755-24-9 
 
C20H18O4 
 
322 
 
 
22, 
23 
 
15 
 
2R,3R- 
Lespeflorin B2 
 
1108717-
54-9 
 
C25H28O5 
 
408 
 
 
17 
 
  
OOH
O
OH
OH
O
O
OH OH
OH O
O
OH
OOH
O
O
O
OH
O
OH
OH
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 7 
S4. Analytical data of known compounds 3, 5, 10, 13, 14, and 15. 
 
(−)-(6aR,11aR)-Maackiain (3): [α]D25  −196 (c 0.1, MeOH); UV (MeOH) λmax (log ε) 203 (4.09), 
311 (3.81) nm; ECD (MeOH, c = 4.4 x 10-4 M, 1 cm pathlength): λmax (∆ε) 212 (−26.64), 239 
(−9.59), 307 (+2.27) nm; HRESIMS m/z 307.0579 [M+Na]+ (calcd for C16H12NaO5, 307.0577). 
 
(−)-(2R,3R)-Lespecyrtin A1 (5): [α]D25  −10 (c 0.0577, MeOH); UV (MeOH) λmax  (log ε) 219 
(4.32), 284 (4.00) nm; ECD (MeOH, c = 3.7 x 10-4 M, 1 cm pathlength): λmax (∆ε) 218 (+11.11), 
238 (+4.13), 303 (−5.23), 333 (+3.00) nm; HRESIMS m/z 363.1294 [M+Na]+ (calcd for 
C20H20NaO5, 363.1203). 
 
5-Deoxykievitone (10): UV (MeOH) λmax (log ε) 217 (4.37), 286 (4.07) nm; HRESIMS m/z 
363.1266 [M+Na]+ (calcd for C20H20NaO5, 363.1203). 
 
8-Prenyldaidzein (13): UV (MeOH) λmax (log ε) 253 (4.53), 306 (4.00) nm; HRESIMS m/z 
345.1204 [M+Na]+ (calcd for C20H18NaO4, 345.1097). 
 
(−)-(6aR,11aR)-Isoneorautenol (14): [α]D25  −139 (c 0.089, MeOH); UV (MeOH) λmax (log ε) 
220 (4.50), 286 (3.85), 313 (3.85) nm; ECD (MeOH, c = 7.8 x 10-4 M, 1 cm pathlength): λmax 
(∆ε) 210 (−28.06), 315 (+1.46) nm; HRESIMS m/z 345.1138 [M+Na]+ (calcd for C20H18NaO4, 
345.1097) 
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 8 
(−)-(2R,3R)-Lespeflorin B2 (15): [α]D25 −2 (c 0.1, MeOH); UV (MeOH) λmax (log ε) 223 (4.44), 
268 (4.23), 329 (sh) (3.68) nm; ECD (MeOH, c = 3.1 x 10-4 M, 1 cm pathlength): λmax (∆ε) 221 
(+10.48), 239 (+4.74), 309 (−6.23), 339 (+4.30) nm; HRESIMS m/z 431.1809 [M+Na]+ (calcd 
for C25H28NaO5, 431.1829) 
 
115
 
9 
S5. 1H
 and 13C
 N
M
R
 spectroscopic data for know
n pterocarpans 1, 5 and 15 (C
D
3 O
D
, 500 M
H
z for 1H
, 125 M
H
z for 13C
, δ in ppm
) 
 
1 
5 
15 
Position 
δ
H  (J in H
z) 
δ
C , type 
δ
H  (J in H
z) 
δ
C , type 
δ
H  (J in H
z) 
δ
C , type 
2 
5.07 (d, 11.8) 
85.8, C
H
 
4.94 (d, 11.7) 
83.9, C
H
 
4.93 (d, 11.8) 
83.8, C
H
 
3 
4.49 (d, 11.8) 
74.8, C
H
 
4.46 (d, 11.7) 
73.1, C
H
 
4.46 (d, 11.8) 
73.2, C
H
 
4 
- 
194.4, C
 
- 
193.6, C
 
- 
193.6, C
 
4a 
- 
113.5, C
 
- 
112.4, C
 
- 
112.8, C
 
5 
7.72 (d, 8.6) 
130.3, C
H
 
7.56 (d, 8.6) 
125.5, C
H
 
7.41 (s) 
124.3, C
H
 
6 
6.54 (dd, 8.6, 2.3) 
112.4, C
H
 
6.53 (d, 8.6) 
110.0, C
H
 
- 
121.7, C
 
7 
- 
167.2, C
 
- 
162.6, C
 
- 
160.6, C
 
8 
6.35 (d, 2.3) 
103.9, C
H
 
- 
116.2, C
 
- 
115.6, C
 
8a 
 
165.1, C
 
- 
161.4, C
 
- 
159.1, C
 
1’ 
- 
138.9, C
 
- 
128.7, C
 
- 
129.9, C
 
2’ 
7.53 (dd, 8.3, 1.6) 
129.1, C
H
 
7.36 (d, 8.0) 
128.7, C
H
 
7.38 (d, 8.4) 
130.4, C
H
 
3’ 
 7.42-7.33 (m
)* 
129.5, C
H
 
6.83 (d, 8.0) 
114.7, C
H
 
6.87 (d, 8.4) 
114.4, C
H
 
4’ 
7.42-7.33 (m
)* 
130.0, C
H
 
- 
157.2, C
 
- 
157.0, C
 
116
 
10
5’ 
 7.42-7.33 (m
)* 
129.5, C
H
 
6.83 (d, 8.0) 
114.7, C
H
 
6.87 (d, 8.4) 
114.4, C
H
 
6’ 
7.53 (dd, 8.3, 1.6) 
129.1, C
H
 
7.36 (d, 8.0) 
128.7, C
H
 
7.38 (d, 8.4) 
130.4, C
H
 
R
1  at C
-6 
 
 
 
 
 
 
α 
 
 
 
 
3.26 (m
) 
29.0, C
H
2  
β 
 
 
 
 
5. 32 (tsp, 7.0, 1.0) 
122.8, C
H
 
γ 
 
 
 
 
- 
134.4, C
 
δ 
 
 
 
 
1.76 (s) 
26.0, C
H
3  
ε 
 
 
 
 
1.69 (s) 
17.9, C
H
3  
R
2  at C
-8 
 
 
 
 
 
 
α’ 
 
 
3.23 (m
) 
21.3, C
H
2  
3.29 (m
) 
23.0, C
H
2  
β’ 
 
 
5.14 (tsp, 7.3, 1.3) 
121.7, C
H
 
5.15 (tsp, 7.0, 1.0) 
123.0, C
H
 
γ’ 
 
 
- 
131.2, C
 
- 
132.6, C
 
δ’ 
 
 
1.58(s) 
24.5, C
H
3  
1.62 (s) 
26.0, C
H
3  
ε’ 
 
 
1.51 (s) 
16.7, C
H
3  
1.54 (s) 
18.1, C
H
3  
*: overlapped signals 
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11
S6. 1H and 13C NMR spectroscopic data for known pterocarpans 3 and 14 (CD3OD, 500 MHz for 
1H, 125 MHz for 13C, δ in ppm) 
 
Position 3 14 
 δH (J in Hz) δC, type δC, type δH (J in Hz) 
1 7.24 (d, 8.5) 131.5, CH 133.4, CH  7.27 (d, 8.4)  
1a - 111.5, C 113.0, C -  
2 6.48 (dd, 8.5, 2.3) 109.2, CH 111.0, CH  6.49 (dd, 8,5, 2.5)  
3 - 158.5, C 160.3, C -  
4 6.31 (d, 2.3) 102.8, CH 104.3, CH 6.32 (d, 2.5)  
4a - 156.5,C 158.2, C -  
6 4.17 (dd, 10.6, 4.8)  65.9, CH2 67.8, CH2 4.18 (dd, 10.6, 4.8) 
 3.55 (dd, 10.7, 10.7)   3.53 (dd, 10.7, 10.7) 
6a 3.42 (m) 40.1, CH 41.0, CH 3.45 ( ddd, 10.5, 6.9, 4.8)  
7a - 118.4, C 121.2, C -  
7 6.74 (s) 104.8, CH 123.4, CH 6.89 (s)  
8 - 141.7, C 116.4, C -  
9 - 148.2, C 156.0, C -  
10 6.34 (s) 92.9, CH 100.0, CH 6.19 (s)  
10a - 154.2, C 161.8, C -  
11a 5.40 (d, 7.1) 78.6, CH 80.3, CH 5.42 (d, 6.9)  
α   123.4, CH  6.28 (d, 10.0)  
β   128.6, CH 5.47 (d, 10.0)  
γ   77.5, C -  
δ   28.2, CH3 1.35* (s)  
ε   28.2, CH3 1.36* (s)  
O-CH2-O 5.83 (dd, 12.3, 1.0) 100.8, CH2   
* = interchangeable within the same column 
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12
 
S7. 1H and 13C NMR spectroscopic data for known isoflavonoids 10 and 13 (CD3OD, 500 MHz 
for 1H, 125 MHz for 13C, δ in ppm) 
 10 13 
Position δH (J in Hz) δC, type δC, type δH (J in Hz) 
2 4.50 (dd, 10.7, 5.4) 
4.62 (10.7)   
69.9, CH2  154.8, CH 8.07 (s) 
3 4.13 (dd, 10.7, 5.4)  47.0, CH  125.5, C - 
4 -  193.7, C 178.9, C - 
4a - 112.1, C 118.4, C - 
5 7.66 (d, 8.7)  125.4, CH 125.4, CH 7.87 (d, 8.7) 
6 6.56 (d, 8.9)  109.3, CH 115.7, CH 6.91 (d, 8.7) 
7 -  162.0, C 161.7, C - 
8 -  115.3, C 117.1, C - 
8a - 161.5, C 157.6, C - 
1´ -  113.3, C 124.5, C - 
2´ -  156.0, C 131.6, CH 7.34 (dd, 8.6) 
3´ 6.38 (d, 2.0)  102.5, CH 116.3, CH 6.83 (dd, 8.6) 
4´ -  157.0, C 158.8, C - 
5´ 6.29 (dd, 8.5, 2.5) 106.4, CH 116.3, CH 6.83 (dd, 8.6) 
6´ 6.86 (d, 8.5)  130.2, CH 131.6, CH 7.34 (dd, 8.6) 
α 3.34 (d, 7.0)  21.1, CH2  23.1, CH2 3.50 (d, 7.1) 
β 5.23 (tsp, 7.3, 1.3)  122.0, CH  122.9, CH 5.23 (tsp, 7.3, 1.3) 
γ - 130.8, C 133.2, C - 
δ 1.67 (s)  24.4, CH3 26.1, CH3 1.64 (s) 
ε 1.75 (s)  16.6, CH3 18.2, CH3 1.79 (s) 
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3.4. Identification of dehydroabietc acid from Boswellia thurifera resin as a 
positive GABAA receptor modulator 
Diana C. Rueda, Melanie Raith, Maria De Mieri, Steffen Hering, and Matthias Hamburger. 
Manuscript ready for submission  
 
 
The abietane diterpene dehydroabietic acid, isolated from a petroleum ether extract of 
Boswellia thurifera resin, was identified as a positive GABAA receptor modulator by means 
of HPLC-based activity profiling and a functional in vitro assay in Xenopus oocytes. 
Incensole and AKBA were also isolated from the active time window, but they showed no 
activity in the oocyte assay. Structure elucidation was achieved by high-resolution mass 
spectroscopy and microprobe NMR. Abietane diterpenes constitute a new scaffold for 
GABAA receptor modulators.  
 
 
 
 
Extraction of the plant material for isolation, HPLC-based activity profiling, isolation of 
pure compounds, bioactivity assessment of fractions and pure compounds in Xenopus 
oocytes, oocyte preparation, recording and interpretation of analytical data for structure 
elucidation (UV, HRMS, NMR spectra), writing of the manuscript draft, and preparation of 
the figures were my contributions to this publication. Structure elucidation was supported by 
M. Raith. Writing of the experimental section was supported by M. De. Mieri. 
Diana C. Rueda!
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ABSTRACT 
 
In a two-microelectrode voltage clamp assay with Xenopus laevis oocytes, a petroleum ether 
extract (100 µg/mL) of the resin of Boswellia thurifera (Burseraceae) potentiated GABA-
induced chloride currents (IGABA) through receptors of the subtype α1β2γ2s by 319.8% ± 
79.8%. With the aid of HPLC-based activity profiling three known terpenoids, 
dehydroabietic acid (1), incensole (2), and AKBA (3), were identified in the active fractions 
of the extract. Structure elucidation was achieved by means of HR-MS and microprobe 
1D/2D NMR spectroscopy. Compound 1 induced significant receptor modulation in the 
oocyte assay, with a maximal potentiation of IGABA of 397.5% ± 34.0%, and EC50 of 8.7 µM 
± 1.3 µM. This is the first report of dehydroabietic acid as a positive GABAA receptor 
modulator.  
 
Keywords: Boswellia thurifera, olibanum, HPLC-based activity profiling, GABAA receptor 
modulators, abietane diterpenes, dehydroabietic acid. 
 
Abbreviations 
AKBA: 3α-acetoxy-11-keto-β-boswellic acid 
BBB: Blood-brain barrier 
BDZs: benzodiazepines 
CNS: central nervous system 
DHA: Dehydroabietic acid 
GABA: gamma-aminobutyric acid 
GABAARs: gamma-aminobutyric acid type A receptors 
IGABA: GABA-induced chloride current 
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1. Introduction 
A number of plants belonging to the Burseraceae family are the source of strongly aromatic 
resins of considerable commercial value. The resin obtained by incision of Boswellia spp. 
(Burseraceae), also called frankincense or olibanum, has been used as incense in religious 
and cultural ceremonies since the beginning of written history and, in ancient times, was 
ranked along with gold and ivory as a precious trading good [1,2]. 
 
Olibanum is known in Chinese and other traditional medicines for its anti-inflammatory, 
antiseptic, wound-healing, and sedative properties [1,3,4]. It is a complex mixture composed 
of polysaccharides, monoterpenes, sesquiterpenes, diterpenes like incensole, isoincensole, 
and their oxide or acetate derivatives, and triterpenoids such as boswellic acids [1,5,6]. 
Boswellic acids are considered as marker compounds of the resin, and they have been found 
responsible for the anti-inflammatory properties. Incensole acetate and its derivatives have 
been reported as inhibitors of NF-κB and potent activators of TRPV3 channels in the brain, 
which confers them antidepressant and anxiolytic properties [1,7]. Monographs on olibanum 
can be found in the Chinese Pharmacopoeia [8] and ESCOP monographs [9], where it is 
referred as the dried resin from the bark of B. carterii Birdw. and B. bhawdajiana Birdw., or 
from stems and branches of Boswellia serrata Roxb. ex Colebr., respectively. Indications 
include the treatment of painful or inflammatory conditions. B. carterii, B. frereana, and B. 
serrata, are the three main olibanum-producing species [10,11]. 
 
GABAA receptors (GABAARs) are ligand-gated chloride channels physiologically activated 
by GABA, the major inhibitory neurotransmitter in the brain. They are heteropentameric 
assemblies with a central chloride-selective channel. Up to now 19 subunits (α1-6, β1-3, γ1-3, δ, 
ε, θ, π, ρ1-3) have been identified in GABAARs. GABA-induced chloride influx generates a 
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negative potential in the postsynaptic neurons, thereby inhibiting further action potentials. 
Impaired GABAergic function results in CNS disorders such as epilepsy, insomnia, anxiety, 
and mood disorders [12,13]. A number of clinically important drugs like benzodiazepines 
(BDZs), barbiturates, neuroactive steroids, anesthetics, and certain other CNS depressants 
bind GABAARs.  
!
In a search for natural products acting as GABAA receptor modulators, we tested a petroleum 
ether extract of the resin of Boswellia thurifera Roxb. ex Fleming in an automated two-
microelectrode voltage clamp assay with Xenopus oocytes [15]. At a concentration of 100 
µM, the extract enhanced IGABA by 319.8% ± 79.8%, in receptors of the subtype α1β2γ2S. 
GABAergic activity of the active extract was traced using an HPLC-based activity profiling 
approach [16], which has been previously validated and used for the discovery of GABAA 
receptor ligands from plant sources [17–23]. Pure compounds isolated from the active time 
window of the extract were tested in the oocyte functional assay to assess their GABAA 
receptor modulatory activity. 
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2. Experimental 
 
2.1. General procedures  
1D and 2D NMR spectra were recorded on a Bruker Avance III spectrometer operating at 
500.13 MHz. 1H NMR, COSY, HSQC, HMBC, and NOESY spectra were measured at 18 °C 
in a 1 mm TXI probe with a z-gradient, using standard Bruker pulse sequences. Spectra were 
analyzed by Bruker TopSpin 3.0 software. ESI-TOF-MS spectra were recorded in positive 
mode, m/z range 100-800, on a Bruker microTOF ESIMS system. Nitrogen was used as a 
nebulizing gas at a pressure of 2.0 bar, and as drying gas at a flow rate of 9.0 L/min (dry gas 
temperature 240°C). Capillary voltage was set at 45000 V; hexapole at 230.0 Vpp. 
Instrument calibration was done with a reference solution of sodium formiate 0.1% in 2-
propanol/water (1:1) containing 5 mM NaOH. 
 
HPLC-PDA-ESIMS spectra were obtained in positive ion mode on a Bruker Daltonics 
Esquire 3000 Plus ion trap MS system, connected via T-splitter (1:10) to an Agilent HP 1100 
system consisting of a degasser, a binary mixing pump, autosampler, column oven, and a 
diode array detector (G1315B). Data acquisition and processing was performed on Bruker 
Daltonics Hystar 3.0 software. Semipreparative HPLC separations were performed with an 
Agilent HP 1100 series system consisting of a quaternary pump, autosampler, column oven, 
and diode array detector (G1315B). Preparative HPLC separations were performed on a 
Shimadzu LC-8A preparative HPLC system with an SPD-M10A VP diode array detector. 
Flash chromatography was performed with pre-packed Sepacore ® silica flash cartridges (40-
63 µm, 40×150 mm) on a Sepacore ® system consisting of two C-605 pumps, a C-620 
control unit, and a C-660 fraction collector (all Buchi, Flawil, Switzerland). The separation 
was monitored by TLC. Waters SunFire™ C18 (3.5 µm, 3.0×150 mm i.d.), SunFire™ Prep 
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C18 (5 µm, 10×150 mm i.d.), and SunFire™ Prep C18 OBD (5 µM, 30×150 mm i.d.) 
columns were used for analytical, semipreparative, and preparative separations, respectively. 
HPLC-grade MeOH (Scharlau Chemie) and water, both containing 0.1% of formic acid, were 
used for HPLC separations. NMR spectra were recorded in methanol-d4 and DMSO-d6 
(Armar Chemicals). For extraction and flash chromatography technical grade solvents 
purified by distillation were used. 
2.2. Plant material 
Resin of Boswellia thurifera Roxb. ex Fleming were purchased by Dan Yang in 2008 from 
Juhuayuan Herbal Market, Kunming, Yunnan, province, China. Identity of the material was 
confirmed at Yunnan Baiyao group Co.LTD, Kunming, China. A voucher specimen (433) is 
deposited at the Division of Pharmaceutical Biology, University of Basel. 
 
2.3. Extraction 
The petroleum ether extract for screening and HPLC-based activity profiling was prepared 
with an ASE 200 extraction system with solvent module (Dionex, Sunnyvale, CA). In total, 3 
extraction cycles (5 min each) were performed, at an extraction pressure of 120 bar and a 
temperature of 70°C. Extracts were combined, and the solvent was evaporated at reduced 
pressure to yield 4.6 g of extract. The extract was stored at 2-8°C until use.  
 
2.4. Microfractionation for activity profiling 
Time-based microfractionation of the extract for GABAA receptor activity profiling was 
performed as previously described [24], with minor modifications: separation was done on a 
semi-preparative HPLC column with MeOH (solvent A) and water (solvent B), using a 
gradient from 70% A to 100% A in 30 min, hold for 15 min. The flow rate was 4 mL/min, 
and 10mg of extract (in 100 µL of DMSO) were injected. A total of 24 time-based 
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microfractions of 90 s each were collected and evaporated in parallel. The dry films were 
redissolved in 1 mL of methanol, and aliquots of 0.5 mL were dispensed in two vials, dried 
under N2 gas, and submitted to bioassay.  
 
2.5. Isolation 
An aliquot of the petroleum ether extract (1 g) was dissolved in n-hexane and submitted to 
purification by flash chromatography. Separation was performed on a Sepacore ® silica gel 
cartridge eluted with an n-hexane (solvent A) and EtOAc (solvent B) gradient: 0% B to 20% 
B in 60 min, followed by 30% B to 50% B in 30 min, and 50% B to 100% B in 30 min. The 
flow rate was set at 15 mL/min. Fractions of 15 mL were collected and later combined to 13 
fractions (A-M) on the basis of TLC analysis (detection at 254 nm, 366 nm, and at daylight 
after staining with anisaldehyde-sulphuric acid reagent). Fractions A-M were submitted to 
analytical HPLC-PDA-ESIMS with MeOH (solvent C) and water (solvent D), using an 
optimized gradient from 85% C to 100% C in 30 min, hold for 15 min. The flow rate was 0.4 
mL/min, and 5 µg of each fraction (in 5 µL of DMSO) were injected. Fractions F, G, and J 
were found to contain the compounds of interest and were submitted to purification by semi-
preparative HPLC using solvents C and D as eluents. Samples were separated under isocratic 
conditions (87% C, 20 min). The flow rate was 4 mL/min. Stock solutions in DMSO (100 
mg/mL) were prepared and repeatedly injected in portions of 20-50 µL. Compound 1 (1 mg) 
was isolated from 10 mg of fraction G (63 mg). A portion (10 mg) of fraction F (259 mg) 
afforded compound 2 (0.6 mg). Compound 3 (0.5 mg) was isolated from 5 mg of fraction J 
(72 mg). Structure elucidation was achieved by analysis of ESI-TOF-MS and 1D/2D NMR 
data, and by comparison with published values [25–27]. The purity was > 95% (purity check 
by 1H NMR). 
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2.5.1. Dehydroabietic acid (1): 1H NMR (DMSO-d6, 500.13 MHz) δH (ppm): 7.14 (1H, d, J= 
8.2 Hz, H-11), 6.96 (1H,br d, J= 8.2 Hz, H-12), 6.84 (1H, br s, H-14), 2.81-2.77 (3H, m, 
CH2-7, H-15), 2.28 (1H, br d, J= 12.8 Hz, H-1a), 2.03 (1H, br d, J= 12.4 and 1.3 Hz, H-5), 
1.74-1.70 (3H, m, H-6a, H-2a, H-3a), 1.65 (1H, m, H-2b), 1.56 (1H, br d, J= 9.9Hz, H-3b), 
1.44 (1H,  br dd, J=12.0 and 7.0 Hz, H-6b), 1.30 (1H, m, H-1b),1.17 (6H, d, J= 6.9 Hz, CH3-
16, CH3-17),  1.16 (3H, m, CH3-19), 1.13 (3H, s, CH3-20); 13C NMR (DMSO-d6, derived 
from multiplicity-edited HSQC and HMBC spectra) δC (ppm): 180.1 (C, C-18), 147.3 (C, C-
9), 145.5 (C, C-13), 134.4 (C, C-8), 126.9 (CH, C-14), 124.2 (CH, C-11), 124.0 (CH, C-12), 
47.1 (C, C-4), 45.2 (CH, C-5), 38.3 (CH2, C-1), 37.7 (C, C-10), 36.8 (CH2, C-3), 33.2 (CH, 
C-15), 29.9 (CH2, C-7), 25.1 (CH3, C-20), 24.3 (CH3, C-16/C-17), 21.4 (CH2, C-6), 18.6 
(CH2, C-2), 17.0 (CH3, C-19). HR-ESIMS m/z 301.2161 [M+H]+ (calcd for C20H29O2, 
301.2162). 
 
2.5.2. Incensole (2): 1H NMR (DMSO-d6, 500.13 MHz) δH (ppm): 5.05 (1H, t, J= 7.0 Hz, H-
3), 5.00 (1H, t, J= 6.8 Hz, H-7), 3.10 (1H, d, J= 9.9 Hz, H-11), 2.12-1.96 (9H, m, CH2-6, H-
2a, H-13a, CH2-5, H-2b, CH2-9), 1.83 (1H, sept, J= 6.7 Hz, H-15), 1.76 (1H, m, H-14a), 1.64 
(1H, dd, J= 13.0 and 3.0 Hz, H-10a), 1.60-1.50 (5H, m, H-13b, CH3-19, H-14b), 1.47 (3H, s, 
CH3-18), 1.25 (1H, m, H-10b), 0.98 (3H, s, CH3-20), 0.87 and 0.86 (6H, each d, J= 6.8 Hz, 
CH3-16, CH3-17); 13C NMR (DMSO-d6, derived from multiplicity-edited HSQC and HMBC 
spectra) δC (ppm): 134 (C, C-8), 133.5 C-4, 124.7 (CH, C-7), 122.2 (CH, C-3), 87.8 (C, C-1), 
85.0 (C, C-12), 73.7 (CH, C-11), 38.6 (CH2, C-5), 36.3 (CH2, C-13), 35.1 (CH, C-15), 33.8 
(CH2, C-9), 32.2 (CH2, C-2), 30.7 (CH2, C-14), 30.1 (CH2, C-10), 24.7 (CH2, C-6), 21.4 
(CH3, C-20), 18.4 (3CH3, C-16, C-17, C-19), 16.3 (CH3, C-18). HR-ESIMS m/z 307.2663 
[M+H]+ (calcd for C20H35O2, 307.2632) 
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2.5.3. 3α-acetoxy-11-keto-β-boswellic acid (AKBA) (3): 1H NMR (methanol-d4, 500.13 MHz) 
δH (ppm): 5.52 (1H, s, H-12), 5.27 (1H, t, J= 2.7 Hz,  H-3), 2.49 (1H, br s,H-9), 2.46 (1H, m, 
H-1a), 2.27 (1H, tt, J= 14.8, 3.4 Hz, H-2a), 2.17 (1H, td, J= 13.7, 5.4 Hz, H-16a), 2.07 (3H, s, 
CH3-2’), 2.00-1.90 (2H, m, H-6a, H-15a), 1.78 (1H, m, H-6b), 1.72 (1H, m, H-7a), 1. 60-1.32 
(12H, m, H-18, H-2b, H-22a, H-19, H-7b, H-21a, H-5, H-22b, CH3-27, H-21b), 1. 32-1.23 
(2H, m, H-15b and H-1b), 1.20 (3H, s, CH3-26), 1.18 (3H, s, H-23), 1.17 (3H, s, CH3-25), 
1.05 (1H, m, H-16b), 0.97 (4H, br s, H-20, CH3-30), 0.86 (3H, s, CH3-28), 0.83 (3H, d, J= 
6.4 Hz, CH3-29); 13C NMR (DMSO-d6, derived from multiplicity-edited HSQC and HMBC 
spectra) δC (ppm): 200.6 (C, C-11), 179.0 (C, C-24), 171.0 (C, C-1’), 166.2 (C, C-13), 129.9 
(CH, C-12), 73.3 (CH, C-3), 60.2 (CH, C-9), 59.8 (CH, C-18), 50.3 (CH, C-5), 46.3 (C, C-4), 
44.8 (C, C-8), 43.8 (C, C-14), 40.4 (CH2, C-22), 39.2 (CH, C-19), 39.1 (CH, C-20), 37.3 (C, 
C-10), 34.7 (CH2, C-1), 33.6 (C, C-17), 32.2 (CH2, C-7), 30.6 (CH2, C-21), 28.0 (CH3, C-28), 
27.1 (CH2, C-16), 26.8 (CH2, C-15), 23.2 (CH2, C-2), 23.1 (CH3, C-23), 19.9 (CH3, C-30), 
19.8 (CH3, C-2’), 19.5 (CH3, C-27), 18.4 (CH2, C-6), 17.7 (CH3, C-26), 16.4 (CH3, C-
29),12.6 (CH3, C-25). HR-ESIMS m/z 535.3412 [M+Na]+ (calcd for C32H48NaO5, 535.3394) 
 
Further purification of compounds 1-3 for activity assessment was achieved by submitting 
fractions F, G, and J to preparative HPLC separation, using solvents C and D as eluents. 
Samples were run under isocratic conditions (87% C, 20 min). The flow rate was 20 mL/min. 
Stock solutions in DMSO (150 mg/mL) were prepared and repeatedly injected in portions of 
200-400 µL. Compounds 1 (3.13 mg), 2 (10 mg), and 3 (4 mg) were obtained from fractions 
G (35 mg), F (200 mg), and J (50 mg), respectively. 
 
2.6. Expression of GABAA Receptors 
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Stage V-VI oocytes from Xenopus laevis were prepared, and cRNA was injected as 
previously described [24]. Female Xenopus laevis (NASCO, Fort Atkinson, WI) were 
anesthetized by exposing them for 15 min to a 0.2% MS-222 (methane sulfonate salt of 3-
aminobenzoic acid ethyl ester, Sigma) solution before surgically removing parts of the 
ovaries. Follicle membranes from isolated oocytes were enzymatically digested with 2 
mg/mL collagenase from Clostridium histolyticum (Type 1A, Sigma). Synthesis of capped 
runoff poly(A+) cRNA transcripts was obtained from linearized cDNA templates (pCMV 
vector). Directly after enzymatic isolation, the oocytes were injected with 50 nL of DEPC-
treated water (Sigma) containing different cRNAs at a concentration of approximately 300-
3000 pg/nL per subunit. The amount of injected cRNA mixture was determined by means of 
a NanoDrop ND-1000 (Kisker Biotech). To ensure expression of the gamma subunit in 
α1β2γ2S receptors, rat cRNAs were mixed in a 1:1:10 ratio. Oocytes were then stored at 18 °C 
in ND96 solution containing 1% of penicillin-streptomycin solution (Sigma-Aldrich). 
Voltage clamp measurements were performed between days 1 and 5 after cRNA injection.  
 
2.7 Positive control  
Diazepam (7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one, Sigma, 
purity not less than 98%) was used as positive control. At 1 µM diazepam enhanced IGABA up 
to 231.3 ± 22.6% (n=3). See also S1, supporting information. 
 
2.8. Two-Microelectrode Voltage Clamp Studies 
Electrophysiological experiments were performed by the two-microelectrode voltage clamp 
method making use of a TURBO TEC 03X amplifier (npi electronic GmbH) at a holding 
potential of -70 mV and pCLAMP 10 data acquisition software (Molecular Devices). 
Currents were low-pass-filtered at 1 kHz and sampled at 3 kHz. The bath solution contained 
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90 mM NaCl, 1 mM KCl, 1 mM MgCl2, 1 mM CaCl2, and 5 mM HEPES (pH 7.4). Electrode 
filling solution contained 2 M KCl. Oocytes with maximal current amplitudes > 3 µA were 
discarded to exclude voltage clamp errors. 
 
2.9. Fast Solution Exchange during IGABA Recordings 
Test solutions (100 µL) were applied to the oocytes at a speed of 300 µL/s by means of the 
ScreeningTool automated fast perfusion system [15]. In order to determine GABA EC5-10 
(typically between 3 and 10 µM for receptors of subunit composition α1β2γ2s), a dose-
response experiment with GABA concentrations ranging from 0.1 µM to 1 mM was 
performed. Stock solution of the petroleum ether extract (10 mg/mL in DMSO) was diluted 
to a concentration of 100 µg/mL with bath solution containing GABA EC5-10 according to a 
validated protocol [24]. As previously described, microfractions collected from the semi-
preparative HPLC separations were dissolved in 30 µL of DMSO and subsequently mixed 
with 2.97 mL of bath solution containing GABA EC5-10 [24]. Stock solutions of compounds 
1-3 (100 mM in DMSO) were diluted to a concentration of 100 µM with bath solution 
containing GABA EC5-10 for measuring modulation of GABAARs. For concentration-
response experiments, the stock solution of DHA (1) was diluted to concentrations of 0.1, 
1.0, 3.0, 10, 30, 100, and 300 µM with bath solution for measuring direct activation, or with 
bath solution containing GABA EC5-10 for measuring receptor modulation. The final DMSO 
concentration in all the samples including the GABA control samples was adjusted to 1% to 
avoid solvent effect at the receptors.  
 
2.10. Data Analysis 
Enhancement of the IGABA was defined as I(GABA+Comp)/IGABA − 1, where I(GABA+Comp) is the 
current response in the presence of a given compound, and IGABA is the control GABA-
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induced chloride current. Data were analyzed using the ORIGIN 7.0 SR0 software 
(OriginLab Corporation) and are given as mean ± S.E. of at least two oocytes and ≥ 2 oocyte 
batches. 
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3. Results and Discussion 
At a test concentration of 100 µg/mL, the petroleum ether extract of B. thurifera resin 
enhanced IGABA by 319.8% ± 79.8% through GABAARs with α1β2γ2s subunit composition.  
Active compounds were tracked with the aid of a validated protocol for HPLC-based activity 
profiling [24]. The chromatogram (210 - 700 nm) of a semipreparative HPLC separation (10 
mg of extract) and the corresponding activity profile (24 microfractions of 90 s each) are 
shown in Figure 1. Fractions 15, 16, and 17 potentiated IGABA by 172.8% ± 49.5%, 344.3% ± 
78.5%, and 119.7% ± 20.7%, respectively. Optimization of separation conditions enabled 
resolution of peaks in the active time window (indicated with roman numbers in Fig. 1). 
Therefore, peak I was resolved into compounds 1 and 2, and compound 3 was the main 
constituent of peak II. 
 
To obtain the active compounds in sufficient amounts for structure elucidation and 
pharmacological testing, a targeted preparative isolation was carried out, combining flash 
chromatography on silica gel with subsequent purification by semipreparative and 
preparative HPLC. Two diterpenes, dehydroabietic acid (1) and incensole (2), and the 
triterpene AKBA (3) (Fig. 2) were identified with the aid of ESI-TOF-MS, 1D and 2D 
microprobe NMR, and by comparison with published data [25–27]. Spectroscopic data of 1-3 
are available as supporting information. The three compounds have been previously reported 
from olibanum, although not specifically from the resin of Boswellia thurifera.  
 
Compounds 1-3 were tested at a concentration of 100 µM in the oocyte assay, for a 
preliminary assessment of their activity in α1β2γ2s GABAARs (Table 1). Only DHA (1) 
modulated the receptors (potentiation of IGABA of 682.3% ± 44.7%), while incensole and 
AKBA were inactive (enhancements of −13.9% ± 3.2% and −19.8% ± 4.5%, respectively) 
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(Fig. 3A). Thus, further concentration-response experiments were performed only with DHA 
at concentrations ranging from 0.1 to 300 µM. In GABAARs of α1β2γ2s subunit composition 
DHA enhanced IGABA in a concentration-dependent manner (Figure 3B). At a GABA EC5-10, 
maximal potentiation of IGABA (397.5% ± 34.0%) was observed at ~100 µM, with an EC50 of 
8.7 µM ± 1.3 µM. Direct activation of the receptor was observed at DHE concentrations 
higher than 30 µM suggesting partial agonism. This suggests that the mechanism of action 
involves allosteric receptor modulation rather than direct agonistic activity (Fig. 3C).  
 
Due to their toxicity to fish, DHA and other abietane monocarboxylic acids (resin acids) have 
been studied for their potential effect on the CNS. DHA was shown to induce release of 
GABA from nerve terminals in trout brain synaptosomes, while 12,14-
dichlorodehydroabietic acid inhibited  IGABA in patch-clamped rat cortical neurons. However, 
modulatory effects on the GABAergic system have been suggested to be secondary to the 
elevation in cytoplasmic Ca2+ induced by these compounds [28,29]. This work constitutes the 
first report on GABAA receptor modulatory properties of the abietane diterpene DHA. 
Pimarane type diterpenoids ,closely related to the abietanes, have been previously identified 
in our research group as a structural scaffold for GABAA receptor modulators [30]. However, 
the potency of DHA on receptors of the subtype α1β2γ2s was higher than that of isopimaric 
acid (EC50 141.6 µM ± 96.5 µM) and sandaracopimaric acid (EC50 33.3 µM ± 8.7 µM), 
suggesting that an aromatic ring C is favorable for increasing potency of this scaffold. 
However, more compounds need to be tested for establishing structure-activity relationships 
for these diterpenoids.  DHA also showed higher potency than the labdane diterpenoids 
zerumin A (EC50 24.9 µM ± 8.8 µM) and coronarin D (EC50 35.7 µM ± 8.8 µM).[17]. 
However, the potency of DHA is significantly lower than that of classical BDZs like 
159
triazolam, clotiazepam, and midazolam, which modulate GABAARs at nanomolar 
concentrations [31]. 
 
The physicochemical properties of dehydroabietic acid are favorable for oral bioavailability 
and BBB permeation [32,33].  In fish, the compound has been found  to be readily absorbed, 
and distributed to most organs, including the brain [29]. Although the toxicity observed in 
fish is a potential liability for DHA [28,34], in vitro and in vivo pharmacological and 
pharmacokinetic studies with the compound should be performed to explore the potential of 
this scaffold as a starting point for medicinal chemistry.  
 
4. Conclusions 
HPLC-based activity profiling of olibanum from Boswellia thurifera led to the identification 
of dehydroabietic acid as a positive allosteric modulator of GABAARs of the subtype α1β2γ2s 
that additionally displays properties of a partial agonist. The EC50 of DHA was lower than for 
other diterpenes (e.g. sandaracopimaric acid), indicating higher affinity to the receptor, even 
though far from the affinity of BDZs. Further assessment of subunit selectivity and activity in 
vivo are needed.   
 
The terpenoids AKBA and incensole have also been isolated from the active time window of 
the extract, but were lacking GABAA receptor modulatory properties. Anxiolytic effects in 
behavioral models have been reported for incensole acetate, but were attributed to activation 
of TRPV3 channels in the brain [1]. At this point the potential CNS modulating effects of 
frankincense are still a matter of speculation.  
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Table 1. Potentiation of IGABA in α1β2γ2s receptors by compounds 1-3, at a test concentration 
of 100 µM. 
Compound Maximal potentiation of  IGABA (%)a 
1 682.3 ± 44.7 
2 -13.9 ± 3.2 
3 -19.8 ± 4.5 
Diazepam (1 µM)b 231.3 ± 22.6 
(a) Modulation measured in 4 oocytes from 3 different batches. 
(b) Positive control. 
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Figure 1. HPLC-based activity profiling of the petroleum ether extract GABAA receptor 
modulatory activity. A. Potentiation of the IGABA by each microfraction (error bars correspond 
to S.E.). B. HPLC chromatogram (210-700 nm) of a semipreparative separation of 10 mg of 
extract. The 24 time-based fractions of 90 s each are indicated with dashed lines. Peaks 
contained in the active time window of the extract are indicated as I and II. After 
optimization of separation conditions, peak I was resolved into compounds 1 and 2. 
Compound 3 was the main constituent of peak II. 
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Figure 2. Chemical structures of compounds 1-3. 
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Figure 3. A. Potentiation of IGABA by the petroleum ether extract (100 µg/mL), by time-based 
fractions 15-17, and by compounds 1-3 (100 µM). B. Concentration-response curve for 
compound 1 on GABAARs of the subunit composition α1β2γ2S. C. Typical traces for 
modulation of IGABA by compound 1. Please note the pronounced activation of the receptor in 
the absence of GABA at DHA concentrations > 30 µM. All experiments were carried out 
using a GABA EC5-10. 
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S1.  Diazepam (1 µM) enhanced IGABA through α1β2γ2S GABAA receptors and was therefore 
used as positive control for the assay. Currents in the presence of GABA (EC5-10, single bar, 
control) and during co-application of GABA and diazepam (1 µM, double bar) are shown. At 
1 µM diazepam enhanced IGABA up to 231.3 ± 22.6% (n=3). 
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S2. Compounds isolated from B. thurifera resin, petroleum ether extract. 
 Trivial name CAS Nr. MF Formula weight Structure 
 
1 
 
Dehydroabietic  
acid 
 
1740-19-
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C20H28O2 
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HOOC  
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Incensole 
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O
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AKBA 
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C32H48O5 
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O
COOH
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In recent years, HPLC-based activity profiling [1] has been successfully applied in the 
identification of GABAAR modulators of natural origin [2–5]. In the present work, this 
approach was used to trace the GABAAR modulatory activity in the lipophilic extracts of 
Pholidota chinensis stems and roots, Adenocarpus cincinnatus roots and tubers, Boswellia 
thurifera resin, and a commercial sample of Bupleurum chinense roots. In every case, at least 
one NP with GABAergic properties was identified, proving once again the power of HPLC-
based activity profiling in the targeted discovery of plant-derived GABAAR modulators. 
Furthermore, these results confirmed the value of ethnopharmacology as a refinement tool in 
NP research. 
 
In the case of Pholidota chinensis (Chapter 3.2), HPLC-based activity profiling allowed us 
to identify the dihydrostilbene batatasin III (1) as a highly efficient GABAAR modulator. The 
lower activity of structurally related compounds in the extract, motivated us to test a series of 
stilbenes and their semisynthetic dihydro derivatives, in order to assess the role of 
conformational flexibility in the GABAergic properties of stilbenes. The results of this study 
enabled us to confirm flexibility as crucial for GABAAR modulation and to draw some 
preliminary structure-activity considerations that might be useful for further medicinal 
chemistry efforts on dihydrostilbenes (Figure 4.1).  
 
HPLC-based activity profiling of Adenocarpus cincinnatus (Chapter 3.3) allowed us to 
localize the GABAergic activity in a rather complex extract. Fifteen flavonoid and 
isoflavonoid derivatives, including eight new natural products, were isolated from the active 
time window by means of diverse chromatographic techniques. Full structural 
characterization of all isolates was achieved by HR-TOF-MS, microprobe NMR, CD-
spectroscopy, and polarimetry, which were ratified as key analytical tools in NP research 
during the course of this thesis. Twelve of the isolated compounds (2-13) (Figure 4.2) 
showed significant GABAAR modulation in the oocyte assay, at a concentration of 100 µM. 
Further concentration-response experiments led us to the identification of pterocarpans and 
isoflavones with potent GABAAR modulatory activity. Structural similarities among the 
diverse flavonoid and isoflavonoid scaffolds provided preliminary insights into some 
structural features favoring GABAergic properties (Figure 4.2). 
 
 
 
178
Figure 4.1. Dihydrostilbenes as modulators of α1β2γ2s GABAARs. Structural features with positive 
effects on potency and efficiency are highlighted in green. Features with negative influence on 
GABAAR modulation are indicated in red. Compound 1 is a natural product, whereas 15 and 16 are 
the semisynthetic dihydro derivatives of tetramethoxy-piceatannol and pterostilbene, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. GABAAR modulators with dihydroflavonol (2, 3), pterocarpan (4-8), isoflavanone (9, 
10), isoflavone (11, 12), and chalcone (13) scaffolds, isolated from A. cincinnatus. Structural 
features with positive influence on potency and efficiency are indicated in green. Features with 
negative influence on GABAAR modulation are highlighted in red. 
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A GABAAR modulator bearing the abietane diterpene scaffold, i.e. DHA (14), was identified 
in Boswellia thurifera by means of HPLC-based activity profiling (Chapter 3.4, Figure 4.3). 
In the case of the commercial sample of Bupleurum chinense (Chapter 3.1), not only did 
HPLC-based activity profiling allow the identification of aristolactone as a mild GABAAR 
modulator, but it also led to the detection of a contaminant in the sample, raising concerns 
about adequate quality control of TCM drugs commercialized in Europe. 
 
 
 
 
 
 
Figure 4.3. Dehydroabietic acid, an abietane diterpene with GABAAR modulatory activity, islated 
from Boswellia thurifera. 
 
Altogether, as a result of this study three main novel scaffolds for GABAAR modulators were 
identified, i.e. dihydrostilbenes (Chapter 3.2; Figure 4.1), cis-pterocarpans (Chapter 3.3; 
Figure 4.2), and abietane diterpenes (Chapter 3.4; Figure 4.3). A number of GABAAR 
modulators belonging to the known flavonoid and isoflavonoid scaffold families were also 
isolated (Chapter 3.3; Figure 4.2). Most of the active compounds obtained in the course of 
this thesis meet all the requirements for oral absorption and BBB permeation described in 
Chapter 2.4 (Table 1), with the only exceptions of lespeflorin B2 (3) and DHA (14), which 
violate Lipinski’s RO5 in terms of lipophilicity. However, their cLogP values exceed only 
slightly the range dictated by the rule and thus, sufficient oral absorption can still be 
expected. Furthermore, only molecules showing 2 or more violations to the RO5 are 
predicted to have poor oral absorption (see Chapter 2.4).  
 
Dihydrostilbene 1, pterocarpans 4, 7, and 8, and abietane diterpene 14 meet the requirements 
for relevant pharmacological hits for further optimization and development. They possess i) 
novel structural scaffolds for GABAAR modulators (Figures 4.1-4.3), ii) drug-like 
physicochemical properties for oral absorption and BBB permeation (Table 1), and iii) 
significant potency (EC50 value) and efficiency (maximal potentiation of IGABA) at the target 
(Table 2, Figure 4.4). Isoflavone 11 complies with requirements (ii) and (iii). Although 
flavonoid and isoflavonoid derivatives 2, 3, 5, 6, 9, 10, 12, and 13 do not meet requirement 
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(i), their physicochemical properties make them suitable candidates for further optimization. 
In this work, they were only tested at a single concentration (100 µM) in the oocyte assay and 
therefore potency and efficiency of their receptor modulation could not be calculated. 
However, their performance in single-concentration tests (enhancement of IGABA > 190%), 
predicts adequate GABAAR modulation. Furthermore, promising GABAergic activity has 
been reported for structurally related compounds reported in Chapter 3.3 and other works 
[6,7]. Concentration-response experiments will contribute to a better pharmacological 
characterization of these compounds as GABAAR modulators. 
 
Table 1. Physicochemical properties of GABAAR modulators of natural origin 
isolated in this work. 
 
Compound H-acceptors H-donnors MW cLogP(a) Rotable bonds PSA (Å2)(a) 
1 3 2 244.3 3.35 4 49.7 
2 5 3 340.4 3.41 3 87.0 
3  5 3 408.5 5.36 5 87.0 
4  5 3 342.4 2.58 3 79.2 
5  5 1 284.3 2.88 0 57.2 
6  4 1 280.3 3.40 0 47.9 
7  5 3 340.4 3.76 2 79.2 
8  4 1 322.4 4.41 0 47.9 
9,10  5 3 340.4 3.77 3 87.0 
11 5 3 338.4 3.07 3 87.0 
12 4 2 322.4 4.03 3 66.8 
13 4 2 270.3 2.80 4 66.8 
14 2 1 300.4 6.09 2 37.3 
(a)  cLogP and polar surface area (PSA) were calculated with ChemBioDraw Ultra 12.0 software 
(CambridgeSoft). 
 
 
Table 2. Potency (EC50 value) and efficiency (maximal potentiation of IGABA) of 
drug-like scaffolds isolated in this work, at GABAA receptors of the subtype α1β2γ2s. 
 
Compound EC50 (µM) Emax (%) 
1 52.5 ± 17.0 1512.9 ± 176.5 
4 8.6 ± 1.6 640.0 ± 53.6 
7 18.8 ± 2.3 491.0 ± 22.3 
8 40.7 ± 4.08 771.1 ± 4.1 
11 2.8 ± 1.4 552.7 ± 84.1 
14 8.7 ± 1.3 397.5 ± 34.0 
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Compared to other receptor modulators of natural origin tested in the same in vitro model 
[3,8–12] (Figure 4.4), batatasin III (1) exhibited remarkably higher GABAAR modulatory 
efficiency. However, its EC50 is still far from the concentration range in which BZD exert 
their actions. In contrast, pterocarpan 4 and isoflavone 11 showed much higher potencies than 
average GABAAR modulators of natural origin (EC50 values below 10 µM), indicating higher 
binding affinity towards the receptor. Although their efficiencies were higher than those of 
BZDs, they were much lower than that of 1. Potency of the abietane diterpene 14 was also 
below 10 µM, but its efficiency was lower than that of compounds 4 and 11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Overview of efficiency and potency of GABAAR modulation exerted by compounds 
isolated from Pholidota chinensis stems and rots, Adenocarpus cincinnatus roots and tubers, and 
Boswellia thurifera resin. Compounds are grouped according to their structures. Numbers indicate 
the compounds as shown in Figures 4.1-4.3. Compounds 15 and 16 are not NPs, but the 
semisynthetic dihydro derivatives of tetramethoxy-piceatannol and pterostilbene. Flavonoid and 
isoflavonoid derivatives 2, 3, 5, 6, 9, 10, 12, and 13 (Figure 4.2) are not depicted, since their 
potencies and efficiencies were not determined. Potentiation on IGABA was measured in α1β2γ2s 
receptors, at a GABA EC3-10. Data points in grey correspond to NPs isolated in previous works by 
Schramm et al. [3] and Zaugg et al. [8–12]. Reference data of benzodiazepines (triazolam, 
midazolam, clotiazepam) are taken from Khom et al. [13]. Etomidate and alphaxalone values were 
measured by Pau et al. [14]. Pentobarbitone was investigated by Thompson et al. [15], using a 
GABA EC20, meaning that its efficiency is underestimated compared to the rest (adapted from 
Zaugg 2011 [2]).  
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 As a result of this thesis, the dihydrostilbene batatasin III (1) was identified as the first 
representative of this new scaffold for GABAAR modulators (Chapter 3.2). It has been 
characterized as a positive allosteric modulator in receptors of the subtype α1β2γ2s, devoid of 
significant subtype selectivity. Maximal potentiation of IGABA elicited by 1 was higher than 
that of any other NP tested up to now, and at least fourfold higher than that of classical 
BZDs. The semisynthetic dihydro derivatives of tetramethoxy-piceatannol (15) and 
pterostilbene (16) were also identified as hits with pharmacological potential as GABAAR 
modulators, with efficiencies higher than 700% and potencies between 20 and 50 µM (Figure 
4.4). Further medicinal chemistry efforts on compounds 1, 15, and 16 should be directed 
towards enhancement of potency and subunit selectivity. Conformationally restricted 
derivatives should be synthesized in order to explore in more detail the optimal orientation of 
the aromatic rings and substituents in the dihydrostilbene scaffold. Animal behavioral studies 
with these compounds are advisable, in order to assess their GABAAR modulation in vivo. 
On the other hand, assessment of their ability to cross intestinal and blood-brain barriers 
should be evaluated by means of in vitro and in vivo models to confirm our RO5-based 
predictions. Stilbenes like piceatannol, pterostilbene, and resveratrol are known to undergo 
rapid metabolic transformations in vivo, which severely limits their oral bioavailability and 
ability to reach CNS upon oral administration [16,17]. In vitro and in vivo pharmacokinetic 
studies should then be performed with 1, 15, and 16 in order to evaluate their metabolic 
stability.  
 
The new NPs 3,9-dihydroxy-8-(3-hydroxy-3-methylbutyl)-pterocarpan (4) and 3,4,9-
trihydroxy-8-(3-methylbut-2-en-yl)-pterocarpan (7) represent a novel scaffold for GABAAR 
modulators, with favorable efficiencies and high potencies (Chapter 3.3, Figure 4.4). The 
EC50 value of 4 positions this compound as one of the most potent NPs tested in receptors of 
the subtype α1β2γ2s. Isoneorautenol (8), a known pterocarpan, constitutes an interesting 
scaffold for GABAAR modulators too, although its modulatory potency is lower than those of 
its structural relatives 4 and 7. The physicochemical properties of these compounds make 
them attractive candidates for evaluation of GABAAR subtype selectivity and further 
optimization of potency and efficiency by medicinal chemistry.  
 
Pterocarpans have attracted the attention of the scientific community in recent years, due to 
their wide range of biological activities [18]. Although they have been reported to undergo 
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rapid and extensive oral absorption [19], no CNS effects have been described to date. 
Behavioral and pharmacokinetic studies in animal models with compounds 4, 7, and 8 or 
their enhanced derivatives, will provide more insights into the potential of pterocarpans as 
GABAAR modulators in vivo. The behavior of pterocarpans 4, 7, and 8 in concentration-
response experiments led us to suggest a mechanism of action involving receptor modulation 
and low affinity channel block. The latter remains to be confirmed through in vitro evaluation 
of the receptor binding properties of these compounds. 
 
The isoflavone scaffold, represented in this work by 7,2’,4’-trihydroxy-8-(3-methylbut-2-en-
yl)-isoflavone (11), provided the most potent GABAAR modulator identified in this work 
(Chapter 3.3, Figure 4.4). The modulatory potency of 11 in α1β2γ2s GABAARs was in fact 
higher than that of any other NP tested so far in the oocyte assay. Although compound 11 
does not constitute a relevant hit regarding scaffold novelty, its high potency and favorable 
physicochemical properties make it a promising candidate for the further optimization and 
development. Evaluation of the pharmacologic potential of 11 must be pursued, starting by 
the in vitro assessment of receptor subtype specificity. Medicinal chemistry studies directed 
to improve potency, efficiency and, if needed, selectivity, can be conducted on the basis of 
previous SAR studies on GABAAR modulating isoflavones [6] or structurally related 
flavonoids [7]. In vivo behavioral and pharmacokinetic studies are also advisable for the full 
pharmacological characterization of 11 as GABAAR modulator.  
 
The abietane diterpene DHA (14) was characterized as potent GABAAR modulator with 
“drug-like” physicochemical properties (except for a slightly high cLogP value) and a novel 
scaffold for the target (Chapter 3.4, Figure 4.4). Thus, it constitutes a new candidate to be 
evaluated for GABAAR subtype specificity in vitro. Compound 14 showed higher affinity 
towards the receptor than other diterpene scaffolds (i.e. pimarane and labdane diterpenes) 
acting at the same target [3,8]. Although reported toxicity in fish could be a drawback 
[20,21], in vivo pharmacological and pharmacokinetic experiments should be conducted with 
14 in order to assess its potential of this scaffold as a starting point for medicinal chemistry.  
   
Overall, the results of this work confirmed once more the chemical and biological relevance 
of NPs as a source of attractive hits for drug discovery and development. The compounds 
isolated and characterized in the course of this thesis contribute to expand the repertory of 
NPs acting as allosteric GABAARs modulators. As a consequence of their significant 
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modulatory potencies and efficiencies, favorable “drug-like” physicochemical properties and, 
in almost all cases, scaffold novelty, all compounds shown here constitute interesting 
pharmacological hits. Furthermore, they can serve as scaffolds for medicinal chemistry 
approaches intended to the design of derivatives with improved pharmacological profile, 
including receptor subtype selectivity. In order to explore the potential of these privileged 
structures as the starting points for the development of drugs with GABAergic properties, 
further in vitro and in vivo pharmacological and pharmacokinetic studies must be pursued.  
References 
 
[1]  Kim H, Baburin I, Khom S, Hering S, Hamburger M. HPLC-Based Activity Profiling Approach for the 
Discovery of GABAA Receptor Ligands using an Automated Two Microelectrode Voltage Clamp Assay 
on Xenopus Oocytes. Planta Med 2008;74:521–6. 
[2]  Zaugg J. Discovery of new scaffolds for GABAA receptor modulators from natural origin. Universität 
Basel, Basel; 2011. 
[3]  Schramm A, Ebrahimi SN, Raith M, Zaugg J, Rueda DC, Hering S, et al. Phytochemical profiling of 
Curcuma kwangsiensis rhizome extract, and identification of labdane diterpenoids as positive GABAA 
receptor modulators. Phytochemistry 2013:318–29. 
[4]  Kim H, Jung, Baburin I, Zaugg J, Ebrahimi S, Nejad, Hering S, Hamburger M. HPLC-based Activity 
Profiling – Discovery of Sanggenons as GABAA Receptor Modulators in the Traditional Chinese Drug 
Sang bai pi (Morus alba Root Bark). Planta Med 2012;78:440–7. 
[5]  Li Y, Plitzko I, Zaugg J, Hering S, Hamburger M. HPLC-Based Activity Profiling for GABAA Receptor 
Modulators: A New Dihydroisocoumarin from Haloxylon scoparium. J Nat Prod 2010;73:768–70. 
[6]  Gavande N, Karim N, Johnston GAR, Hanrahan JR, Chebib M. Identification of Benzopyran-4-one 
Derivatives (Isoflavones) as Positive Modulators of GABAA Receptors. ChemMedChem 2011;6:1340–6. 
[7]  Karim N, Gavande N, Wellendorph P, Johnston GAR, Hanrahan JR, Chebib M. 3-Hydroxy-2′-methoxy-6-
methylflavone: A potent anxiolytic with a unique selectivity profile at GABAA receptor subtypes. Biochem 
Pharmacol 2011;82:1971–83. 
[8]  Zaugg J, Khom S, Eigenmann D, Baburin I, Hamburger M, Hering S. Identification and characterization of 
GABAA receptor modulatory diterpenes from Biota orientalis that decrease locomotor activity in mice. J 
Nat Prod 2011;74:1764–72. 
[9]  Zaugg J, Eickmeier E, Ebrahimi SN, Baburin I, Hering S, Hamburger M. Positive GABAA Receptor 
Modulators from Acorus calamus and Structural Analysis of (+)-Dioxosarcoguaiacol by 1D and 2D NMR 
and Molecular Modeling. J Nat Prod 2011;74:1437–43. 
[10]  Zaugg J, Eickmeier E, Rueda DC, Hering S, Hamburger M. HPLC-based activity profiling of Angelica 
pubescens roots for new positive GABAA receptor modulators in Xenopus oocytes. Fitoterapia 
2011;82:434–40. 
[11]  Zaugg J, Ebrahimi SN, Smiesko M, Baburin I, Hering S, Hamburger M. Identification of GABAA receptor 
modulators in Kadsura longipedunculata and assignment of absolute configurations by quantum-chemical 
ECD calculations. Phytochemistry 2011;72:2385–95. 
[12]  Zaugg J, Baburin I, Strommer B, Kim H-J, Hering S, Hamburger M. HPLC-Based Activity Profiling: 
Discovery of Piperine as a Positive GABAA Receptor Modulator Targeting a Benzodiazepine-Independent 
Binding Site. J Nat Prod 2010;73:185–91. 
[13]  Khom S, Baburin I, Timin EN, Hohaus A, Sieghart W, Hering S. Pharmacological properties of GABAA 
receptors containing γ1 subunits. Mol Pharmacol 2006;69:640–9. 
[14]  Pau D, Belelli D, Callachan H, Peden DR, Dunlop JI, Peters JA, et al. GABAA receptor modulation by the 
novel intravenous general anaesthetic E-6375. Neuropharmacology 2003;45:1029–40. 
[15]  Thompson SA, Whiting PJ, Wafford KA. Barbiturate interactions at the human GABAA receptor: 
dependence on receptor subunit combination. Br J Pharmacol 1996;117:521–7. 
[16]  McCormack D, McFadden D. Pterostilbene and Cancer: Current Review. J Surg Res 2012;173:e53–e61. 
[17]  Rimando AM, Suh N. Biological/Chemopreventive Activity of Stilbenes and their Effect on Colon Cancer. 
Planta Med 2008;74:1635–43. 
[18]  Goel A, Kumar A, Raghuvanshi A. Synthesis, Stereochemistry, Structural Classification, and Chemical 
Reactivity of Natural Pterocarpans. Chem Rev 2013;113:1614–40. 
185
[19]  Manickavasagam L, Gupta S, Mishra S, Kumar A, Raghuvanshi A, Goel A, et al. Determination of 3-
hydroxy pterocarpan, a novel osteogenic compound in rat plasma by liquid chromatography–tandem mass 
spectrometry: application to pharmacokinetics study. Biomed Chromatogr 2011;25:843–50. 
[20]  Lees G, Coyne L, Zheng J, Nicholson RA. Mechanisms for resin acid effects on membrane currents and 
GABAA receptors in mammalian CNS. Environ Toxicol Pharmacol 2004;15:61–9. 
[21]  San Feliciano A, Gordaliza M, Salinero M, del Corral J. Abietane Acids: Sources, Biological Activities, 
and Therapeutic Uses. Planta Med 2007;59:485–90. 
[22]  Zheng J, Nicholson RA. Influence of Two Naturally Occurring Abietane Monocarboxylic Acids (Resin 
Acids) and a Chlorinated Derivative on Release of the Inhibitory Neurotransmitter| γ-Aminobutyric Acid 
from Trout Brain Synaptosomes. Bull Environ Contam Toxicol 1996;56:114–20. 
[23]  Schramm A, Ebrahimi SN, Raith M, Zaugg J, Rueda DC, Hering S, et al. Phytochemical profiling of 
Curcuma kwangsiensis rhizome extract, and identification of labdane diterpenoids as positive GABAA 
receptor modulators. Phytochemistry 2013;96:318–29. 
186
ACKNOWLEDGEMENTS  
 
I want to express my deepest gratitude to Prof. Dr. Matthias Hamburger, for giving me 
the opportunity to pursue my doctoral studies in his research group. Under his careful 
supervision I have learned to approach science and life from a whole new perspective. 
Professor Hamburger has been an inspiration during these years, a constant example of 
discipline and passion for knowledge. I am truly honored to have had the chance to be one of 
his PhD students. I am also thankful to Prof. Dr. Steffen Hering, who hosted me in his 
institute in Vienna several times during the course of my doctoral studies. I felt welcome 
every time and was offered the best possible working conditions, which made every stay in 
his lab an enjoyable and fruitful experience. I also want to thank Prof. Dr. Anna Rita Bilia, 
who very kindly agreed to evaluate my thesis and come to Basel as co-referee for my PhD 
defense. In addition, I’m very thankful to Prof. Dr. Angelo Vedani, chair of my PhD 
examination.  
I’d like to express my gratitude to the Swiss Federal Commission for Scholarships for 
foreign students (FCS), and the Basler Commission for Scholarships for young professionals 
from developing countries, for the financial support during the periods September 2009 - 
June 2011 and January 2012 - December 2012, respectively. Special thanks to Mrs. Andrea 
Delpho (Mobility Office, UniBasel), for her invaluable help during my first months in Basel. 
A separate paragraph must be dedicated to Dr. Inken Plitzko and Dr. Chee Seng Hee, 
who proofread my whole thesis with great patience and dedication. Thank you guys for your 
always helpful input, corrections, advises, and encouragement. Concerning my thesis 
document, I am also grateful to Dr. Olivier Potterat, who carefully checked the 
Zusammenfassung (translated by Inken Plitzko), and to Daniela Eigenmann, one of our BBB 
girls, who kindly offered her help to read and comment on chapter 2.4.  
Each and every member of the Division of Pharmaceutical Biology deserves a special 
place here. I’m grateful to you all, for your constant support and the great working 
environment you create. I feel privileged for having had the opportunity to share and learn 
from each of you in every aspect of life. Yoshie, Anja, Samad, Christian, and Tasquiah, it 
was a pleasure to share the ride with you. I wish you all the best and hope our paths will some 
day cross again. Janine, your patience and caring guidance helped me through the first stages 
of my PhD. I couldn’t have had a better guide. Thanks a lot for your friendship. Inken, 
Melanie, and Maria, I owe you girls my current NMR knowledge and skills. You were 
187
always ready to answer every question with the greatest pleasure and patience. Thanks for 
sharing your experience and for your friendship, which I really value. Orlando, thanks for 
keeping everything going well in the lab, for your help in all technical aspects, for your great 
diligence to help in everything you could. Manuela, thank you for all your help since the very 
beginning. You’re the coolest secretary one can ever have. Alen, Carmela, Daniela, Eliane, 
Elisabetta, Evelyn, Fahimeh, Justine, Karin, Maria, Mouhssin, Niels, Olga, Patrick, Petra, 
Sofi, Teresa, thanks for the moments we shared, however short. It was always fun to be 
around you. Last but not least, special thanks to Dr. Olivier Potterat, who was always ready 
to answer every question and share his wide experience. He always found the time to help 
every time I needed. 
From the lab in Vienna I’m especially grateful to Angela Schöffmann. Not only was 
she a great support in academic issues, she has been such a good friend. I owe my gratitude to 
Neda Panic and Amela Resic, for their caring support during my first research stay in Vienna. 
Schwarzwälder kirschtorte in Aida will never be as good as it was back then. I’m also 
thankful to Dr. Igor Baburin and Dr. Sophia Khom, for their technical help. 
I cannot stress enough, how thankful I am to my good friends Yoshie Hata and Inken 
Plitzko. My dear girls, this experience would have been very different without you. Every 
single day, 24/7, you took care of me, listened, comforted, helped, advised, scolded, 
surprised, cheered. Thanks a lot for your valuable friendship, love and trust. Last but not 
least, my very dear Chee Seng, I am constantly amazed by your capacity to give, your 
kindness, your big heart. Your devoted support kept me going until the very end of this 
process and made it much easier. I owe you the happiness of having someone to share this 
with. My deepest gratitude to you, for your love and patience.  
Dice un proverbio chino que el viaje de mil millas comienza con el primer paso. El 
paso inicial en esta cadena de eventos que ahora termina, se lo debo al Profesor Roberto 
Pinzón (Universidad Nacional de Colombia) y por ello le agradezco inmensamente. A mi 
familia amigos en Colombia les estoy profundamente agradecida por el permanente apoyo 
que, aun desde la distancia, me mantuvo en pie durante estos años. Mami, Papi, Lina Ospina, 
MaFe Zuluaga, Gina Bernal, Laura Pineda, Angelica Sandoval, Angela Zambrano, Nadia 
Vergel, Yasmin Cabieles, David Becerra, Miguel Dussan, Juan Carlos Galeano, Julian Serna, 
Francisco Romero, los quiero. Sepan perdonarme aquellos a quienes aquí no menciono. Son 
muchas las personas que han jugado un papel decisivo en el curso de mi vida. Tiempo y 
espacio escasean, pero en mi memoria los llevo a todos con especial cariño.  
   
188
